var title_f41_62_42976="Groin hernias PI";
var content_f41_62_42976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Groin hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hernia is a weakening or a tear in a tissue layer. When a person has a hernia, internal organs or tissues can bulge at the hernia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42976=[""].join("\n");
var outline_f41_62_42976=null;
var title_f41_62_42977="Patient information: Inguinal and femoral (groin) hernias (The Basics)";
var content_f41_62_42977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15876\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/62/42976\">",
"         Groin hernias",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/6/23648\">",
"          Intestines bulging through hernia",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/53/14162\">",
"         Patient information: Abdominal wall hernias (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/inguinal-and-femoral-groin-hernias-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16277433\">",
"      <span class=\"h1\">",
"       What is a hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A hernia is an area in a layer of tissue that is weak or torn. Often when there is a hernia, other tissues that are normally held in by the damaged layer bulge or stick out through the weak or torn spot.",
"     </p>",
"     <p>",
"      Hernias can happen in different parts of the body. When they happen where the thigh and body meet (called the groin), they are called inguinal or femoral hernias. Inguinal hernias are a bit higher on the groin than femoral hernias (",
"      <a class=\"graphic graphic_figure graphicRef64249 \" href=\"mobipreview.htm?41/62/42976\">",
"       figure 1",
"      </a>",
"      ). Both of these types of hernias can form a sac that holds a loop of intestine or a piece of fat pad that normally sits inside the belly. The fat pad is called the omentum. In women, the sac can hold female reproductive organs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277440\">",
"      <span class=\"h1\">",
"       What are the symptoms of a groin hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Groin hernias do not always cause symptoms. But when symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A heavy or tugging feeling in the groin area",
"       </li>",
"       <li>",
"        Dull pain that is worst when straining, lifting, coughing, or otherwise using the muscles near the groin",
"       </li>",
"       <li>",
"        A bulge or lump at the groin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hernias can be very painful and even dangerous if the tissue in the hernia becomes trapped and unable to slide back into the belly (",
"      <a class=\"graphic graphic_figure graphicRef76003 \" href=\"mobipreview.htm?23/6/23648\">",
"       figure 2",
"      </a>",
"      ). When this happens, the tissue does not get enough blood, so it can get damaged or die. This is more likely with femoral hernias than with inguinal hernias.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277447\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See a doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel or see a bulge in your groin, or",
"       </li>",
"       <li>",
"        Feel a pulling sensation or pain in your groin even if you have no bulge",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In most cases, doctors can diagnose a hernia just by doing an exam. During the exam, the doctor will ask you to cough while pressing on the bulge. This can be uncomfortable, but it is necessary to find the source of the problem.",
"     </p>",
"     <p>",
"      Most of the time, the contents of the hernia can be &ldquo;reduced,&rdquo; or gently pushed back into the belly. Still, there are times when the hernia gets trapped and can&rsquo;t be pushed back in. If that happens, the tissue that is trapped can get damaged.",
"     </p>",
"     <p>",
"      If you develop pain around the bulge or feel sick, call your doctor or surgeon right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277454\">",
"      <span class=\"h1\">",
"       How are hernias treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not all hernias need treatment right away. But many do need to be repaired with surgery. Femoral hernias, in particular, usually need repair. They are more likely than inguinal hernias to cause tissue damage (",
"      <a class=\"graphic graphic_figure graphicRef64249 \" href=\"mobipreview.htm?41/62/42976\">",
"       figure 1",
"      </a>",
"      ). &nbsp;",
"     </p>",
"     <p>",
"      Surgeons can repair groin hernias in 1 of 2 ways. The right surgery for you will depend on the size of your hernia, whether this is the first time it is getting repaired, and what your general health is like. The 2 types of surgery are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Open surgery",
"        </strong>",
"        &ndash; During an open surgery, the surgeon makes an incision near the hernia. Then he or she gently pushes the bulging tissue back into place. Next, the surgeon sews the weak tissue layer back together, so that nothing can bulge through. In some cases, surgeons will also patch the area with a piece of mesh. The mesh can take some of the strain off the tissue wall. That way the hernia is less likely to happen again.",
"       </li>",
"       <li>",
"        <strong>",
"         Laparoscopic surgery",
"        </strong>",
"        &ndash; During laparoscopic surgery, the surgeon makes a few incisions that are much smaller than those used in open surgery. Then he or she inserts long thin tools into the area near the hernia. One of the tools has a camera (called a &ldquo;laparoscope&rdquo;) on the end, which sends pictures to a TV screen. The surgeon can look at the picture on the screen to guide his or her movements. Then he or she uses the long tools to repair the weak tissue layer either with stitches alone or with mesh.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your hernia has reduced the blood supply to a loop of intestine, your doctor might need to remove that piece of intestine and sew the 2 ends back together.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277521\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/53/14162?source=see_link\">",
"       Patient information: Abdominal wall hernias (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/62/42977?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15876 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42977=[""].join("\n");
var outline_f41_62_42977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277433\">",
"      What is a hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277440\">",
"      What are the symptoms of a groin hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277447\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277454\">",
"      How are hernias treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277521\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/62/42976\">",
"      Groin hernias",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/6/23648\">",
"       Intestines bulging through hernia",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/53/14162?source=related_link\">",
"      Patient information: Abdominal wall hernias (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42978="Zucapsaicin: Drug information";
var content_f41_62_42978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zucapsaicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/12/42179?source=see_link\">",
"    see \"Zucapsaicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13265100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ZUACTA&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13265102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product;",
"     </li>",
"     <li>",
"      Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13265140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain relief in osteoarthritis of knee:",
"     </b>",
"     Topical: Apply a pea-sized amount to 3 locations around affected knee 3 times/day; allow at least 4 hours between applications (maximum: 3 applications/day).",
"     <b>",
"      Note:",
"     </b>",
"     Should be used concomitantly with an oral NSAID or COX-2 inhibitor.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13265141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13265159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zuacta&trade;:  0.075% (30 g, 60 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13265158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13265142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only on intact skin; do not apply to broken or irritated skin. Gently rub into affected knee until no residue is left on skin. Do not cover treated area with occlusive dressing. Wash hands thoroughly after application. Avoid taking a hot bath or shower immediately before or after administration (may cause burning sensation). Avoid contact with eyes, lips, and genital area. Avoid concomitant application of other topical medications to treated areas.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13265103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In conjunction with an oral NSAID or COX-2 inhibitor for short-term (&le;3 months) treatment of severe pain associated with osteoarthritis of the knee that is not controlled by NSAID or COX-2 inhibitor monotherapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13265123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Local: Application site: Burning (22% to 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Burning sensation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Application site: Warming (4% to 6%), reaction (4%), anesthesia (3%), irritation (1%), pruritus (1%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eye irritation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (2%), sneezing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Application site reactions (cold sensation, dryness, erythema, pain, swelling), dyspnea, limb pain, osteoarthritis aggravated, photosensitivity reaction, rash, skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13265106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zucapsaicin or any component of the formulation; application to broken or irritated skin or areas with a compromised skin barrier",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13265107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cough: May induce cough; do not apply to the face. Wash hands thoroughly after each application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For external use only. Avoid contact with eyes, lips, or genital areas. Avoid application of other topical products to zucapsaicin treated areas. Safety and efficacy have only been assessed in treating pain associated with osteoarthritis of the knee; use in other arthritic conditions (eg, rheumatoid arthritis, psoriatic arthritis), musculoskeletal disorders (eg, fibromyalgia), or severe neurologic or vascular disease has not been studied and is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13271221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13265104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not demonstrated adverse effects. Use has not been studied in pregnant women. Systemic absorption, following topical administration, has not been observed in healthy patients. Systemic absorption would be required in order for zucapsaicin to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13265105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in human breast milk is unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13265130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actions are thought to be similar to other capsaicinoids, such as capsaicin, which is a transient receptor potential vanilloid 1 receptor (TRPV1) agonist, that activates TRPV1 ligand-gated cation channels on nociceptive nerve fibers, resulting in depolarization, initiation of action potential, and pain signal transmission to the spinal cord; capsaicin exposure results in subsequent desensitization of the sensory axons, depletion of proinflammatory neuropeptides (eg, calcitonin gene-related peptide, substance P) and inhibition of pain transmission initiation. In arthritis, capsaicin induces release of substance P, the principal chemomediator of pain impulses from the periphery to the CNS, from peripheral sensory neurons; after repeated application, capsaicin depletes the neuron of substance P and prevents reaccumulation. The functional link between substance P and the capsaicin receptor, TRPV1, is not well understood.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13265132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Systemic absorption is negligible",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Szallasi A and Blumberg PM, &ldquo;Vanilloid (Capsaicin) Receptors and Mechanisms,&rdquo;",
"      <i>",
"       Pharmacol Rev",
"      </i>",
"      , 1999, 51(2):159-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42978/abstract-text/10353985/pubmed\" id=\"10353985\" target=\"_blank\">",
"        10353985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16820 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-40A0E85E25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42978=[""].join("\n");
var outline_f41_62_42978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265100\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265102\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265140\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265141\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265159\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265158\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265142\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265103\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265123\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265106\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265107\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300242\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13271221\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265104\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265105\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265130\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265132\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/12/42179?source=related_link\">",
"      Zucapsaicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42979="Ciclopirox: Pediatric drug information";
var content_f41_62_42979=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciclopirox: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?43/40/44676?source=see_link\">",
"    see \"Ciclopirox: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/32/39428?source=see_link\">",
"    see \"Ciclopirox: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciclodan&reg;;",
"     </li>",
"     <li>",
"      Ciclodan&reg; Kit;",
"     </li>",
"     <li>",
"      Loprox&reg;;",
"     </li>",
"     <li>",
"      Pedipirox&trade; -4 Kit;",
"     </li>",
"     <li>",
"      Penlac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ciclopirox&reg;;",
"     </li>",
"     <li>",
"      Loprox&reg;;",
"     </li>",
"     <li>",
"      Penlac&reg;;",
"     </li>",
"     <li>",
"      Stieprox&reg;;",
"     </li>",
"     <li>",
"      Taro-Ciclopirox",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1005707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1005732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/40/44676?source=see_link\">",
"      see \"Ciclopirox: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;10 years, Adolescents, and Adults: Tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis: Cream/suspension: Apply twice daily for 4 weeks (4-6 weeks for tinea cruris; 2 weeks for tinea versicolor if response is adequate). If no improvement after 4 weeks of treatment, re-evaluate diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years, Adolescents, and Adults: Solution (lacquer): Apply daily as part of a comprehensive management program for onychomycosis; remove with alcohol every 7 days; 48 weeks of continuous therapy may be needed to achieve clear nails",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;16 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tinea pedis, tinea corporis: Gel: Apply twice daily.  If no improvement after 4 weeks of treatment, re-evaluate diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Seborrheic dermatitis of the scalp:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Gel: Apply twice daily.  If no improvement after 4 weeks of treatment, re-evaluate diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Shampoo: Apply ~5 mL to wet hair; may use up to 10 mL for longer hair; repeat twice weekly for 4 weeks; allow a minimum of 3 days between applications. If no improvement after 4 weeks of treatment, re-evaluate diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as olamine: 0.77% (15 g, 30 g, 90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.77% (30 g, 45 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loprox&reg;: 0.77% (30 g, 45 g, 100 g) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 1% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loprox&reg;: 1% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [nail lacquer]: 8% (6.6 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciclodan&reg;: 8% (6.6 mL) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciclodan&reg; Kit: 8% (6.6 mL) [contains isopropyl alcohol; packaged with Toetal Fresh&trade;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pedipirox&trade; -4 Kit: 8% (1s) [contains isopropyl alcohol; kit contains one Pedipirox&trade; 6.6 mL, one Pedipirox&trade; 3.3 mL, 15  nail lacquer removal pads, nail file, and pedi-sorb&trade; foot powder]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Penlac&reg;: 8% (6.6 mL) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical, as olamine: 0.77% (30 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1005736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, gel, suspension: Gently massage into affected areas and surrounding skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion: Shake lotion vigorously before application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Apply to wet hair and scalp, lather, and leave in place ~3 minutes; rinse thoroughly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution (lacquer): Apply evenly over the entire nail plate and 5 mm of surrounding skin using the applicator brush; allow to dry for 30 seconds; apply at bedtime (or allow 8 hours before washing). Solution can be reapplied daily over previous applications; remove with alcohol every 7 days. Avoid contact with eyes and mucous membranes; do not administer orally or intravaginally.  Do not occlude affected area with dressings or wrappings.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1005722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light.  Store ciclopirox topical solution (nail lacquer) in a tight container, protected from heat; the solution&rsquo;s solvent is flammable.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1005708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream/lotion: Treatment of tinea pedis, tinea cruris, and tinea corporis caused by",
"     <i>",
"      Trichophyton mentagrophytes",
"     </i>",
"     ,",
"     <i>",
"      T. rubrum",
"     </i>",
"     ,",
"     <i>",
"      Epidermophyton floccosum",
"     </i>",
"     , or",
"     <i>",
"      Microsporum canis",
"     </i>",
"     ; treatment of pityriasis versicolor caused by",
"     <i>",
"      Malassezia",
"     </i>",
"     species; treatment of cutaneous candidiasis caused by",
"     <i>",
"      Candida albicans",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel: Treatment of tinea corporis and interdigital tinea pedis; treatment of seborrheic dermatitis of the scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Treatment of seborrheic dermatitis of the scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution (lacquer): Treatment of mild to moderate onychomycosis of fingernails and toenails (not involving the lunula) and the immediately adjacent skin caused by",
"     <i>",
"      T. rubrum",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F151248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Ventricular tachycardia (shampoo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, contact dermatitis, dry skin, erythema, facial edema, hair discoloration (rare; shampoo formulation in light-haired individuals), nail disorder (shape or color change with lacquer), pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning sensation, irritation, pain, or redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Eye pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1005712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciclopirox or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5598876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in immunocompromised patients and diabetics.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F151202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies, however, there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5598923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resolution of skin or nail infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1005724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes intracellular depletion of essential substrates and/or ions by inhibiting transmembrane transport of these substances into cells decreasing protein, RNA, and DNA synthesis.  May chelate polyvalent cations (ie, iron, aluminum) which can result in inhibition of metal-dependent enzymes for the degradation of peroxides within the fungal cell.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1005726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Rapid but minimal with intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Present in stratum corneum, dermis, sebaceous glands, nails",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Conjugated with glucuronic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciclopirox olamine: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciclopirox gel: 5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1005738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/32/39428?source=see_link\">",
"      see \"Ciclopirox: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact physician if skin condition does not improve, if skin irritation develops, or if infection worsens after 4 weeks of treatment.  Nail polish should not be applied on treated nails. Insulin-dependent diabetic patients or those with diabetic neuropathy should use caution when trimming infected nails.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barber K, Claveau J, and Thomas R, \"Review of Treatment for Onychomycosis: Consideration for Special Populations,\"",
"      <i>",
"       J Cutan Med Surg",
"      </i>",
"      , 2006, 10(Suppl 2):S48-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42979/abstract-text/17204233/pubmed\" id=\"17204233\" target=\"_blank\">",
"        17204233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gallup E, Plott T, and Ciclopirox TS Investigators, \"A Multicenter, Open-Label Study to Assess the Safety and Efficacy of Ciclopirox Topical Suspension 0.77% in the Treatment of Diaper Dermatitis Due to",
"      <i>",
"       Candida albicans",
"      </i>",
"      ,\"",
"      <i>",
"       J Drugs Dermatol",
"      </i>",
"      , 2005, 4(1):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42979/abstract-text/15696982/pubmed\" id=\"15696982\" target=\"_blank\">",
"        15696982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13063 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-9B44C2D3FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42979=[""].join("\n");
var outline_f41_62_42979=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151213\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005707\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005732\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151195\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151182\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005736\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005722\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005708\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151248\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5598876\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299041\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151190\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151192\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151202\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5598923\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005724\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005726\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005738\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13063|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/40/44676?source=related_link\">",
"      Ciclopirox: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/32/39428?source=related_link\">",
"      Ciclopirox: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42980="Combined hepatitis A and typhoid vaccine: Drug information";
var content_f41_62_42980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"31\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Combined hepatitis A and typhoid vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/25/18835?source=see_link\">",
"    see \"Combined hepatitis A and typhoid vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13269812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ViVAXIM&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13269815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial);",
"     </li>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13269855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.: 1 mL single dose at least 2 weeks prior to expected exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Booster: May administer 1 mL booster dose 3 years after previous dose in individuals requiring a booster dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13269854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.: Children &ge;16 years: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13269856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13269870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ViVAXIM&reg;: Purified Vi capsular polysaccharide 25 mcg and hepatitis A virus 160 antigen units per 1 mL [contains polysorbate 80 and neomycin]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13269869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13269863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mix vaccine components immediately before administration according to manufacturer labeling instructions. Shake well until white, cloudy suspension is achieved.",
"     <b>",
"      Do not administer intravascularly or intradermally.",
"     </b>",
"     Intramuscular administration into deltoid muscle is preferred. Do not administer to gluteal region. May consider subcutaneous administration in individuals at risk of hemorrhage (eg, thrombocytopenia, hemophilia). Subcutaneous administration may be associated with greater risk of injection site reactions.",
"     <b>",
"      Note:",
"     </b>",
"     For patients at risk of hemorrhage following intramuscular injection, the NACI recommends weighing the benefits and risks of intramuscular vaccination. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 5 minutes. Patients on low-dose aspirin or long-term anticoagulant therapy (warfarin, heparin) are not considered to be at greater risk of complications and should receive scheduled vaccinations (NACI, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Simultaneous administration of vaccines helps ensure patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13269816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization against typhoid fever caused by",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     and against disease caused by hepatitis A virus (HAV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     National Advisory Committee on Immunizations (NACI) does not recommend use for routine vaccination but does recommend that immunization be considered in the following groups:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Travelers to areas with a prolonged risk (&gt;4 weeks) of exposure to",
"     <i>",
"      S. typhi",
"     </i>",
"     or travelers to areas with endemic hepatitis A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Persons with intimate exposure to a",
"     <i>",
"      S. typhi",
"     </i>",
"     carrier or who are residing in communities with high endemic rates of hepatitis A virus or at risk of outbreaks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Laboratory technicians with frequent exposure to",
"     <i>",
"      S. typhi",
"     </i>",
"     or individuals involved in hepatitis A research or production of hepatitis A vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Travelers with achlorhydria or hypochlorhydria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Military personnel, relief workers, or others relocated to areas with high rates of hepatitis A infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Persons with lifestyle risks for hepatitis A infection (eg, drug abusers, homosexual men), chronic liver disease, receiving hepatotoxic medication or with disease(s) which may necessitate use of hepatotoxic medications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Persons with hemophilia A or B treated with plasma-derived clotting factors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Zookeepers, veterinarians, and researchers who handle nonhuman primates",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13269810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       ViVAXIM&reg; may be confused with Vyvanse&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13269838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site: Pain (90%), induration/edema (28%), erythema (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (17%), myalgia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (5%), malaise (3%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (3%), nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening; reported with ViVAXIM&reg;): Arthralgia, pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13269834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to typhoid vaccine, hepatitis A vaccine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13269835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acute illness: Defer administration in patients with acute or febrile illness; may administer to patients with mild acute illness with low-grade fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Patients with chronic liver disease may have decreased antibody response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Typhoid fever: Should not be used to treat typhoid fever. Not all recipients of typhoid vaccine will be fully protected against typhoid fever. Travelers should take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water sources.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vaccines: Simultaneous administration of other vaccines at different injection sites is not likely to affect immune response. Hepatitis A seroconversion rates are not lower with simultaneous administration of immune globulins (at separate sites) however hepatitis A antibody titers may be lower. The NACI recommends simultaneous administration of all age-appropriate vaccines for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids); may have a reduced response to vaccination. If appropriate, consider delaying administration until after completion of immunosuppressive therapy. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neomycin: Formulation may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Polysorbate 80: Formulation may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and is improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011). Due to the long incubation period for hepatitis, unrecognized hepatitis A infection may be present at time of vaccination; immunization may not prevent infection in these patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13271215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13269831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. The Canadian labeling does not recommend use in pregnant women. Although the safety of vaccination during pregnancy has not been determined, the theoretical risk to the infant is expected to be low. Inactivated vaccines have not been shown to cause increased risks to the fetus (Canadian NACI, 2006; CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13269832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13269833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (Canadian NACI, 2006; CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13269866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hepatyrix (AT, DE, GB, IE, NZ);",
"     </li>",
"     <li>",
"      Tyavax (FR);",
"     </li>",
"     <li>",
"      Viatim (AT, DE, FI, GB, IE, NL);",
"     </li>",
"     <li>",
"      Vivaxim (AU, CO, HK, MY, NZ, PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13269845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provides active immunization against typhoid fever through production of antibodies (predominantly IgG) and against hepatitis A infection through production of antihepatitis A virus antibodies.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13269847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Seroprotection rate at 14 days: Hepatitis A: ~96%, typhoid: ~89%; Seroprotection at 28 days: Hepatitis A: ~100%, typhoid: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Kinetic models suggest antihepatitis A antibodies may persist &ge;20 years (NACI, 2006); Typhoid: 3 years",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization (NACI), 2006. Available at file://www.phac-aspc.gc.ca/publicat/cig-gci/index.html",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42980/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42980/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16818 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-DBEF2E8A07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42980=[""].join("\n");
var outline_f41_62_42980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269812\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269815\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269855\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269854\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269856\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269870\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269869\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269863\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269816\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269810\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269838\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269834\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269835\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300190\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13271215\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269831\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269832\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269833\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269866\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733210\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269845\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13269847\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/25/18835?source=related_link\">",
"      Combined hepatitis A and typhoid vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42981="Olanzapine and fluoxetine: Patient drug information";
var content_f41_62_42981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olanzapine and fluoxetine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/13/30937?source=see_link\">",
"     see \"Olanzapine and fluoxetine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Symbyax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olanzapine, fluoxetine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11269 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42981=[""].join("\n");
var outline_f41_62_42981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203424\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022696\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022698\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022697\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022702\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022703\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022705\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022700\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022701\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022706\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022707\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/13/30937?source=related_link\">",
"      Olanzapine and fluoxetine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42982="Clinical features T-PLL";
var content_f41_62_42982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clinical features of T cell prolymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 513px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIBAboDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6E8eeMLTwbp9ldXtlfXv2y6FpFFZiMuXMbyZO91AG2Nu/pXIt8Z7BRk+FvEoGcdLP/wCSKb+0ISNG8Lkdf7aH/pHdVxngHwnb+I9L8Sarq/iLVdPg068aHFsLfy0iW2hlZj5kLtnMjd+mOKht3sjpp06fs/aTvvbQ7U/GiwBwfC/iT/yT/wDkinD4yWRGR4V8S49cWf8A8kVxXwt0Lwt8SNKu7rQfEvjCFbOYRSw3kdikgyMq2FhYFTzjnseK5fw1qF5e6Dpc9yd809rFK7bQu5igJOBwOtTKUo7m9DD0K7ajfT0PXj8YrQAE+FfEuDx/y5//ACRQPjHZkkDwt4kJH/Xn/wDJFeaSPudFfdgcAD+KpVjG0FeuTk1PtWdSy2n1b/r5Ho3/AAuKz2hv+EV8SYPT/jz/APkinH4v2oUMfCniXB6H/Q//AJIrzgROzrsyEJ+ZjyRVlVJchCHRflHGaPasr+zKXd/h/kd4nxjs3ZVXwr4kJbgf8ef/AMkVK3xagXO7wn4kGPU2X/yTXnUAeOb5AEAOR6mpJoXkHymQ88gd6PasTy2iur/D/I75fi/asMr4U8SEeubL/wCSKU/F225/4pTxJx72X/yTXCXUbJGCylWcYCA0yNNiEuDuP5Cj2jF/Z1Lu/wAP8j0A/Fu3H/Mp+JPzsv8A5Jpp+LtspAPhPxLk9P8Ajz/+SK4iJnXGcEDvioZFkeYupLDsMdKftGUsspdW/wAP8j0H/hbEOzd/wifiPb/vWX/yTSL8WYWYKvhLxKSfey/+Sa4GORoyu/gLweM1oRRDcHCDGcrzzR7RkvLaa6v+vkdg3xVjBA/4RHxMSeODZH/25prfFiFNu7wl4kXd0ybIf+3NcuuCo8osjD06ZpVX5wWwx7HHP0FP2jJWX0u7/r5HVf8AC1Ezj/hEfEhPs1l/8k0N8VI1bafCXiTd/vWP/wAk1ysqeWR5asN3buamt7YyQt5qum08KRyfenzsTwFK17v+vkdJ/wALUT/oUfEn/fVj/wDJNNPxXhU4bwl4kB92sv8A5Jrm7hDG+CjAYB3dqgOxcvcKMOQEB5Jo52P6hS7v+vkdWvxYhYfL4S8SnnHWy/8AkmlHxVjYkDwh4mJHXmy/+Sa5BkDTAKhViCMA4AH0qbT1EkR3Hd3JVupHajnZDwNNK6b/AK+R1EvxXhhYLJ4S8SBj23WR/wDbmpP+ForwP+EQ8S5PbdZf/JNcbfSRfal8t/LMfVRgsatWtszhpo2zIRyA3z+wqXUE8FTSTbf9fI6z/hZT7iv/AAh3iXI/2rHH5/aaa3xP2Ha3hDxIrehexB/L7TXNk3CxujLGwBBQbs1LpzTu+2S3YhgQMjI/PtS9qy1l8Gr3Z0I+JZOceD/EfBx/rLH/AOSarn4rxCTyz4T8Rh+mC1l/8k1RcR+UPk8og4K4rF1Cy89WaNmYZ4LdcelP2jCGApSerf8AXyOsT4oq77F8IeJS3pusf/kmnP8AE7y8FvB/iQZ/27H/AOSa47T7eSBx8x9Ru61b1OOQDdsbLc70OQPbFPnZTy6kpct3/XyOkX4oqxAHhDxJk9AWsf8A5Jp6/E0s+1fB/iTd6b7H/wCSa4m2nnklxtyccvmtaBSzgl2Bx98880+dinl1OPVnRP8AEl0BLeDfEoA6/PY//JNRP8UVQ4bwh4kB6/esf/kmuamlmiBGW2g53EcVRuLlFKkSBjjJ96XOwjl0JbNnY/8AC1Y8gf8ACJeJMnphrL/5JqP/AIW3AOvhPxKPqbL/AOSK5V5VVd64BYZwB0p1rHHKu2Ri3qCO/vR7Rk/UKa3b/r5HTt8XLdQM+E/En52X/wAk01vi/aqMt4U8SjH/AF5//JFcnc2qq7ADd6VQeMNIyHGT0bPT2NHOy1l9Jq93/XyO4/4XHZAA/wDCLeJMHp/x5/8AyRQPjHZlcjwr4lx/25//ACRXA3FspVXAG08fSq8ZYo6tlmB4PQkUc7BZfSfV/wBfI9Bm+NmmxHEnhjxIDnH/AC5n/wBuKYvxw0tmCjwz4kyenFp/8kV5fcW63Mh2sSwO3AGMe1RLpkkVwHOcL0zS55FSy6gur/r5HrLfGrTlBJ8MeJMfSz/+SKZ/wu7TNu7/AIRnxLjrnFp/8kV5Y8eOMMBkkkCq91Ai2uVOFJyMng1XOzN4Cmur/r5HrX/C8NL/AOhZ8SdM9LT/AOSKQ/HHSggY+GfEuD/s2n/yRXj4hWQAxg78cn0pZoGiZMjA7kdKOdk/Uae13/XyPXP+F7aPu2/8I34kz/u2n/yRTm+OekqAW8NeJRkZ+7af/JFeNPZmTfhgnsO49KRxm3KkZYcc9RRzsTwVPo2exj476MRn/hG/EmP920/+SKQfHnRSxUeG/EuR/sWv/wAfrxB1HCu2MCq0hLAhCcDuKOdkvBw6Nnup+P2hAZPh3xLjGfuWv/x+mt+0DoKttPh7xJnrjZa//H68FyZYRjg87vaoSAI2Z1O7GN3tRzMh4WHdn1D4A+LGkeNvEEmj6fpur2dyls93uvEhCFFdFIBSRjnMi9vWvQ6+X/2cCv8AwtJwnT+xbn/0fbV9QVad0cdSKjJpHlP7Q+f7F8L4BJ/tocD/AK9LmuP8KaBrPij4VeOtD8OXFra3d/rIhkmumZVSE2tr5mNqkklcrj3PNdl+0E2zSPC7c8az2/687qvHdT0jR7yYXFzplhNO2PMkkt0ZmwMckjJ4wKzlLllc7aFF1qHKu/6HsPgT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa8h8Jy58H6GsSh2NjApJ6j92tZ03hrSJJR9n0XTzngL9lTn9K37PTvs4iSJVRIkCYQYVVx90DtUTnzHdhcJ9XbcpXuaFvH5a7coZOhPYfSn20MofaWCxDndjk0uY4gqhtzn5QD0/8Ar1M5UDDFWVRhj71l1OteQ15A0fkjgs3ODyR9e1Edw3EYyMN/CKghi2oC7fIf4h1PtTpSslwPJJ2YxntTKaVywyxq4CqGZecDuasee8ahUU/7XoKzo5EhwpKt3yO9Ks7M4/hU8KccUw5b7mnbvFIZCB8rfe3HJ/D0qk8pVtqRMMH+IZ4pUk3RAAhcjLY6k+ppkUj7SYywB43Y5b2oJWjL2BLEqyZ3gZ46KKWEDBRiy56HNQWyTq5eRlTB4U8lvrViAjz2Kgv/AHiKYmybYkaIoYnd/Ef6UsccZIA3EMeAvcf40KizucEhh2X/ABNALpJvU5wPTABoJRbUJgxBMRE8qeg9z71Yk8tVRVU7gPvHpj2qGMbVDgngdT2z2qF5C+zMvB5Jx29B6U0Ta493W1XIkxk9SelPmupCpSFC3IxtPBH1qnc2MF6hWZZNi4IyfvEdKmMcoQqqrtQbdwOSAPamh2W5eLtcweWwQOAPvHiqLukcmXVCd20HsD7U6NBHCJEVmkIIBYdT9Khgs2mJLyNtHJGen40ydF1GmYRytGgYtJw0gG4gU6GW1hwIgflBDSY5zUVwi+YoMu1hxlTwB7/Wo7UqrueWIGQCP5CgHZq4QRxRXrmNFZjjLN2HvmtWCbcMgBwpyoRtoY+lZjBnUP5Lqqjn1P1qKR0UxlpCdn3VAwc1DQcqmX5ZZY7oQlUQHqCD8ufetGK5WANCpOD/ABg96w3mkMAkRtz8gKTzn1rPg1sxL+/UM7cLlslD64qW0tzphR9otDqvtMkikqzHnnK4IqR2SYSecu4oOVVsZrnbPVGmuUO8cgDZ2FdBFG0sZCYxnow5ari0zGrD2e44WitudHJUj7ueRTWykZiiR3bB5PBH51dijQBeSrgYw/T86guUWZ0DNyB3PB+hqjFTuQNaJLBlVSN8ZZc4z70ljDIspbIaPGD2/SowzrKwM+CeOV4HtSXzNFJGYgM+x4P/ANegE3e1yxqbsinIZxjhDxurDNusrbgoQYyQa0HmeeNTOm7+EZ4ZapuXWUBX8wdCuOVoNabcY2I2hLyJJGR5Z6bTzn3pNrRyFk5bOSfWpJVX5DnAHZetPmlUod5Ax2C9BQPmb0Ip7wy7cAKvQnuDVL7Pjd5i5TPrgmllaNWHljHmfMfTNU7i5d1eMSKW4AI/lU3KUGtiW5uHRmjQhkz09PrVSZ9qiRTjjB9aGnWZWiYBZF4Ynp7U1HW2i/fKJFxgHqeaE7j2GyzoCH270IycnBPvSTXn7rByfr6e9QfL5g+RRjgACppo1MaeVyxHIPbFMiSSepUEzGIbQoQHDZ5xQ5SYFX2KAPlPQfSmxwsszKTjcMt6CnKIxlGyfUkUyZNdCAuYJAIwGU8Nx2+tMv08z5hIVzwBVtGZg6hUJbtUf2UwxNvGcDgntRcxctbFPzIhCQd3mgDLVTL7wQwwT6+tWvMR0kG3+HgntiqjuiqQTnocf40DuQybX4ycYxn8arTRNApKYKH+Lrk1YjYjeQQQDwPSm6iodgEYqNuSB0NBk73KCSr5ajHzMeSeKjvinlkx9TUlwgEDCPqoxk9cVQlkO3OAeKZL0PRf2Z1KfFW4BOT/AGNcn/yPbV9T18sfszkt8VJ2I66Nc/8Ao+2r6nrWOx5lZ3mzyj9ocbtE8MDnnWe3/XndV5cqqsYG0cDgEZP1r1b4/nbpXhc4zjWf/bO6rzawZgryNGGIGQx5NY1dz1Muv7N+v+QWhYthlwy9xU7yMqOCuwMcgetDMhO5SVOfn9SaS4dPs+HxknrntWR6CV9yW2EYRizDzMYx1IpbWGNkaRs8/wATVQ3iAgHbnqCeeKuwMspIjwD79KLF25SWOAZaVGBRRkAnrVILIZvMGXQfMQP61OwkeYqDti7nHSoopyLho1jCoBxz1piV+gxFMkw5JRQTgdKWfEbBXOQBkheh9s1YnKKpMRG1uoxgVSuXZpEQjbgemBigFJMnaRTCuxypzgqBVi1ilduD5mPuKB0NQ2lptm4Uu5PXPArVhDRqdrMzDsBwaLmTl2I/KlE4Vy+SPmIPH51cKgZQqS3oDj86fI7OELLtY9VHf8KtCGPYoGdpPzfX3pXFd2K8YAlRVBPsF4q9JbHGSoY5+uKmhiiQt8u9h1YdqZOxjiBgTc3fB4H/ANenchNt6FNlVMKEyRkjHzHNIkSybfPlMQ7g8k04PIWLSYVSMcd6ZuDbUgjO8jHJ7e57VSNXoT3LldqFS6KPuk9vU02N4hH5icndllB4FVLgHJidyJG/h7U632QoduNx+UFuM/QUyElbQtCaRpgcZUf3upqO5kJUBcK3P7scD8aia5dI/Lijwzc/e5Y/0FMkt2mAd2jHGTlsn6CmS4pasbcxCODEpSWRvmIB4B9KW1ZzJjjjGeOfp9KjmHlSLGpVSWGcgkj6UsjeUcSYZCeMNjB/rQO11YS9umWUQkkH+Lyx2/Gm20BJzbnynkG7Ln+fpUd/IdseGTewwRxkCn26SSoyo8YQcOAevoKlhbTQuLCyho41QKDwccn1rH1DTYi4eNQMndszhhjvit20tUaJ2ZPNdOGw/wB0/wB0etTwozku4iDpwu5fmAqbXHCq46owILR7dw8QXa3RjxXQWU06sRPE0i4GAvNSSiJ8LKrZQ7sPwD9KnhXzCfJVl7iRcEH604pIJ1PaLUiJk8/bHIyDqVfoDTmtZSwLKUOc5XlTVjEgQ7t3zH7rDP40pnHk+WQVJ4yvSrM7voZsoaNgFRtwB4yBt+vrUUzGW3DNGhGf4eDn6VcdQAJHcvzwTyFpEw43yDJGeRQD01M5zI8DkxbdvGSetVXygjGPkPc9Qfb2q3P5BLCMyZHY85pyXEbJkorFuMsuMUGnN5FRLvEjBiGAxx0NVNRul80hUJ/usD0qy9rD5jv8w5yQo+bH+FUL62aYGRG4A7DGKltlRcUylNMyRPsKksPxH0rEvbpjKMkjJwccYq1LbzK2NxcA5BqRbRZOHXLHqP8A69RZs6nNRQ2y84KzyAEt1Oe1aEUbeajzoDHjGR0pVIjhEMZCgfe3DNN85ipVuB0x61okc1+YguVih5jyFz3PT61CzhGeTzPlI2tu9asXEbeSQzKSowMdvrVFfNmYBgoUenemTa6uyzb48tmHODuy3IxULgPISoxvGcDpUxieGArwN3rwPpVdQNhAVlX1z0oI7tFdpnV+QFwe3eoJrqRwy5LIw5x2q3Mu/codSOoIH6VUi4Cs5AwccdD7UWIdtxDamKJSJAdzZ+b0rOmC+ZyM7j27VqSb5oGXYVJOfm5x9Kzpcx4ZlO7+Inp+FBF++41UTe4+Yj/ZHSoMxu2QxIHQGnyTurkhTuxjjp9apLJ50hxwO/tQFna425l8t5CAMY61nK0eWJGRnGPSrOpLIqEg7lbpWTAkhmJk+VRyT6UyJ2toerfs2E/8LVmB6DRrnA9P39tX1JXyz+zUT/wte4yc/wDEmuf/AEfbV9TVrHY8ut8bPLP2gGK6V4WI6/2zj/yTuq8n1G7a2iRd21mGTg84r1f9oJgmkeF2YgAa0Dz/ANed1XjOpxPdSMyL8y469xXPW3PXyq3I79/8i3Z6k3GDu7cnpWjOyCMSKc+v+fSsXSNNkM/mXGFiHO31Nad8w3htyouMAY6VPQ9GpOLlZEF2GnnypCo2Ov8AStC3BVF2HLLwCelVYgs64UHgc5qaW4QwoiruK9HXgg0ESm2rIt3Mu1PmYhVPzb/U1VRuGK55OSR1P+FVpp2kcFgSB0HXn3oeVlssqoIJJOOoprQi/RFp7rbwXXcPuqRnFS2qbmIXJfrg/wAyf6VgQPLNKuCcZ4Y9B711OmWjLEWYNnsD/OpuOpaOxcjjSGDefvMM8Gn6fcIDlAxk7kjj8KsyWrSxqpUAf7NMhijtXO7Lv09cVGqZMGreZchjYREqFbnPPXNQhkSVpJcg8jYTwT60qSbnPzgj+E5xWbrkkhiwgOCcZ9DVvRGtOneVmW5tUeT5UCxq3zbicdP51PHqLRnaSpJHb+dcibs+WIpYztByGPIFNt7uRyRH85J7jFKO50yoRS2Oxe4SQhSMuO+cLikU/wAcDAIPTnP+NZ9oHaIKAEbGOvX8avRweV8qSEt1JA4A/pWpxStsiO5nMYLMUDPwB0Jp25lZV2BGAzucVKYkSRZSu5gMKznJA9QPT3pwLTZjw3XPHJP1NBN9NBEjXBYqGY9Mj7x+v9KUxyMx+4hPGR1I9ParUkBWJd5wBwFUZIqGSFrgh4ikXYEnP44qjNy0ImjAkwqu4Ud+apXSIWRuQX4ACdD7VPdym1JZ53c7eR1yadZMHQuPMB6/Oc4NJjV4q6IJbVYo4/NCq56RqB8vuadb2YjZPJGxXbgjrn3qtqN9AqSlmZ3UYMnv/hTNEna4dizYkx+7J5AHc4qWU4S5eY6W1t5IYQkUh8zq24jrVmxDHcwaQADBeRsjPeoFuFUCGNiGK/cYY3e5Pap4fuLmSEqow2Rkj8aErmSvbUcXRgwyr7Rgq4/rVSzLRuRHHkHoQcY9qsRBlkClAo6BScq49RUq2rCQE7YsdF3f0qrDWmhUkSR43wHjYf3m6VnhrgMi7XZAdx2c/iTW5PlnCl2KjjkcGqs8LBGfy9jDJAAyD78UnoWqtly2KE98N2BGRt46YzUFtdFpmjRPkbPJPSrDwrcLiRnDEZ+XpVP7GkDgB5iRzhuP/wBdLXoWpwtZlpIXeLcVKbTlmxwfpVILIkUj5wCf4DWnC7QWrqrs0g56f0rMub0GQF4wAeBg4xTb0Ji5PYzZdXCfuyDvU4LN3FRpqaPhZDlfQVNe6dDeRtKgEbNz6GsZ7FrVgWkVgRUam3NTmttTRAWRF2binOc9qhL4bAQrn8qFkSGLy94GBkHdwasfZo2t2kkmY5GUwcjNaWsYvTcqhwGcMMluACf1qtwsoaaTAc4IUYp0jqsu0jzNvUenvVadZJJVAQ+X79BQUn3NSWQDCoAAOCSOSPWsoRGO4ckKvzbhhs596sKZI4lVudozkiqF3dBNxU4PQZoFCOmjNFbjfGI2wQOCCMn8KruxVH89G6j5we3pWat2xi+U4BGevOasWl67RgSkEdCDTTJlG2wjyN9oAiGYzxnGM+9SbA8TRjPByQ1QvdMN8caAKvBx3p3mYiUAlWAz1zn2oM5KxC7Ozb3Y4HAGeKjdQbkqQeBlT15pyOGcNCpAPykn078VHPIkkwOGVl4wOKCGVL9PLX5WG0dcDrWWyspIwFzyMGtKcDlWfqc81n3TJGSIjnAzgUCb0sQGUsQhBYj7vtVed/l+719sVZeULDvAAz39DVGR2bPzAd+aDGR6P+zLn/ha1zuPP9jXP/o+2r6qr5W/Zl/5Ktc8/wDMGuD/AOR7avqmtY7HnVfjZ5T+0PAtxonhiJ/utrP/ALZ3VeZTQLbxDnBHG7GSa9Q/aBO3SfC59NZ/9s7qvJ5GmJG5geOh71lU3PTy/wDhv1/yAOWXliVJzx/FT90bkLcFc9lHYf1NV5W+zjDqW44I4xVYLEx85dwKjls5rM7nY07l4cqsLiMj+EnrVMny5CSQxPbP61CZ41GVQEEfjTIYmkOULYPJ4pDi0kTecGJw4yex4A98UkZaY/u2LqOp6A/QVZ0+xaaQLHH5uepPTNdBaWVvakLIAzg52kcLRcad3ZFLSrHLBwrMRyC3A/AV0EcblkITMa8tnpUiqMl8fL2z3p3m70YsSqdAOmKRcYL5hPMWU+X1PHWgM4CxlclvQVDtaMrsUsg5BzwKsJLKUchepxnHTNOw2ktiM2RBV2fG3sKq3JU+YJclenJ6Vaw4T/XcZ645pv2ZJ2DurlN3PzYzTsNzS1kc9LpxmkUI3yHj5TWxYaTFblcH/eJHJPpjtV+S0ij4hjOM8gHipGRPLwjFT39/8aFGxlOtKelyAwI0gVnVQOfLHzEfjTgEhJaWflQdijkZ96kWVBAscSsSeML2/wB40z7HbCRJTPumXPyKfkye596epCat7w6ORHU7dpc9eMmnxOZ3CAkgDoOB/n2pCj87slccBOn40sDhVUIqxsDk89f/AK9NMHoi/PFcPb4JWKMdGPAH4VWSA2sbg7QG5Mh6n8KuxSFEI5Zz1Y5O38apajC8ke9d4OeZNv8AnFNMw5r6GfdbbsBiwUAbQCvJqL7MfLlO5i3A+9mp7WIBD5YO9M5BGfxzTEjBaUTcd9qn+dBqnpZGXNpEmp7lUZQfeBHymtTR7AacSWjkO3AxSvMtuY0VDGGHDMcf/WNatlt2eaxd5GHO0Y8z6VLS3CrUnbXYqxNLLKwbDKuWwwyT9PWkgvDDLsRCCTnaB+hrSjgUSK0gPlE48phk59iOlTJaQQz5MuC3QOclfpQmEasV0ESMtHGX8pmbk9selV3lkSPaUG5CcZ71dMZVgnzMpzycAiqgWFFWOdZOSc89PxqiYtdSvBfIisCSsgPAx+fWp4pzMvCrz1wTnH4VHJp8Ybeu50B4xzirFtbQWjnyFc553E8fj6UFy5HsIuACiK45zuXn8/aq92u6R1Zzwo+Rhx9am3l5yVmUENzkfpmptRsy20IzLL97nqR6Zotcx0T1Mh7lAhjOVweucFf/AK1U7i0F1EH+cnOCen/661fsEJMm8srEZweRVKWNQ6Ro2I843N0BqdzVP+QoL8gWM7XB44P+NVpLd5XxHhecgDmtG6tZCS20P/u9vfNRxPKh3tbndtzkcYqht21RjXUA2vsznocKODVdJQgSIygKfTjmtW8XJwp2SDnDdaz7m28xSMjj+Idc0FrVakNwqRgEMAfXFRyFNh2Nwe/rTZInjCqQHGf4jijymlAGWGOelBLaW5VaYp3znjOcn6Vn3MYnBf5txPQVblszHJvBc++Mg08lQg+Yb89COlIltXvEqWyohCuuEx1Yc5oeWNCcOozwQaVXXcGbaCvfFVp0SWTJKkN1x/DTIu7krP5iEgjjqR1xUMUoJMRB29jn+dKsKRqyjIHbHNVzEqNknLCmK9yyjEp+6JyAcqTVaQMfL3gZPGM1E7yoNwQ7SM+lMikLDEi4J5B9KCbjruPk5bI6c9BVGWMK0fB5HX2qxdXCryTyfQ1VLbiu/O0Cgh6DFZAjgjduFZdyqAnaTkjj61oCNRuIcEN1PpWfe+Wqr833enPWmYM9N/Zi/wCSq3HOT/Ytxn/v/bV9V18p/swA/wDC1Lhj30W4/wDR9tX1ZWi2OGr8TPJv2jDjQfDJzjGsj/0kuq8mjkbapJVsDPNeq/tJ/wDIt+G+M/8AE5HH/bpc14sobZtTIXPOTWVTc9HA/wAN+v8AkWbq4Z5FfcQoGNvWoUZYwyxjluuOAKckTs/lp8zf7POK2LLRnmVfOCBOoVerH3NZXO9XZjNG4GSc56c81saLa7iFuQWXP3RwKfLYSGcoqDA4GK2LS3FsGaX5do5GOam92dcaUVG71Zo70t7IiMKgXqQMcelQRsJhgbvUYH9ayrm6lupNq/IvZRVq0YJIFRmbIznvmmilT5Vc17eNyASM7eVxUdwBLNG0/RSSMr0P9atRXaxx4lCjAwRjk1XnkXG+MNj3HIqrGcW07ssxTJb2+1YC+e7fzqtcXJYBSHAPXPaow7uhJHA5z1pZI12ruYtJ7jp7U0iGkndj4VeQ8KuAervV+VvIQEYbPQIM1Uj8vYrxMpkHUZqSN2LAvJgLwFNMxlqwimkS4LFcFuOe34VdjthPl5wu7PArK+1yFiPlVCevc1atblMSESFCevPAoJknuW3AjdxOU2478H9KgDxqFESx5buq5P8A9eqJL3UgCuX55IU4/GrUjrZDchAc8EDgVPMUlsl1NGL5VxPISccg9ab9oWFWMUCRduoJrn7vUwzAB9pzzgZJ9ifSoI71pphhmKqc/N0FJMv6s0rs6hCHXM8uecrk5qO6miZCX8wonXk7awNR1aOGLYgLyH7oJwAfcVz1x4gvBbNbyvuRzkj09vpT5kOGEclzHWrN5hZYHjRGz1ySTVaViIzG0oZ24HGAD6GuWsrya4uV8kYXPTP611qiOCKOec+ZIeQMDCj1+tVHUU6apsgi0q5edbi6n3Kn3QPmz+Hat9Q80xO4gKAEZl5H9BWLbXs9zdGPdiA8uHPYdq2bRhLbkrbho1GFDZ/8dHf6mkzCd7+8adsY7WInlA3325O7/CnXKAxpJFxDg4+bk+9QJIhhIl3x+qK4woqeD5lxtLKRkbTnI9xSRlzNalKzeAEnzmZ8Yyynn3qMwlZW2PkZzlen60XUbrMPJLjthV27frVGWG7Qqdu6IMS5Y5H4ehqzZavQs3d6YURVwpHX39Kz77VreGQQy7pztHmBW2hCf51BrJa6gLRsFA4H/wBeuHub025KTM2/o6Dv9KXNZnXTpxlG/U7S/wBUtPPSSxMpiZVDibaCrD+6B1Bq5baw13COd2znk9a8/a4EsI8iRQMYwOK1/Dm8FUJBIPQ9/apcrvQc6UeS76HaeZPIQygk46jr9KkewklVQ8u0nnmktIwpWQyBWx/q171beaaBjv2FH+6ScbTVnC5u/umXcySwqF3EKwAOBml89pIiiEAEdWGP1qSVxl2bY3GAQCDn39qz5LyNdy8AY6L0PvzSvYtRbWxJcwHaEZk3+rnk1Wlt43j3SoQVPQDOa0oniuIVwhLAjqtWYbZAhUoQ5OcscflRe5m6jitTmprfEJJ2K2cgk9R7Cs+SQTvsDiZ1+UlDjHtXY3WnQynH70sOh4xWOdHs7eZsJL5mckADr60GkKsJLXcxEiwSkchyeit0pk2luwU7omK5IznrW9cWqoUbJAxjA4FRLGgjUDczc4OcgUMlxvsc4bPZneuD32Gs64hMTERx7mbue1dWqSBHYqGUnrgcVQuYEdSTEmO9CJ5JHMSrKFVsEEHGRVUTRhyZBnJ78YrorqytzGC4dMnPy1mXWlrLGGtrpGGf+Wi7SaLkNNO1ihIyuDtwQOuD2qlcXipFtzwox1qW+tLq2GGi/d+qncDVAurfK/zFuRx92mJuxAzeeEabjbyOanjljbaCSw9jVdyhx0Ug889aZHchGJaMMP5VRlJ31JpznzBECAevFZdyoVcbcnHHpV17o8smVX0PQ1UuLhWQ7uD2oM5SPUv2YP8AkqU//YFuP/R9tX1ZXyd+y1K0vxVus8AaLcAD/tvbV9Y1otjhqfEzyf8AaKi87Q/DMY760P8A0kua8xtdFRwPOkJA5wOOPevVfj4SumeFioyf7Z6f9ud1XAROxtBgbTnG5h1rCruerl8b02/P/IbawRxA+VGojQEKoGMmrVmJgjFlBduBjtToSFQKgIkHJYjNNnlit5NzMfp6tWZ6NuiLEcWyYLuPmYzz0HtT9Rsk8tSZSMfM3uaqzakkVsiooLdjT9PuzLMDcDeQOQRkCqVilGS94gGmLI/8W48gdq1bO0igiQhAXPBz60s7mVttvtX9CKYJWjiIdRv7ZPSmkKUpSVrlmS3AAdsgt/DwahcoJNkZPAyd/GKqI8itiRsqx6E/ypw8njf8qjv3P+FIOVoe21kKhi2eiqMgUxhlVE0xEeOVUYx+NSyRxK4aA7mPALN0qlLbeW3EnuRmrI3L8MiICI0JjH8RHBqFoprosYhsUcHHFSWUbSRJuJTPTeOvviry2UhPJbHfIxmpbsZ81mU7a1jWBxIeAOXA6fQnvVzToUYZt43IUfecAZ+pq0kMJBjbG0HPHQe/NNLFT8vzDpktnFG5F3LQlRwTtysaj0HFR3iQzQmOWTcD3Cjis6+NyVyuWX1HU/hVBRfTSjPyrjHA7VLdjoVFWvexNLoKSt+7uCV9+P1pP7HmSIpbxDI+8zH+VaVimyMBpOB1J6H/ABrTjmTGQ+TjGOlPlRlKrNbao861HTrhGO1XY/3gOKxf7Kuri4VVilZs9gQK9gufJABIQjqAe5+neqqQhmTCkEnJXGc/l0pclmafXJqOxxNjpyWEJFwhdsY2KcBfxrUs3m1ABBDD1CKp4475rYvtJjl3Pu2qDknP9KbF9htMEo+WwqtnLN7YHQVZDqcy0WpXWwlspCqpFvkIUM/X3Iqaa9QKwDjaTtDSdW9fpUV5czEn5RI0ed2Bwv8A9euR1S8eVyGLqoBxk9/WpcrM0oUufc7BLgwSKxlRVj+8QQc+gxWxp96skfnSyqFfjawwM/h0ry+yaeSTl2kT/ar0Hw75oKq3RufmHyL/APXpqVx4iioo0bmWN5CqqrrjkDOc03ySzYgVkToSoOD9c1ZuAjsiPiRQeVKkk+wxTls5TtKYijGfk5FM49kZ5sluMx7Q75xuK4IFYWt+DFu0JXerf7K8mus+yMjB/PmwR8wBBFTSO0agsCYscEJn+VJjVScHeDPLYfBk9u5/eOcnGChBNdBZaQtgpBDF8ccdK6osJCQjAt1+8eKqyLcK53EbP9kgmp2KlWnP4mZ0VvNhTE7A9MgA4p6W04hkWQOzuc7uoq/NOsSYMa9MjjFUl1IbizoQDx8vSqRCcnsUboSBlJjfaoIO3oaz0hQShnVsnoBzn2rfmvISAIzyfyp6eXMdrJgd3IxQ1c1jOSWqKUEMEKllBDHnlv0qOV5zOsa/cU5GG7VauY7MxlS7Db0z0NZxlt45MbyTjgDn86dxKO7aNiJ2XO5UwvOCeaqXCwtIXF1sUdAoyW+lVby6lKjBUj0HFZTzTSXGEibGcbSKG7Dp0E9b2Na4v4UjCRAMpG1i3Bz9KpFtqAhOB6VYNgJGhkyVwenb8aVz5fmGQMQDgEnj8Kq3UuHLtEz7tHJyvEbcVClq0rMHIVVHBxzUNzqTCUkdB3zUttcNcxhlb5h8x/wqb6msoNIqy28hfCPhTzjPFUdsUc5DMQ2SMEcGtpnDsZifucFdvFZuow+ZIxVMqefSixj5FV4diZB+U9s1hTWcMqvuiUkHkEYP4GtpFfYVaQZU5w1JII239yR2FOxLS2OMvNFCncruAT91+QDWfPBNFH++GAP4lGRXXznaCAS2exqgGkj3p5YKnqO1O7OWdPzORnIc/I26q0hCp1OTxXSTWcEkjkx7WPPy1lz6f82VIY+jU7nPKm0ej/srKV+Kl3nvotx/6Pt6+tK+Uv2YYmj+K11kYB0a4x/3/tq+ra0WxxVPiPMfjuwWw8KFhkf210/7c7quBEitcKrDCAZI7Cu8+PQzp3hQf9Rr/wBs7qvPoY5Wd3K8Dpmsau562Xfw36/5FuFkdwPNIbdnbjpSXFlHcXIaZz14A71X3tDFvdQCD949az5NYie5wjB3XjOaz0PSjCT1ia8llHIpXy9mw8HOansjHG6+UCrJ1I5zVeC6kkgkEQTzSP3e4/Ln3qywlSNXKKH4yFNUkhPmWjZLI0cgQoSZAemcVRW2by5C05bkttY8irUSQyRlirAg7enJNQsAAd21EHQk02rkqTWhiyag8MncN2Y9QR0NMk1W5upiWJd29ByT9K2V06GWRTIGkVv4R0P41rWlhbwKfLgSNh2xyazaaLliktEjL06OR1VWjJkPJz0FXpoCsqb4wrHo/p+FWolnRmEaJCG/izj/ACae7xxn99mRh958YqkzmblKQ+OKRSrINxYYZpD0/CppXIQK8m/H3h0BqnNegRER7QnbHJFZd9qKoUBcAscZ6YpNmkaLkbsbFm5KoBweOtSrJkkM2Vzwc8/T6Vy76xbpbqCsj3OSD82AB/WlOsgIGMaqSSQM5AHpTvbQ0VBtHW7IYlDtwenLf0qq88cYOxd/0HAqlpF3JdlgwXbjua1tkSRDeoORkY71ZzSXI7PUyorxhIWZEbOQFfn9O1T73Kh42xKe3YVPMiSAFANoHI6k1XmT5xubZ7AYoHGSews8xgK7yzserJyadBeSKG8jfjqzN1qSK1dAS0kSqRgEc4qSO3iQZNwZGHZelApSVrWGac63Ds0olR29OdwqG9sVglNxDut2Ixub+gqwd4kHkl245RCBj61DqOxlEzu74GAuc0WM4X5tBI7Vp7cK77scqR3929azr3SLe4EzykBVGC8YyfwFXrUvNaMWiJbOFQtgfjSW9tPafKsRjhDZZovmZz6VLVxpyi3ZlOx0BInWOLZubnLZ4A/ka21jjt9kYkLrkE5OMn1ot5MySgyTdclSuCfp60XYeSRSi5XGAAvNFi7yk/eZYKTM8jxuxDjlsjj6VLuuFYYmLg8ENTIxIIFBcqw4Kkdaeiy7A6oMnqW7VRDfQPPljcKApJ6lhVjzCI2KsGz1CA/yqFpR9oVSxLEYA29DUzsViCs20gZJxg/hTE/Qay5kDYKcZxSP5eAZMAZ7Dk1XknY4AII7mqzsJJQ3ms208joMetSCptkzqHl+ZHVPU9qqXNhbSEbmk9c4HFaHmRgYYqT23tjNQyzxlWZSgGMHHrUitJbIw7q1eBz5aibPQr/hUE1yY1wIyGHrnI/Ctmd45lDr8+3jg8iszUruEhRuWQ9CO6/jQ3ZaG8OZnPXl3OxOehOQSetGnGV5NzEH0GP61tQRpdDYGiz23jFKlqYW3IEwfQ0opvU2nXduWw2PEx2OFAUfMQeR+NESxxTqySMv94Mc5qdI2VmxEORnIPWoETbON0JbAPJ6VpYwi73THX0s8gZMtyMgpVAN5j7LhsL0GRir73HmRmN0VMc5HUmq0yweUMtuYdeelMcb7WM2802NJwvmbmb7oHIp0cKQQyKAd69hxmppGjSPEcnOfTkU2F1VQm7JI78frSSKfPbVlJpXRmZcsykZVjgVNczD7MHk2jdyAvY1FOpfdu4XPUmq13Gm0qX3KOQQaohrmZHN5Mh3bc7hyR61n3SKiK9uTvH8NTZjA2bj14waiBjNyB0kXgEdKQMzJ3csCSu7uKbdzbAXKYyOgrUezilEqMACPmHvWTLDIqspUtgd6Rk7Mp3MZdt8fBIyDWdIMjcQRjrWnJkoBGTjsKptHIHw5GMUGTPQf2bc/wDC1Ziec6Nc/wDo+2r6jr5c/ZtOfirMvpo1z/6Ptq+o61jseZW+Nnlvx+cJpfhZmJAGs9v+vO6rgrGZzECcbMdz1rvfj/zpXhbP/QZ/9s7qvPbdNkEYGcDoetZ1Nz1MvV6T9f8AIy/E96zW4SMEJ3xXN2s3lSI/UAhjkcfQ12s1ktyn7zaVxg1lzeFl3q0c5Ebcke3pWNrM9SNWMI8oumal50pESkIDwK6m1QxjfKoeQ8bc8/hWVpelRWpXAZmB5JrZSSISgMf3mflAHStDOdRS+EjjVRcuTKFUfwdSD7VaJt5gFIwenzGo7iAykHK7s9h1+tPi00kFicE9wOaDOXLu2XYpIIlSMkbhwFHf2qwwAkDjYoPUd1/Gs2eMxsrM5BzjIrD1fUZi6oGYRdDt61E9CqeH9o9Do31G3EgQks/c44pyToRvJDL/ALVc1a63FbWzpBaKrsMea7bsHuQO2aW01AyyjOF28ZBzuoWht9XSvY6EeWz7VUc5yAP1rm9f02RrpD95Y+fu/eNdHaGPYOQ7E54NW5nwmRDnPUmnOKsYqq6crI84uVnyAUJOew6Va0vS7u7mRPLYqT8xIrvIIIAy74FLsfugVaZfLfaCqKP4QaixUsZJ6JFKx09baBUY7WB/OppYQQ23eSOmTVxSyR7lChieNw5NVWZllw24H0Hr71ojn1buxILeeIGQkRqemepqeKLeT9oVUJ555NFwsjIrEc8Z5qmLmZQ/y4I6D2+pqhqPMrl66eFUwpOMZPHSqs0aDYZg8aMAy9s+/wBKwNW1CTy2UBg+c5HArFS/uZZArOxAOBuJ/lU3tudMcP7l7nfebGkGYdr9jsPJ96zpgZH3HAQqScdapaeZY4wF6Duq5/SrxRJsRGfb6hRlqpNs5mlF6C6YhG7bGEdTuQOc/ia2Io5hE01uA+DnqVLGsWJpopMbWij/ALzcswHqaum5l3LKeR0Xdxgeg9frQrEODb5kX7dCiAvGI5T/AAjnH/AqrXc8keB5bEg5BY9KYxbfEgfY0vKqTkcVbkUNFiYRh+2cikF1HcQtN9nTyzGu4Z604CRYsMdx9BxVebzYVURsFX7pz/SltjNkqyBfcnINMHaw54dhDecd3T8ankwtuiXJ+YggYPWqt9fRKm1kU/ToKp3d7HKg+YYC84PWmy4wlKzZZfy3jZVdsjg47VUkYI2ImyVHLMflAqnHMGWQgvsA9elYmqTShDG7ZgJzgjmk3ZHTTp67m3Le6aYXFxqI89P+WYH3/ZTjj61k6jqkbuhtZslV5cnJY5rlrtoiAwYrL059KzblphJ+4YkYpXTRv7JR1udrBrLJIok+6x5I7D1rSEdre/PG+G9681s7nYWBY5brzXV+Hmd1Jdzz0NZ7OxnOMVqnZnQx2EibpvNWTHRB1FXoyd6mSPae5qkqlCu6XnPRetTx3s5t2xEQAcFT6Z61qlY5J8z3ZO8X70FSAvUn0q06ZiOEBOOHzWcxEhMioQc8sDSRzSQpjfucngUyOV7leWxaaTejkv0Ix2qnPZOku6covPGDit9ppBtd0xkenNQXNva3qguWWQe/WkUqkk9TnhAkdx8siscZ5qz9ndoQY04J5yelPi0+RLgtGpwO5q+6lUwVxnvnAoFUqroznLqF0lLvtYHj5QePwqI21uYirFlY889617gJvZyeTwM+vqapt5LEJIrOw53DpTE5aaGMluoj2yKcseq0k0EW4I3yDHH1+taBktllwqlc8Zzn6mqOpZ37DyuOw/rQxJSbsZTxukg2PlTwT6UksUqw5dsDnr1qUyiPG5AU6ZxSTN5sR28gDg96CJNmQ0ALGQSZPp/9ao70k4xgVZeMmVRyBjFV71hEduSwApGbO1/ZsUr8V589To1z/wCj7avqSvl79m/afipKy550a56/9d7avqGtY7HmV/jZ5d8fhnS/Cw551nt/153Ved3GI4VHzK2MYr0j47LvsfCi+us/+2V1Xm7TK7kqQTGNo3DjNZVdz1Mtu6bXn/kSWoWO3IIZTnBJ5zVmKaIMQXyoHAxzVVGckM5zk8L2qaN4hMykFh3NZ3O5x7l6C9iYBoAr4GCVGRU8c0ZBcOQ5/hwM1RQrlooyuw8llHepVighkSXexfGDgUxKCRZjYMTuZwFOeRUzzRhGy+Cfu+pqvbr5pDBWQk/ec9atSRKxUFhkH7w7fWnciSsytahwrCUqyHkHOTWNrGlTyJuiUkHkAcGtyCKMSFMseeorQZTaRAhGkB6EnNDVy1UlB3iebLp18XI8ltvQ8Vu6dotxEB9owjN0DDkV18MxlAJX5PQ96ljSOZi0itu6cgmptYKmIqPRlGzsCgQyPgqMDb3p8s8cBZcBmznaOa0FhQw5G5D7dapyWsKB05OeS2efpQl3MYtN3kMhnW4Yb0MaZ3YNVZ7qN7hg2SFb86sQwRxSBnlZfbHSrpt7Z4t6qGbOT6mm4l3UHsVLSQvMHVC+3oT2rUR02mRz8+eeM1UhuEhBRsKhPOBk1JeND9lLKzAE9utUiZu7SJJGEqZibBAyKrtblpFJYODwx7NTdMTdvYliMYwwxmn3QWNi0RLN/czwKDP4ZcqKs9jHK+JIlYDgBeKYmm20KD9xGCeQ5OSTV+2eWQ4kTbj+Jae6p84U/KOoIyaLD5pXtcp20Ozfhi69z0xTbOIpMzLIEY8dB/PvVmJSPkWPCY5dz2+lWDHDv3lmkK4AGMAU27AnujKvY1W7Q4eSTrtY8L9QKlQjzlA/eEnq3Cr9KsraRNP5wJyDkljwPwpbxzCqDYXB7no30qb3K5r2iiGSDy5I3jG4k9c/d+lW4pRK+zeGzxnGSKfanZCXn2JI3dDkjmr1qIsklst6bRmmiXpuioH2L5ci7W7bhmkkjdxtifY2O69q0GiVnwYkfvnPIqC6Q8qoKOTnnNKxne5yuq2U5hZkJLgcgjrXKn7RuK4YYPNekzoYCXBOWGC1Q/YlkCtMqr7nktSae51QryhE40Xn2eBMxjBHPPFYd/rjxyyRiMEnhRIMg+w9K7/VfDq3MbCH92SMZ6g15/rHhXWbSYn7K8yZ+9Gdwpc2tjWjWpyvzbmH5kNyXyghkJ5BPAPtQbWQKfKy/PGKc2n3kjbZbOYMvXKEZre0bSrpdpdGXnhTTLnWSW5lWmjylt0kZUZ7Cur06xeOIBsr2HvWnHZOoG9gCfX1qfypI3XzCp29MZqkrHM6zlsQwQMmRKXAPfHApzziNyoz5Z4z6mppkLsN2QuOKrSWD8vE5ZR26Yqrk6/aLEayEKUaPb0KkU7yUVsRoAVOST61Ggu4rcMIy316ioPtN0ZyDb8HoD0FIlJk5SVVJ35/2TyBVZBLGv8ArUyDn1xU+1nj/eHZnqBnmoGtww2xofdj0NAXsPXUdrY3DPcr3qld39y7nYyBB2JqyljG+Cqr8vJ9aryR28shHlvjJ+bbTuK8d0is80Nxk3JIbORg1nzyuGJj+79Ota11ZrHGDDgg9RjkVTDyFQhCpjpkd6CVK+qKDlTsDIcdQaS9mjaMAD514OehFSMRl9z8k85HFMDReWWkKtuGOO1Ipu5QuYvMhUR/nVGK3lilDnnB5960LgbowYCflz1qsI5EPmMR6ECmQ9EZ108jzHA5FUblXSfD8qema3mKR53EkjnkVk6jh1JwT3GKDO5237Oy7fipJgYH9jXX/o+1r6cr5k/Z3J/4WmwJ6aLdf+j7WvputY7Hm1/4jPNfjcN1t4SHTOtf+2V1Xnd9Z5H7krnPT1rvvj2xXTfCpXOf7Z7f9ed1XARMhVeB5i8tmsau56eXXVNtd/8AIkjiiCKJeJDx8vFTFlKvHGoBAwGHU1EXfCuqqTnkdadJBGZVIdkYjJIrM9FkdvDMvLnGD36mtFQZEKxLn0JHBpr7ZIRGshP6E1JFi3UgHc3UCmS53JLnMXlLkc/3vWnxcj5yNzenNJIY5NryLhlI4xnrTzDmQlWIGem3GaCObSzFi2wkncM+oHQ1LHLHgh1MvfoRTFsX84lhiPtuanta7SHR1JHSncPdHIIXKkTLHg/dJ61pqfkO2THGPSsaW3JAkXah7kdqnRYyoJlbdj7wGaRE0nsaETKArPIwH3cepqG4QeYyrNz1xjAqCMqARDncvYtnNSNdYIjETE9wB1p2BLl1RI1rHIoMjt5h75pUtliQgHqM7j1qYAkopjIUcZJ4/Co3DsrOqhlB6EUrkpylo2Rh4/KPzAkcH5eaQ4mQLukZT7YqUKs5yybV7gnFTxW+7IQJsHYnNFxydkV7e3eNMqDz/ePapXt1PMY4/iAHf61O7iBcYI29scVBBKWVnU5QnpnpTTISb1GzZjjAX5we3YUu870Vyoz/ALVSIApJDSPk8L2FRzwSNk+YplH3RjGKZas9CWUFThgW9vSltR85UqobqCTkYqOUyQW6mVRuxy3WsSfWo/sZJ3+aG49MfSjRlwpc6906RLQKsjFwd5/CoJ1aGdd6K6r0HpUGk3UtxbebJkDGcntVyKHzoWdgee+ev0pbGTXLJ3ESL9/uch888qMD8at28Cwq+5+X6VCtuDBuVySvAB7U8xulsoY8jqAOtMG7rQmZzDGQuZOe3ahllkQkYVx0J61DGBtGGbGeB71MhZC5OASfvUyGrMbkSqokbDL1JHFUr6VVJZCAMYIPf3qeYlCTgvGTz2waqajbyCDcqhh2FBrT5ebUpPNdu/8Aozeayru2YwQPXNZqeIZYZf3wI5wWX+orM1Rrhn2wCVDnpnjHtWS9tOXxhg2cktzUNrod6w9J6ux6Jb3sdycxtuf+63NXURZI/mQK1ctoQ8khpGbbjnHrWy80hj3RAmQn+L+VNK559WjFStEuNbQgZESHI5JFZM8KmZjPGAin5QueP8avxx3E6jzkZGHPWppohsIYnj1qkiYpRdjIkt4zsMcTE46DtUqRSRocp17elTo0wBEIQg92PArFu9cltZirBdoP1oehuqU56I0mEwVmRQyj2qoDLJkqqhwe/Wo7TVReuFLhU64HFSKuJGCElvUmknfYnk5HZobMZzg5QduTUjyIFXdy2MGqt1IImKhWLdcds+uaj8wzZ8xgr9MgUxOnfUkuJFk3GEhGA6A9aowmRo2KqC2elOEEiTArubcep7CpmB8xgg2EdWz196SFypLQpRSzuzGSM5BwVHSoLlHdgR8qCruxpSfnw/sOtNmjIVTLEfYDvRcjZ6GLNYbAX++T3B4xUBij2hDGRgcnPWtieAJGRHJ15xnFULphtKOvQfeouFygsEkbM0ILcdD6VFHC0gdiQQOwqa5aURo6YCY+8nOajjuvkJwcng5GAaYmrlG52Ru0kpHT5RWVJKjPtWRSpPTuKdrFxl24xGOma5mK4LX2Fzt5zSuXVpKMbo9b/Z8iEXxbmAOf+JNc/wDo+2r6ar5l/Z4cv8UjkdNFuhk9/wB/a19NVtHY8Wv8bPMfjunmWHhRfXWv/bO6rzi4tWExEPJfqfSvSvjiM2nhPJwP7ZJJ/wC3K7rgbQJKZZY3+Wsqu56eXNqm/X/IqWMckLlHdiT/ABYq9bxhmJmc7envUsKoWxtyfUnFQRxTPIcjZGDwQ2c1meg3zIlWDa2YsAA8AjORWikHmopXIfvk1V3xLKokBLY6+lXoZ4S22PLP2x2xTREuaxHErROWcsQpyc0+JpLl8SggdjnFWZSs8W0j5jycnNMtAsm5GUK2M4FMhtvUlikkUmIoOPuk85q2kRMYxhGPPSsae7eF1JQ7wSMj0q7b3Ukq/IxZ/SkVKk7Jln5mlKtGMDvimyhufmXHoarozed5c6Nhhj2q+YUWBwUO0Dgg8j6UGclZoLCNdpJIYHsB/WlkgSbL2+dw4znFR2gjSEeWjKR/GTnNWQxdNufmHBbpVWE007kEMgVWQ4HPOTnJpIrqF5TCGAI6ALUE1pIhZllIjZuh5zVm3VIQgmVUPSgp8q1Mm8e5hkI2eYh6sPSptOu5C+5EZFXrW1uj37ZArE+3FRXkRKqoCbD2XipSZTrcy5WhVZbhsSFRxwO5qLyvInHlxqT9MUNarG4Eancozx0p8ssiklUZzjv0FUZrTREqeaZsh8gjAQjpRLGFdZGILHg5qpBeTRybnfI/iXH3asvO0vCqgjPQ96ZMriXkgeJxkN6qKxIdMt55HZyQ+ckMuK1nCLsVNpOfmHTNWpnEcRKRruYYHtSZSk6asiKwtooo/LDbgexPFXY0IYr8u30xmqAjaGDczs8g5C+vtUcV9cyxOFi8s9AT0FJtEuLlrc2flCsqNnnoRSFGdMktx1qnC0scRM7ZPUbVxUtpdmbJZWx29KdhcjWxEkEvlFgzBwcgE9frTojIcl1ORyc9KbLPPJdBGjBiJ646VPIoLOCevTBpjk+jI0uFklCbvmHJGOtF78gJKPtI7f54qNYBBydm8c/NyaklVjkozHPvxQLTdGZcW++LciBsjlT1rJ+xSyyECLHf5RwBXQSW0kqbvl5464p4VVZYgBkDk7qVtTRVGtEV4hBBFtUAuV5IHFJBdoihF+ckkZA4HtVuFBHG24b/AE4wDVVhvBKeXCgPRRg0yEua5Fd3b+cAGIXvipZXldvmcCMjvS3sPmR5QgtgcjvRCpeNFdWcqP4jjmi43ZK6Of1OKdVJU5UdGVulcreQytMWO5ie+a9E8mMM5eMLEeo3d6glsoZUVoIeT1DdaTVzpp4nk6HHaZaS+aW+dVHU+ldDBcgMAIwVPGepPvUhs0VSZtw9gaRrZEEYlIii6j3FCjyoJ1FN3Y2ZbqeTHlAc9QOKjuISqgMgLAZyDV5y8uPJZWjX0NRKjOpZkKvnGDzTMeZ2MaZZnCsvyduRU7qIoFLsGbGc1ryhYYG3J1Gck8Vyup3aEkggLjtSN6cfaovPfwIihpFDHvjmoLy9HlGRW5HG4HIrkL263FufpzUdjfSNKEJ+VuME9ai5o8PGL5i9qGoyjliAO2D1qOx1gXAEdyueMcd6hv7GUkEDKmiz0z7OfMkGTjgU0mRUVPl8zXCxmEBEypPA3Yqg6FDllORnI7U0z+RKGZTg9QvQU+ImVT5MgK9weuKo45QcWYup2K3CkkhV5IwayrPSkiDt3HVq6W4UM4En3R0FUG3KkrYyvYe1Mzk7rc7H9n1dnxWdQcqNGusH/tva19MV80/s/wC3/hapwxJ/sW6zkf8ATe1r6WrWOx5dfSbPMvjr/wAeHhXH/QZP/pFdVwiL/o3DBD37V3fx2x9h8KZ/6DX/ALZ3VcAjeZkzAhVbhcdayq7np5f/AA36/wCReghkdVkwpIXJHal3rHKWbCoOMYpkSyKrGOXk9PYe1SwqG4Ch5AM5JrNHffuPDqF3Rp8xODn0qeGL9550BTcDim2wkOBIF2nkg1ODE25IjjByEA61SJuxEhkV90zAk8kZ6j2p9zL5SKG24Pp1HtUaCOQZd2J3Djb92rd2qeWML8yfxEUWJbTauLBbI8IYouTz857Vat4V3bYtuP8AZHFZtpIvl43Fuelaqz+SoLlVOOlDREm9htyoeWMKxKr1IxzUhIMRK5z0wRWbO53HagOTkEdjVlJ/urIGz146UxSi7IdEmGJYHPTg8VXLyPI3lHBXge9aKPDLDgYBPt3rOuEEUqCPAweuM0FwkupetpYxEisevUjnn3qcFWjIHX+F1GaqsyLGFjjYFhkgDg1LDMFiVdm0Edh0oMXrqidUWNQScjvx1pzkFAcYRe+elVRGjPl2LY4xmnEFSQflQ+nelcBt3MuzzI3Uj60yz1GN2KDG/uQOKbKkLLgMM+npSQRIo2q3A9Rg0XLvHlNKJEdydnJHLY61Wm+STZHgA9jShWTkHr1JNRNgbRIQX67x6Uama3uNhtG3u8zE8cVagiAyF3HFIsoRMFztPAzzmiIsi7ty/N68EUWYNt7liQIuPkO88bic4qrMuD8rqHPbpUzSBwrttGenPNQy8suxTyeSRUhHTQmM37pgFXHT1qtYKjXJiA2rjOBxzU8kcgjwrhfQgA0scYjIfC47lupq0yk+XQtTbYk+XJ57UwNKysQAqjuRSeaXI9KGcEhQ2Rn160zO/ceiK8RMu0H6ZxTyi7QVVGA98VFM52kpjKd6Zl2wFYhT1zQHmIFKh2ZQFz1ByKrTsGZAgDMT0A7Vanl8s4J4PUVAZflVVCk9zjFARlbUS5hkkkzHJGUVeQRjBrKMUpn2ErgnOQa1C0SE72BP8W7jis28mt0mBUksvIAFBvCTeli/LbYgVVJ9stWexuIZVLklO+TTvtEt1gRt5RX1PFSXkMkkCpLKCy88DrQEXZ2ZLFCtwNwJAz3FOkMqRfO+VHAx1PtUGn3KW6sZGcrnAHvTZrtTIWUMOeABTsS03JozbiL962d53cjjNSzWUhjBUAcdSelSxalvkCyLux+dLcyRm5Ys7qp/hHINBalJOxHbQsEPXaepFLNEzOpWUKBwcmnvMdg+zA7fXNZsgluJSwkAYfw54NISTk7stX8H2iEqrhTjG7PWuV1DTnI2oQz/AOzya623hjeBUk5JOT83Sq0lvCiFdys3txSauVTrODsjzq40i9djtjxnuan07R1hO66f5vbtXZFxGhFxsJOQCp4x2qncW37rep3g96nlLlVlLcr7CIw0ZBT370vnAwFdoOeDgcipYp4pYdrgqQdoYdzVW5RjgYbg5BHGfrVmD10My7ghabO4KTwR3xUAiiiBa3VdoHY1a1CUM+SmVHDc81nmREyrj5W5BxxQDV1qNnKzSBuAR94Gs6S4TEiv8qHoQepq1MVMYc7i2eMVU1BI/IbnHfNBnK19DtfgAR/wtZgvT+xbr/0fa19LV8y/s8nPxTbnP/Eluv8A0fa19NVrHY8uv/EZ5j8dhmx8KAdf7ZP/AKRXVcJCiPNmXcGVdv4etd78dG22XhNvTWv/AGzuq4ayYyyS+aAI88Gsqu56WX6U2/P/ACHRGOY7EDLzjcBUqp5U4j2HOOv9aicSK5EY2hfuj1oXM0RfdmXue59qzPQstyzIjqzSDc4I456/Sp7SaEcynD/WobFlZsSO2U6CrMVvGJvMkQYHXIqtiW1sy1DGFYZJx1561NfTLFFt2lgeoJqo0kkrgpjCng1Ms/zrHIA5x1pmfL1KvnKY02gIx4BFV9VXV7i4sX0i7h8lHKzxyjO8fWtC5gSVdsR5ByVqWzjCIWbk5+Vc9KCna2g4xY+UM2W5POCDVtExbgMo4GSSeagh8yTLPtOBkAdarXt87qDtKY9aDJxc7F8mML8rNtHP/wBamTSGRPlQD0x0JrOgu3ZhgkK3XtWn5oMYZNqY65oCceUj+2MgG8E9mGOhpUu/O4zzjgCqlzdeVchQvyk8nHWr8bDYpjUHscjkUXE7LVoS3jZW3BQoJ5J71V1K7KkAPn0z2rTDr5bBhg/WuY14fMyMCf7pqWXRalLUhm1IBmZ2OAcAHg0+LVlKZVs1yV2LhJTtRmHQE81Lp9nfTyYVHVe/OBU8yPQlTha7O+sbpr1PklYeo7VoAxojK7Bj3OKxdNhjs4USSUBzw2P4a1PM2KSNzL2461pe55tRe9psMeQh1CDO0dW7CrGTs4YbR3681n/by1xGFiLZ43dAK1EkCx5kALDn5fSghpxsEQMkZC5AHqO9OZxGucE44HFQwyBhvRCeeetPZwV2xn6HFQDQsMpb5pdyAdulTllmQgHcuPWqpDykByD9QKfHGoPI49mxTTJempWSfyiEdj5fbFPEkQB2HI69c1UvI5XkY4OwdPXNO0/YVY5IAOMdKo0lFWuXPPDptGW9RUiPtIHJGO/QVGkqhtqI2QOpHFHnF+JYyqnvnBpmbXQWV9xwWXr1z0poiPLBsN6A53U1nKgYQgE45GeKR7lIyx7gdMUCSZGRFNcKz4ZwcEUl3NGh2oiljxUM0oYGZQqlepxgkVXF5G0m3cxc/d4zQbqL+IcjyNtyjEZwfarfmRy5TCYUYIas6e5kVwrRlcDhieTUEFzkuqRsT6daewuRvU0zFGoZFJJYZxxgVGVe3QyN91R0Heo7cyGdpJdwIH3T2qaWSIR+bIDt9KVwfMmupQTUFkc7YQo9QverD2wkjGHO0kHkUltdwvcBETLnsBwKttEHlRnYoQfu+tASvF6aFZpY4hsADHPJ6A1RuJUVgFhGe57VPM8cUzov7xicYPaobhIokBmIGRkAc0FJcrKEouDNuQHaepXoKmRJn/12Qo9am2lrdiJQFxwvQmi0aSW2USRtE5Gduc7fx70ipTvuilJF5m5IVT6nmnC3ZIepBA4z0qK5LQTkBypPQD0p8jpNCoRirA/eagmSbS7GfJd7XdflcqeAOgNI1wyW5d2DE9hUs6QIjbmUse9ZbxtGT5Kl1PY96YWUkQ3BM0bADJ65AxiqcpZovLfaQfvHuKuCR2Rl8lo2A5wKzlVmlZy5VVz1PWglroMuCVC+WVZRwazbtwbYlhxnlatyuyyKN2Fas+8IEbfNzQZvyO7/AGdhj4pv2/4kt1/6Pta+nK+YP2c33/FWXnpo1z/6Ptq+n61jseVX/iM8w+PP/IP8Kf8AYa/9s7quNIQwjyyQMAnbXZ/Hb/jw8Kf9hr/2yuq4OIMhZgSVx26Gsqu56WXL92/X/Inw848wYHYDNWRAMYBCKTklO9VY4zNwMhcjjNW+ShjRgoX1rM7pO2gwK8Z3xKG9/SrsLllDSsx9iOKr26mMSbnDoecCjaJA5LMrdAAcUwTuacaJBAzhVXd94jkVWZlmjCJgEngjtTIA3kmNuA3vxRDbxKRkk7TwAe9NInRassr+4dhvIDcAkZ5pUZVcdSDQ8m7hTjIqtKpV8ksFXsO/1piTuaMBAfzBkH0zRJJHcMUdVLE8dqoi5Vbbblcmi0mUEM527e3XNJolx6k8WnnzXw5ABzg85qO4aOKcKXXHde9Xo7gsjMi8njA6ms+aAhvMkVcHnk5IqQi3L4h0jNOpdRvAHA4osZmijPmgYPQE9KsWsULICvDdduKa8MbzAyQuuD1p3E5RvZoaZiykZO/OR2p0cPmDdOVZSPuk9KmljWNMRhdvueaqi3ebEivweoxQCcX5En2a3JIXZgDj60xQI+GhwD0LHOPwqaHKRlZAoHY5qO7njiXpvIHoOaVhqLbsQx6RbxSzzW5m3zNubL8Zpf8AS1IWN0CqMYJ61E2qbIshcEc4AHSm2V9Bdychi6888DNNF8k1q9jVt48oBNgtjJGOlWYfLI3Bs59e1Zhuo1cs0e0njO7rVq1kQjd6j7uckUMwlF2LaruiK7iR+VVZm+zoECkDP3s5oe6t4yAM7iehbFVp38wFl2MhOB2FJBBPqTxzsLkEgMCOCAcirSvudnHBIxlu1ZcZaFuikZzhRmnpfMpIOYyew5NUi+S+xqxOrDHLHoT0FSCNG69vXFZgkMqKVwOOTnk/WnGSWKAqcsT+NFjNwv1LUqRtjaVwOSc96rEo0wfcdw7YqaB28oZTnHzLUTlxIzNs2Y4AGaoWuw59/l5JYNngscfhUXlyyJ+8/wBZ1G1sgVn39xJJgLyo/hHFJbGdID5mRn7u480jRQstyyXKnDk7OnoQarW5hNwNjYx7Z/OryKZbVS0YL9s8YqokZjDSmNcg4685ouNSVmie4WOQbXGXA6kcVDHGY33fN07CoWnErSI8bqAeuDTYpIkUobhsk4wDRcSRe8zzgEy0bdyR1qF4oA2yeRWI6cVXaLKgySkIOcn7xqpcr8ytBGZADjJ70yorsy55It5BIsq7DwABVpLlihZMOy8DcOKrR2wZA7JuIHCnoKhdfLYRykbT0A9KBO0iSZ2L7ljBfPJHY1VnhLShpZCnU4PP5VZMttGztGW+Ud6gj/f5yxbPOD2oGrrUpOILaXks5PI5xzU9peCSR84/A5xU93awRosjgFu5rLmeNI3FrHjJzn3pFrlmifV5g3DqOBwOlZcrs0SMinjpnrVjzZTtR1XzCe4qyY9yFJmAwP4etLqP4FYyomPkncQSx9OlRzs2B5LDP8RH+FWZkiUlXJVQfpUOE3hYjuBH3h3FMUmnqVbycQgfOCSPxrOkAlEnyjd71Zu0G9j8oGcY96rhozGEZvmznIp3Zk9NUZs6uqLkD5T0rPuZo2ZwOSexrWvWQZBwwIx71jSxAnLYBzxQZOeh3v7OQI+LE5xgf2Nc4/7/ANtX1BXzB+zn/wAlYm5J/wCJNc/+j7avp+tY7HlVtZs8w+PIJ07wqFOD/bPX/tzuq8+hRoo+ZMrnAB716f8AGXR9V1fTNBOiabLqMtnqYuJYYpYo28v7NPHkGR1U/NIvGc815/HoHizcfM8GasR2H2qx4/8AJis6kW3od2CrQpwak+oyK5WIfMpOVyParUeLgAsT93nFQHQvFxYZ8GapjP8Az9WP/wAkVZh0nxZG2P8AhC9W2Y5AurHr/wCBFRyS7HZLE0d1IXykjVQSeOmKdtLqHDZx2ps2m+LnGE8E6oo9ftdjn/0opY9K8Vom3/hDNY/8CrH/AOSKOWXYFiaVviJlGfuY6ZPPAolwgwpwP60jab4oK4PgrWf/AAKsR/7cUjab4pKEDwXq5PbNzY8f+TFVyvsT9ZpN/ETW+8n52HsTUki7RucFn7jORVRNO8WIQV8G6wDnn/SrE5/8mKlt7TxaikS+DtZb6XNh/wDJFHK+wniKSd1IkcosCkJub0PNRxQh2DSEjJAA7U5rHxMZAy+CtaBxz/pVhz/5M04WnicMCPBetAdx9psP/kmk4yF9Zp23JFjcRuQTHjpjvTYoPOOJGPTAJPepUi8TKSD4L1wqf+nqw/8Akmqq2PihWYf8IZrRUnP/AB9WOR/5M0uWQvrFN/aL8MYt/wB2HUhR8xB5ojBlYknKL0Gazv7P8UKML4L1ogjnN3Y8/wDkxUcGn+LouP8AhDdY2HqPtVjz/wCTFHJLsHtqb+0jXmG5MbRnGc1BG8gRgkgzjpxxVV7TxaZBt8GawqAYx9psef8AyZpEsvFQLA+CtXCN1AubHJ/8mKOV9hKtTX2h8Ry58z94f72eBTrq0jmZd4I5/hbnFQnT/FUSlbXwdrQU9nubDj/yYqRLXxWkYx4N1ppPVrmwx/6U0ODY3iYJ3UirPo8Yl5Z8damt7GGPP3QAevTFSC38WZGfBWrkd/8AS7H/AOSKZc6d4mmyP+EK1kKe32mw/P8A4+KPZtbDeKi1ZzHuI550aPaVXgNikim8ic4fdkc5GAKrx6T4mij8tfBmtlR0zeWP/wAkVOtl4oVsjwTrB453XVief/Amjll2D6zTWnMVml86Te7LuzwAcg1Mty7MUaMMOnynjFMbTPFPmbo/A+qDPUG5sf8A5Ip0en+Kw+W8FasoH925sTn/AMmaOWXYbxNJ9S1DBHjzTAWUHuSOaZeL5jKE2LjjIHSmG18XAHZ4M1cNn/n5scY/8CaGs/FcgUSeC9XwP7txYc/+TNLkkTHEU9+YtRQSFSnmqPTvUnmvGjBQXKdT6mqP2LxQuNvgrWSM5Obqx/8Akmnvb+KmH/Ij6sD7Xdj/APJFXyvsJ16berJxO4HIPP3iBwKiheWNsSMQrchz0x/jUf2bxXt2/wDCE6uR6m7sf/kiobnT/F0yqP8AhDtXAB6fabHH/pTQk+xSr0trl+JkuMlWHBOTjB/Co2LtGQ2zcG+Xd396rQ2HitISv/CGawGPdbmw/wDkilj0/wATqfm8Ga2R3/0ux5/8mafKyHWpJ6SJnndUXADkMPumi5kuXdFGAvXHqKcbTxGYgp8Ea0SDkYubAY/8maie08VPIWPgzWSMdDc2HH/kzS5GCxFPui1KQsZ3FvmGCMVVS0iVgdoLDn/65qMWPi4SceD9ZKehubD/AOSalay8T4A/4QvWm9SbmwH/ALc0KDBYiC+0SbQmWZN+PQfpUoCeVnp6KoqnJaeLQpEPg3WOf71zY8f+TNNsbLxbBCRN4O1mRz3F1Y4/9KKOV9hutTt8QebIHClyFzjBpXTam6YgYHGKgm03xdLc7z4N1cJ2X7TY/wDyRVgWXiraFfwTqzL/ANfNjn/0op8rKeIpLaRVaIPEDLgfjyRTIfK6QvjHTNTT6V4plYH/AIQvWAfa6seP/Jimpo/idMlfBOsZ/wCvqx/+SKOVlPE0rfEUboy87jlKdFFGYhvbBJ/SrEukeL3A2+DtWH1ubE/+3FRDw/4pPL+DdYJ/6+rH/wCSKOVg8TSas5EBswJt5mVvYdqjuZIhKSpAbHUVaXQvF4358G6r8x/5+bHp/wCBFQS+GPFcinPg/Vyc5H+lWP8A8kUcrF9YpdZGXLIWbBhLA9WzT0VU5VcFRitCLw74yjUj/hDtTbgjm6seP/JiqNx4W8eyMNnhC+H1vLL/AOP0nFlPEUpK3MirdrHIFBAz16VkSRhGwQBk8cdK1n8HfEA8/wDCJXuf+vyz/wDj9OPgzx05Jk8IX/TAC3llx/5HoSfY55VYR2kcnqERD7gM76zpJQY/mALL1BrsJfAPj1uB4Tvse95Z/wDx+qFx8MvH0kjMnhK7GR/z+2fP/kanysiVWDW5sfs2uH+K85H/AEBrn/0fbV9SV89/AXwH4q8O/EC41LX9Ek0+yOmTW6yPcQSZkaWFgAI5GPRG5xjivoStY7HBVacm0cD8ZPFuq+END0q50NbE3N5qAtGN5E8qKnkyyEhVdDnMYHXua8vPxe8bg43eGifbTp//AJJrsv2kf+Rd8NY/6DQ/9JLmvNNEi0nTPhD478U3PhvQNX1aw1NFhfVLBLgbTDaDaScNj52OARyayk5OfLF20KioqHNJX1Ng/GDxso+ZvDYP/YOnP/tzSD4weOOd3/CNj0/4l0/P/kxWr8L7bw94i8W6rouseC/B5W3soLyCVPDv2CWQP979xNucqCcbxgH8a8c0B2/4RvTQud4tIiM98IOKzqOpBfF+BpSVOo7cv4np6/GDxser+GgOh/4l0/8A8kU//hbvjYJuL+Gx7HTZ/wD5JrzP7bC/AcbHB28dD3H1FR/2pFkMSfMxznopHWsfbVO5t7Gn2PT3+LvjdRy3hweudNnGP/JmoW+MvjRM7n8MqB66fPz/AOTFeXS37yEkyqFPoM8VCLkTMyxOpJ53sQMH8OaftqncPYU+x6PefHfxnBMYYk8OzS4yFXTpwcf+BHH41SP7Qfjfy3dLfwywXoPsc+T6/wDLevLbi5is5ZVEjTzsd0hHA9s+3tWbfXbTHmRA/wDAfuJ+o5rSM5vqQ6cF0PYf+Gh/GyXHlz2vh1E/vixnP448/pUqftA+NmlkUQeG9q9GFjPg+n/LevApryVoo0kmyij5cfw/jTre5Cs3mqQ7DHHRvTFXzT7kckOx7hb/ALRfjmaUx/YvDQcfMFFpMSy9yP3/ACR6VoTfH3xqsCzxReG5IGH3vsE4wfQj7RxXgL20lzBFJFnzIxuQN3A6irWnas4YOBG7sAHWX/lp/wDX96HKXRjUILdHuFx+0F41S18+G38PSqOXxYTjaPX/AI+KuaN8dfGepxblHhpJAMsgsJmwP/AgfyrwuWaJllWJEKS4DIjFXTPUr68ZqCC/NlKZ0LxzKSoLJx7Z+o4I/EVPPOxXs6d9j6QT4u+NWba0vhlT2zp0/P8A5M1OvxU8bsARL4awf+obP/8AJNeRWGpRalFGC+GcZXb69x9RWtG81qBuY+XjIccg/UdvqKzdWouptGhSfQ9J/wCFpeONgPm+Gc5xj+zZ/wD5JqUfE3xxjLTeGgP+wZOf/bmuA88MgdGO4+nKt+NWIJyu05BRvTtU+3qdyvq1Lsdr/wALQ8ag/NceGwD0P9lz/wDyTSP8UPG6gnzvDZx/1DJ//kmuQlJYELznkHsKRWOcKuMjv60vrFTuP6tS7HYJ8UfGzKGE/hvB/wCoZP8A/JNSD4meNyT/AKR4a/8ABZPz/wCTNcYFMZLDnOOP51ZA3rwOV7Yo9vU7h9WpdvzOrPxM8bYyLjw3j/sFz/8AyTTB8TvG/P77w3x/1DJ//kmuWjUncpOQO/qKWUFYiRg8d6X1ip3D6tS7HTD4oeNzn994b/8ABZP/APJNPT4m+N2GfP8ADYA6/wDEsn4/8ma5BFaRyRkY4xU0bdQFA57Ue3qdx/VaVtvzOqHxM8bn/l48Nf8Agsn/APkmkHxN8cc5n8NcccaZOT/6U1zDjDbcdRn6VEX8tiWBAJ7d6ft6ncX1Wl2/M6z/AIWb436ifw2f+4ZP/wDJNRt8UfG4IHneGzn/AKhk/wD8k1zff5KjkXLBccfqKPrE+4fVqXb8zqF+KPjhiMzeGhn/AKhs/wD8k04/E/xwOs3hsen/ABLJ+f8AyZrlEXZJsbnjK8U5lJzxR7ep3D6tS7fmdP8A8LR8b54m8Nn/ALhk/wD8k0n/AAtPxwPvTeGR/wBw2c/+3NcjOqmQLyTweOlRM5DHYAAD26Ue3qdw+rUu35nZ/wDC0vHP/PTw39Tps4/9uaiPxX8cgkb/AA1x6abP/wDJFcRcX+WZI2zj7x6//WrMuNSZAu11QNxuY4H4etNV59yXQpLoekv8WfG6kZk8NbfX+zZ//kmq03xl8Ywk+bP4YX0zp03P4faa8qvdakLiKxR5JGH+tk/hHrjpn0FZY1YRyMzNAGXlVBZmJ7kn2q1VqPqZujTXQ9fuPjn4tgjz5vhx5TwsSabOWYnoB/pNV7v48eNbW2MkkfhvzAuTGLCf8s/aK8WuNVlu70tJELhEUqvOxFPduevHFY99qZklKxSOyx8sFJKnHp7A4q1Kp3M3Cmuh7t/w0H42EZeSDwyoHBxZzElu4A8/mpG/aA8Zxttnj8NI4XLL9hmJT2OLivn8PLHB58pPm9FJ+6n/ANeoZJnjh5cmST5iW7D3q7y7kckOx71J+0f4wjmVGi8NbW/i+xT/AMvPq1B+0H4xkJJHhhY1OGY2U5wfQ4uK+dVVkcEhix6E8HJ9BTjEqcAFJF537+ntTbl3BRj1R9H/APC+/GjDMMGgyD+8NNnC/mbgU5Pjz40xmeLw/EP7x06cj8xcV8822o3kZKC6kEY4LY/nWtFeSTOiQXbCRuvmAFKiUprqUoU30PfIvjX40lxsbwyQemNPn5/8mKlb4yeNwM48OEZxkadPx/5MV4SjyW77ZZJcdCNwwp9scYrTttWmt22THdGBjevOPYj+tR7Sp3LVOn2PYv8AhcvjU4w3ho55/wCQdP8A/JFIfjN44yAB4bJ/7B8/H/kxXlsV6kjAqeccY9K0I5IpYxtIYnjJ7VPtp9x+xp9jvz8afG4BJHhrA7/2fP8A/JFC/GnxuSQy+G1I9dPn/wDkivPlyck464yaiZsMyuxVgOCaXtp9wdGn2PePhH8SvEXirxpJpGuJpH2b+z5rpWs7aSJwySQqAS0rggiU9uw5r2avmX9nk/8AF1HGOP7Guv8A0fa19NV10pOUU2cdRKMmkeRftJ/8i54bz/0GR/6SXNedeENV8JyeAfFnhTxle6nZR6pqIm3WdjPKxjENthldYnX70RGDzwa779qGVoPCPh6VU3ldZU7c4z/otzXzpc62p8sooZGJyQ4x06H3rKpJxqXXY2pxU4Wfc958N+LfhtoXiSTXZ/EuvaprBs109Li/0qcGK3U7girHbIoGRnJBPv1rwPT70w6Lp9u/yyC3jUo3UEIBz+XSsi/1yNgfMZt3ZFOP5VhyXAPJQiRjwCO3oPSpk3UWqLjFU9mdJfW8kpaa3lIY5JKvhWI9v8Kyhezo2dxdieQen/AaqWxaQF5kbylG1Vifac+554p7SW0h2wxywoMEAP5mD65470lGxSkXoZXueSpYA8oW2j8fWpZ7sRnYtssmDzs/hqqkAmUuzmOUHowOHHqD2NH2O4PmRrIzBB8y52nb7EdaWnUp3sQNeQoisiF5mYnC9ue/pTV1B1l3xwrGXBLl/m3D+9z71o2ekOoE0cBnCDc8RkBUg8ZyDkGpnttoaOCJ4Y0f54pVztPofb2o5kieVsxY0MrtGU2vuJAH3jnqAKguLVYlidFZ42AJVgQVPeure0hngVhCbXDhQU/h9gT1Hep7y326aiXKF8OcMo5XOMj6Z5/Gl7Sxahc5ax863aSCMNvwcK3Ix2x79arWtuS5VtoLZUFuCPqPSupW3gicpMN0kDcsTjeh7E9jjv7VNq2kwukkcY8i9hXBBH4qw9QR6fWqUxOnfRGDp6xzNCjFovKYkoRna3qp75q9qdrFPIG3ERvjeM8AjuP/AK9Nkgms445ZVTbOgZCR/rO2M9h1Gav2lm0sYSNv3wG5I353jup9Tj86UnbUcFdanN29vcQtsidw7fMmOASDwwrs/D+uXM0J+1J5qocSbPvxkd8d6x7/AAbiDAwi/MnHK/4ippHa0mjvUU/ZZf3UrIcZI6HHb0zUyfMio+6d7YvDNbmS2kRgwzxyD9R/nFV7ppLaZfLBEFxwRn7rGs7TzsVZ7VgS/Q4+Vwf4W/x9asazOX8PzuhxLG4ZCP4SGGKyaN4m9azb1D8ZBwQfWpB8zjjIJy3PrVLT7gXUYnC7d4G5fRhWokQUKc8E85qSxyKdrIQMj+XY09NyqHA5I5x3pEJbcehxirsChFwx/wDr0h2KaxhOpzxgU9kwApUc96mcFTgDGDn8KbHlyQeMHFJAVpEYE7FORyR60IDnOOO4q4FJG7sOBTANw54NMroQyfcU5+ZG6e1OEW8AMKdMNysqjGc8VLGGJU8bgRkUE2YgRRDkDPNRxoWZzxzgfjVlkMiHkrQkZXpt5NICkUIGTgsjc/Q013OWXA71ayQCWXI55FV7hMSLgAAgL+NMRmzZ+2FP4I493HHfGKx7243znzG2xKobAyAecD8P1rSuV2zXbH7uFXr2zXOFf7VuYwJWjxmQ4754VfwH86pIhvUluLhVhLuNlvGDwP4j/X+VYMt7Ahlu75nllPyRQIfu+2e3P51e1ad/N+zMqhIPvGP+Ijso9P8A6/esaaM24inlVGl4aOLGQOOuO7H3q4x7mblcpTy3UzO037pJSSyx8Fh0AGeQB0z71HqimCCOJEWFCcNFxuY+/oPrWiPKsoRc3jiabq2ez9cH2Uc/WseFLq7vobnyyySSjZkHLkHP+fSto2ZhJ2K2prNAhhISN5HKvIScnHX2AHtUNrpsh3Hb5adtx+YjPp6+1bT2QgumZHNxefM00xG5I88lUz1Iz19asRI4t42t4wBgqrNySB95vc5OKpytsQld3ZkXsSROEEYdkHYcsx/vH0psGmuhFxeBpecmNTyD7+3tWpFaKkxXgXchwrdRGO+atvHG5ENuAn/PSeRuAvc++fWpcrFKBy80kmZTHGrOxI8454/2RRb2bb1luCrXDHIik5+hI71vizhhZFtlMmPmVnXOR647DPStD+z7ew0/cLq2W/kPz+WTIyD0GBx+FPn7C5O5x9xHNFIFYguflCgZAHpx/Kq0DeVKSrssg6cYB+ue1bN6DEzRxOY1PJBB+TPf1yapXFhI0CP9luUC8GSYkbu/Gen05qk7kyTQ03CshK7reXgsSxww+n+FNgmmVNxmKO33cEYb/PeiESwzrJESHVduGGR9Oagn810dnQMM54AyG/AU9BXNJ1vLaGN5TiOTOxiw28ehB+X6Vb03WpIm2PcuCBwTzkehrmlyMq5VATwQvX3p00SjGJkkY+uVx+dJwT3BSPQodTuwrMLcXER/i3AH8hVmPUPNCORhGHysrbgw9Ce1ebwXM0AXyZHQKfvRvitK11G/V2jlG9HO/naM57jtj1/OodI0jUXU+if2dyD8U24wf7FuR1/6b23NfTdfKH7LV1PcfE6dLqLy5YtGuV6dR59t+B/Cvq+uikrQSOWq7zZ4r+1cyp4I0JmUMP7ZXgjOf9GuK+SbxhLdMC3zH+GLoPTJr6v/AGupRB8P9FkZVYDWU4bp/wAe1xXyN5oKs0ZO0/Mxbqx9BUVF71y6b92w1k+zLuY7c/dHf61IE3Y3blfA+Y/Nn3xT7S1u7xnfy5JHxzjkgegqw9pcxKGMLxxt8ok2/L9M+tS2aWHQW3kYkjkRcYB3NtI/CtFUinuBDqCbUYAiWJh/6EOPzqrBAyTBd/zDu3H6960orPzFKoAJlGWQj5X/AA/qKyk0bRjoLPpBi3GyvYVGPuSuAQf9ljx/Ko7SFw6wzxeU4PyqSVRvdWH3f5VPaRSREbt0P95XG5T7eo/lVtrd0+VkYQytu2v0yepU/wBPyqLjtYhOnb1aS384To375cbHyOc8cH1yKs6enn3Ky3AeWJSPOEf3gvcj1/Hil2Ou0xyCZV5BxyCPY8gVftJWi8nkkRncM/6yIHuP7y0mUkVZnQQ3MCMXibDJuAAZQe47Ng1bsCs2m3EDLvkjHIIwSB0NMnt1aZjtBjlLABcAN9D2PtUlivl+TKRv+XbJt4ZcdGx7jr7ikUkZV0jQ3WCTg9sZGPenyJh0W4cx+Wp8txyCvYZHb0rW12xEsMrwYYxJvG0/fjzww9aiguLdrSzlZd6b9vPI54ZG9PUUDOc1LJ8pZVZoirK6noQT1HoavaX5k9msds4a6t2/dkD5nA/rxUms6ebO8NokivEG8yJx02kf41BYZtLlbqKMqdoAMY6Edj+vNXe6syUrO6H6rHHI9ndmJkhnLAnH3W6EfQHt71PAhuNMaZVG2MZkHXO09Mev8xitbV4R5UFzE6NZTkSZA+UN0JA7E96ZYKtlrDxCM7ZUDQ7vuuSOUP8ASpKK2js9nKzrGJIxIwdAMhgRwR74/Ots2S3drcpC4kWUAqOnbk49+KzraEQ3dxCjHy5G2xuO2OUI9xgr+FaenSYntixGZWL8cbT91x+ob8aQ0xfC4d7eYM2QJQOeCuR0/Ct/aCCvIKAcGszQIlW7vEVTzIC3swyDXReWiyMwAKnGPUnHf2qZI0i7lZAOTgeuKsggBc8buBTWRQgKckZPSnCNvKGGJOMrkYz71JoD5Y7vX9fpUJysz7epAYg1YUfOG/iYZI7D2qOFFE0rkNuJoEhY/uHr0z7U5FCquBkkfWpiFCgbSM8DFNOYiMrgA4IoKGGMMSTjA70vk8HIwR6GlYlzgjoe1SoEBJyc9MetAmxpBCj5s4GcU2NMuMLz2xUqgByRw2MYz1HtSybViz5bHA5ZT/SkiSt5XzBTxg9vQ1Wu1KsXyqqF3ZJqyxZpwMbSFB/Wq18N+QzgopAbP8XPSmI5PVJNsCNPu2yMMITgyAHqf51ST5DZmI/MxZAgGMYyc/1/CrPiRme5t/LKvthcKo5wc8sT6dqp28RmeBw2ZXMxLN/ECoG7249KtGUtxYrdLmRFZQWdGKn+7zhR75OSfYVyk8MmZLneixhzCkhOVbHUoD6dc/QV1d/KsNtM6mSJZiYYWT/nmBg4Pq3P0HNcxql2DLB9njTdHhQNvyKv8OB6D7xPfrWkX0MpIr3UDRvGl3GrlVDmIZG0dVDn1PUj0pJL6f7dJcoV80xmGNtu1Y89RGv8I7Z+vrVizie6u1iX58bjI7dGbqXJ75/lUz2IlvYVHyxk5DN/Cg5LH3OOPbFPms7C5b6lKZXt7aO0UFnkAklOeSPT8fWlVZQf3oUY2/KOg/uqPbvVyaIxTTzy85Odmck84C/qKlsrWY3EMZyJAvmkH+HuXb6DtSchqI/TrPFzEBGkj7dzg5wCBklvoOcewp1tYtfXjvcjKu3mZY7A47Z9B7e9aqRtJAllCNolXM8jdQvXk/0oa1kmm3Kp8tExHv6gf3if8noBS5huJh3jvJO/2OJvLyd0qp8pb/63pUn9owlFtre3YznjzFXdj6nr/IVpS2rKkUECBo0zueUfL7ttHpVKWDCMtukg8zp8uGl9W46LRdMTRj3WIHMjmF5RyCg3bD6knqaozPcTXTvLC17cScCSdjhf91a6CPTTHFCJy/zElEQbmI/2R0X/AHjmm3elyLFudvKVvuxxnHH+055ZvpVqSRLgc3LpywruurqLJ4EMbbvwwKkWz+zSJLbefvK5BTAKnp6+laQtorQlIYy8jDOFIBI/HtVO4huvkZkRDnI2rjH5cmqUiXAozRlUDzQMQgGS4OSPSqd39lYKVU7O+5Tj6g1pNZX0u5WeIAcn5c4Hue1I+nSGMM0nmADjd0/KqUkQ4s525hVJcIyMvYqdwqe0lClAIUd1bgN0z0/yKuSWe3I/dMQuVCjP4Gs54mhmVgFz6Ka0umZNNH0V+y0Iv+FnztCjpu0a53KScA+fbZxX1hXyL+yVc+f8TrtSeV0e4yPQme2/wr66q6atEzqO8jwr9sFS3w60YDA/4nMfU4H/AB73FfKEVs7xKqDLuc7sY4r6z/a5Uv4B0NVXcTrUeB/273FfPmm27KFDwEsR/wAtD19gelZ1pcrNqEbo560tWTcsiNux/cJ2/kc1esI5Nnlx7ZBjlWJKt6cGujh0+3kdVIa2lBwrHlSfQHt9K0LfStj7wNsicb1H3SfUd1Pcdq5ZTudcYWMW0sPPwqRAnkhRw6/7ueo9q04bBnjWNSFcDO14iAfy6VsQQKx3GHEg++gP/jy1spakp5kTfOvKk/1qL3NFE5gaaboAT745k4VlbJQeh9RT006WFGiwu1vvbRlTz94D/wDUa6pbWKYBtrCRTyOjIamW1zGBIAx6+n4/WmPlOQXSWD+YygqvzAgHP1HepFtNtzGkgDcfKW+XPfC9q66W1WRTGu5HVflYdSPWq8lkjLsdcJwpQcBT/eX05oDlObe0aGTKrvTPmRgjG4jqufUjkH2pwtGaUSRDKtyOxYH0966CO2KFo5SDGSVBBwVbsR7/AEqJ7XapiYbcHdleNj/3h/smkPlMWygUW5V1BMJIYHgMp/kD+hrKW3W2ZhMCLbfsnXHXsGI+nf2966j7O0c4kk+V+FdsfKwPr7f/AK6W7smSYbeY5Pk5GcHt/gfUYp3JOS1CzImhs5QxRS0KyZycMOmfryD/AIVXlR4LaKVwzIzeXPj+FgcZ/kR9SK6W5sneNEwwaIYibqQByF+o6Z9KdBapKqyFQ0FymJI+2R2+oouSjO0iK0a3n027J8sEMNg6o2QSB2wetSRWzzRq10cXFs/2WYqcleRscH64/OoHtpbK/UhSZk3FcH/WjHIJ9WX9RV6Uxi8+1gMbSdVjnA4YDoH/AN4Hg0XHYdeW4eOR2BDW0uQB/EGw3/oQP50y3t83SyKdu2bI9lYf/qrQusI20MGmlKCTPcKTn/H8adY+WLtFByYtyEbevPyfpxSepUS9a2iQ3shQgiWdVGTjseT+tbcaBkc4TgkFgc9PWsplxA8i5IWePGRycZ3fzNatsE2FVJMhkJYDp14pX6FoVVCEsucA7QzdDRDGsfPyuqZ2gscn39sVa3oHjSNz8o3N8o4b+v0qSPaiySCISEcMSOpNSMzpI/LMZIbkEkdxn/Gk2ZYkjCnpk1cuNxCljmQkMxJ702ONfnwN7Lz83QCkhpkMdv5u7D9PyzTmhY/LnkjOcdMVKm3e4DLggEA9jSyO+EkSR0KgfMOPqPrTGVJIFIPTLY4HB/KnqoTYGB2+n+FE7nc0flnBOQ2f0zUQc+SzAtu6lSPSkwsMvIyLaV94IAPB6qT3q+gDHyZUywwu49sjg1BGIbmN0Y4G3O3+93wKk0/KyNudn8zOQeoA44p3uJojmhT7QA+0bUIDj69vSsiUqkm8yEKC0h3dAApOT+lblwV81iGyVzksefrWNc2yXCyxuxC7Q3LdAeTz6ZFNEs5VrN47S4lnAE3lHzPVQFJVP1B+tRX2nxgxokpgSO3QOVbA27RuHrkniuk+zpKt2Lp9vyh2LD+8OfwwK5iWI3t2hkVg0hJCf3IgMD/gR/lmrTMpIwrqOK/c3RgZLOJ/JtkdyxkYdSc9u/0pLaBE0+e8u1Lz3e5I8DkR4+Y47E8D6VrTxRz6lIZlIs7EFMJwJXHL4HucDPoKjsYHkWdpSTIpCInZVALYH/Aj+NO4rFDToWiVpJVLSTRqAi8BicDaPwwPzrUuLWP7VunPyxoHkcLhT7/pgD0ArTtLINfQFVB8qNSmRwSBgE/U5P4VBqsLviGMs7lyy553PnG5v8OgpMaRk6dAbqWOaSPID5iXqSTkkk9uMDNW4rEhJnI3LO+CVPMg6nHovGM+1bNvp7BdoZtgGwv0Lk/ex6Zx+VX0tVU7kQFVAWMDgZ/w70PUpRsZNvZmXzGIyEO58ceY/Zf91R+dSLYMxZ2LSSMRuA7nsB2AFbMECouw/NGgJZuhZu596uCArFk/KAAAq8bR6n3oHY59tNDShXI8mMZIBwvHqfapF00XO/ylIQnJLdXPrj0/nW4LHfICVHlqM7T2qQIZnCkGOM/Lx958fyFK4ciOWbT9kjRW7HzG4eUjefop6H6dqrPo4YZVdsgG0sx3yH33dFH0rtHiRFWFY1wgzx6elVvIUuxXhD0GOp96YrHHto0VujCJVQHlpXBZnP8AM/jWdLpYeQYDs+cZPO32wON36Cu6nt/O4bKjGPl/xqrLbFFEe0LF/sjt6Ci4cpw17pxijw6qQOVXOFBPsOprKn0tnzJeSrCnZUiBb8zXdXkfnFjbqMjgyMOB7Ad6xptMVpcYLnO4yz8/ktNStqTKFzhbzRgMGJ3jVSceYwXd71jXFsEZo2fc/oTn/wDVXolzYQOpZgNijBYgDP4/0FY1zbWpytrEzrjpHFgfnWsKhhOmd/8Asggj4sakTxnRpjj/ALb29fYlfJf7K9uLf4r3gHBOiTnH/be3r60rrg7o4pq0rHjH7U6LJ4N8Pq4JU60mQBk/8e1zXgmn2x/1kJ+Q9MHp7GvoP9phS3hnw2A20nWl5/7dbmvGrSBI87ECv3U8Z/xrlxO52YVXiQxRSEEyJuUjBI6n6jv9a0bIBV2Nn29/pUlrCxKscFT+lSz253AnlB6VyN2R2pE1tsJUkDPb2q/GqxvhvuH/AMdqrCq4zjBB9OvuasQoyXAVvv8AUA0lLQposmEM4kII+XDY7getTMMRIHB29CR1pYzkYHO7kOR+Z/A1YOCu7H7rJ3Mem6qTuSyAwDzBuyGB3J3C/X2p4iMwMhUKw4ZT2PpQxKAkH5QeTjpikO/aw4JfgH+96ZptgRC2+RkI5xhieQPSomHmAO2Q68NmrhJUHcQcDkt60jKY+ecEZOSOf/r0rgyn5SggHo4+U44PsfY1H5Q8ry2B2Zxj+7Vsx/KUORjnBppUmQscZb72RjOP60XFYoGAtH8/3143Y5Poari0EU0gCHy3G4qDyCepFaWGVzleT39ajbJHy8FaLjsZVza/aIirjDYCl16Hurj6f/WqvDb/AL9DJgNMrRSR/wAO4cj9Pz4rdjUsAehB4HpVa5gEkjjpkBh9RRcErGSimK6gZsFVQhge44A/Tj8KbcjbOxh4keFTtxgfKef0H61fnjV5Y2yM8pIPY9P1qFLcm5aR85iTaPx55/CquBtwbXhaTIKllbj6fzqWwmzZozYUSkyN6+34VTtoAtgEVmAZShJHb1x61bhiVYkQMREoCnDckYqWNF2JmaFUKhFI3nby2Pf0qSKUYwuAQSwUc5zVPeEDAcLnkKeSKbFcHCnC5z8zdycgFfoBUjsaE4ysWOm3nI49vrUdxJ5a7QyhwoYjvxx+NDEkqy5ALEBcdF6iopVUgkuPNYHjqR700CJbd/MAkERKJkHAzv8AQ1A7Fok3MQwfDelWLTb9n4dzIMkoF4Iz0+tPdXJl2qyITna2MjNA76lUThHAaXbvXB4yGqEYjbaSpHChs0wsjoQzZdHIXH6/pTTtTBUgow5BGcehFA7ksCGC5jZkJVGOSD14zViUjc0pO3IYoccHHY+9VlJ2BYiAFOSKkkuAqoq7c7SeBwT70hasZFMZYnLqu+THDDk/SopIQ0jbjnhVJ980m4K+CSoPKt647U8lVDYUlhjIPHHvRcRQv1RodrgKuN0merAdvxNYdjG4h+1IwM0qSMWP8JP3f0ya19WI+zy7TukYBQD3PpSw2hjt40PzMRgdh0wKaIkjIexiSMQrnyBhMj0HP5nr+NLZ2xSSRmxljtBA6tnnH0z+la/2bc77mBHRfb1P51NHb7SoAA8sYBPanexKRSEG2RhASN5wX9ABjj0qVbMEJhcd8eoFX0iRVzgEClRM7mJw3qfTtii5ZCkf3gABgADNI7AN5CA4/ib+n1qyE2KvGWY5zT/IGd+3K/xE9OaLgRJHjacE8/KuOlWTEVjIwSg7Z6n196kTZ5xxnbjk9zTTKEfaOACBkHJP+fahsBsZTO0htwGPx+lSSj5GeMqzZ42/wgVBMdqZBCEn5uDxToZcxnlQHOfep1GNYEx5UcHP4/Wokj4OAS3c559qlLMTkgF1BHzd/fNIcHDKvPXaDkYqrdREUsZAOCCeoz0qk4yxWbJH5CtQAkgHDBlzkc1VuFBjySSR/kfSnqxmW6KhfABIqlcW4lUuV5bqOwraWAhQCOD7VSuUVVOMg9MetFhHOXsShATHvboqnuay5bSVsruID/eYcD8BXS3UXIypHHBIrPnjGCGHy4/M0XsyJROo/Zps1tPixc7Xdy+jXOdxyP8AX23T86+p6+Zf2eyf+FsygrgDRbkdev7+2r6ar0KLvBHl19Js8l/aNXdoPhkYHOtDr/16XNeUIisu0qNqnI969Z/aJOND8MHOP+J0P/SS5rypCcAhRk+tc2J+P5Hbg/gfqSOi4JX5T3x0/GpbOMyKS/AHbsKjQhQVxyTkjsKmSRYGCYDA8kDvXMdlh1suZh/EOgHv6Vd25kymZDjLeox2qFEVVjbzAg67gMgU9JX2He6hCwOF656fhQo6DZbWLbFgjc3BPGAM9M1LGRtIuGDJjgA8A5/rWdcOUQlXZV7leQfSq0M7Mp+ccjB4xj/61NJEtG27LI3zkuCDk+/+FUri4AOF+YEgDPWse+1Iwvx8o4JGf0FJbXvnOzIxIBK8+o64qrpAkb/mIykHJA6Ammccgkncem3jFZnnrvJLEYHI7077apByMDrknpSsgsao2bME8jjnnj0pFJAx1x1GazYb0Hcd2cn061cinc5I5U9utIRK+NxwAM0zysdeM0qSbmO4kdyDxTmfBwxO0+vakIhC7fu4A6VFJEeCTz61aGMgDt39Ka/B4HHakUZssGcjGQ2R9KNmzduJ6AZq24w+R0PWoz84IJ/+vRcY23myrKeCBwnscc/jVyWRWkAVMHuP5VnIMzMxIAAweOtW0YK8cgO0qwYN2zRcLFiRfkba4yRy/wDOi0SPdGzr+7GF2jg49ai8wT7iSdhYnP8Ae9hUscvygIPmHGfWgaLMsrD/AGTjIAOaUbPLLFRknaSOmKgjxI56n5scc1YkO2U7mbO7OU64oHZE8Dy4UIwUn5eAMgA9/Sq9xKEyBl2OcjPXBzxQoK4bGS+T97GOe59KWZZAfLK+pyMfoadxWRV+zLEJfIwAr705zgnnHvUExO1x8wyMk/Wp2dhEg3kr2GB36/iOKZI2QoyckYJJ/nSvcLjYifJw/KheMDp71BcMcRzISVUjryT2zVqI4jCvnCjDJ71UuSu5vJOHPzMp6GgESMFyCmDlssOvtUmPnZQeuM5NVkLA7QQVA9KA+8ZU/WkIZdIhl6fvOPyzyanUEMV7D+tRL+9cyHp90A+lTrnkgj5j+NMQbdpx1705V4ycUq/KMtz61KMKNvBz+NADQoZKUoARkDJ4walQbenyn34pLwrE5z8uOcNy1UIUAHAJye5OePwpjbXIBI4APQ8+1Vxcq6eYjZGckE8GoXmYEtlR/s5zRYEX2lXbtJbd7rwaqtOpmY78KflB28sB6ms6W9yCZJH44wvHFZjaoYgzs42qDnA6ilYdjozcFdpcjzOzCooZTM4UqpCnGCcev61y41ECYlnb92gzzwCef5VUstZ86+mjUK+3AQA+pJx9fenqLY7JLjyziVgYwMDb1z1wfU1pQ7fKXKgOSMkcED0x/WucEqFUL7VC8gYzz64q8urIkYlkcM23cGfkfjVobNZAxLZBKoMswHIGaquC8p+T7xxx0IqOyvIpUZiXdSM7FOCc1IGbPmKBhDyR0XPr6mnYBsnAPX14qhOQzquOver8zpn5WPy/3apyKrTlwQMD86QFK9TcpXr/AI1kTIR97BYdAK2pGLOxxwBjpxWdcxjcxGKjqI6z4CIF+KQ2jA/sW7/9H2tfSNfOfwLx/wALTT/sC3fP/be1r6Mr0KH8NHk4j+Izyj9of/kCeGP+w0P/AEkuq8qDYDA/KueM16p+0Vk6F4Zxj/kNDr/16XVeS2oFxIwc/KvbNYYn4jswfwP1HmV5pAseSFHLdqnitHZxlmPYFO9WbaONE+V1Q/eyePwpJZlQ/fVT/s8/SubQ7UyKfCYWSVsA8KBiqd/erbw/ewCdpJ4Iz6/Q1X1C98uYIzEp2J4JFYHiDU0jUoXBDg5Xqc47+1F2xHRpfmS0yGRScKcHrn/69ZDa4gRg7Dlcgk4HHB/WuMs9TuS/2ZX29drH+IdRz6j9akfSZXmZHLPkbgRz71SiK6SuX5db/wBMd5G3KNpGD325q7o2rsYSvzMxYsSOB9KxbLSJpZy8iFVeMSJnvx1+hFbek6E3zH7u6IPjOOnB/Km0SpIsXOtSBNqxkuTgYOcmq515pGwQ+xRycfeNYuoQXTaiY4lkCKGYL/EFX7zH0HNSWH7t4Elj+eT5iVPABPHH0H9aXKPm7HYaXfRtGoMu4j271sQX4C9fr/hXLXctoluPkDN0AAwc9hT7ASBTJBKHAwuxzjJ77T+gqWmNO52UN2MjeO3QGrUUzZy4JzjHFcxDd5lWOQNGynlW6itq3uUK4OcZ609B8potlTwCR3xSOSVwevY+1MtDhSN24Fsk5xn/AOvTyCzEHHrwaHoIgd9o45qtuZm54HarUibeQwPPU8VDIRk4AxSceoXGmTGSFB96dGwJAbnPTiqkpYYJPyihZDzjt1PpUgaRlUqowNq5x70ffVQ3CZwQDiqayFh7HoTTlmyccsB1PYUFRL8EoEjIzsAo4C8YNTgjkBiq55IHWqAYsp2DBxlielCyBmUbjkUBY1Q6+YNrRiM9mzzVnczjyw67cYIODn2rIgVxK7uQyngDqR71MTgbip3Dg46mgTC9/wBcwUbT1Iz3qkZpN3z429CwHIqe5kkDlzySeh9PrVUuM5yQp9aAbCWd1clDuH8QIqCebDY49qWWYqvABBGCDxg+maqPIx2gjleQD3FOwJllpyqZwScdqS3zkoSR3+ntUCOWK54z1qeP72e+MZpCZfiAbrxipgAp5HAqGF8MM+nWpkG87gT1xTSuFx6nkHBJ6gKKfCQXIcDbjjJJ5/Cmxj5S3fpt6d+tNEnlxtDHLvJ529F/E1fKJMsOY40X58E9Se30rL1OciNlTAJGMKP1qC7uZUJaNsuO3r9Kwb3Vt6vFGMsOCB0T60n5DSJG1MZZJDtBG8E/qPzqpcapIxAgjLAnh3+UfSubv5phLICGaeM+bF8vDeox3B5qSOS61lEMRbCc4B+6McGnyhcmvNSlEv7y4OVBcrGPyH51jz3mGKuzqE+dyO57D861X0+53PNCihpHRRkZXA6Nn0J5p8egiaYmV3NrE43uRxKSeo+gz19eKpRM3UOdS4cW4nkMqZO4kn16D61Bo1y6XokjkZDIxzx2rsLzSJbuQJbRhLdOLeNuAD03t602Hw5HBHbJEAqR7t0jdcHHP55P41Vhc12mRLrFzDEXkIcAHkcH8jVJfEDTIIlIGVUDPQdiff2FGvaZJIxZp8WnsDvf6f41h/Y3dzMYnEA+RERSdzdgPekopopy1PQ9I1aEl/nbGV69TkYx+ldK1+iQxgE+Y5wiD5jmvG7e6ntLobPmKZIX73tXUaNrH77zbxvnQElRn5Bjge9Q7opanoKlflSRWCNk7uM8Dn9aSeID5VwGxnjnP1rCs79ZX8zjLAcfeI9B/U1sxPMxJnGCx3YVMZ9qSYyrLMsAPmNj8KozAOxZc8itK7QSQ/vV3EcjjpWawYqdhx6e31pMDrvgWCPiqM/9Aa7/APR9rX0bXzt8EI2T4qJu76LdkA/9d7WvomvQofw0eTif4rPJ/wBos40Hw0f+oz3/AOvO6ry6wiXyVfbz7GvUP2i13aF4ZH/UaH/pJc15YsixqG2kIeDjjmufFfEjswXwP1LNzMqplgFUdCOlYuoXqkMyshYDBGe3+ehqW+1JAcB1ePHrzj1AritWMN9ct9ilZeuWVv0rmWp13sM1XVWuXMbFVUH/AFnfjpj3qvaCVZNs1qLqNufMibdn/e70+2gvFZQ3lzr/AAqq7j+OOn410mnafHHiWa1hif8AhCD+daJWM3JvYz38O284WS13KjHJG77o9h/StuztWhhRLibLR8qV5wfx6cdqi1bUobKPfO2xPQdfyrlL/wAS3UpYWai3j/vv8zH3x0FaJGb03O6VreNQQg2r0wMDP0p8F5boWAAXksMHkE9cV4/e6hPNJma5nlJ9XOPyFVPNGS37wfRiKqxPMkeySwWsis4UJI6lN7cnB5OTVC6sIzPNPEi7mdNm3+EDp/XiuH0rX5bKGWOGRiWjMaGYB/LJOdy57/XtWjYeIrmHat5GHj7vHwfxHQ0nEpSTLt5aOuphHciRcZVTkRhj1LdzgHNaujzSMJZMAoGwu5cqR06U+1SG+ijdDtRm3k85b2qe/fyre4S3gPmSykxqpwWGOw7AY6ms2zWLsOEkVwAMY29s/dHrnrj+VSwXTQShJWypPyt2PoKq22myCPzXKsFAG2PIA74z1NSSyBYikyB4ujADGB/T61El1Nkux0EVywCFSCp7Yq9DK+NoyxfjHr/9f3rmYHaHbsYvHj5T7VrW8wYDHzZ9anm7g0be0bmikTy3VeQT+nsapyqdgyDgDOMdKZaTyk5yODlFDcg96uSMGQttz5hww9DVxd0ZtWMucBlG3I4qoxwByefTtV6QAb1AwRz9ayrl9p+lKSFcnhYqxGdyHpnqKvFwUCqQM496yreRd1X43VSOgPtUWKTLcXJ+8ef1pcBpdpAz1zjtVcPt6EgnpilU/MCSRTC5oKQuG6Adqlkc/eG4k981npMp+U4BBqTzQPmHb3pWAW7k2g4dgQeao+a4wzgH261LNNk4L5IGQKqPJgEEHHUUxEjcxkA8HtVfBVNrHO3r70LOsi8GoXk3564FAXJom56ircAycms2Bx5mM4rUtlYgYHvk0JXJbL9qmQDjPoPWtEQ42jBZ2GSCmAPbJqraRsQqqSc4JO7GK0JFVBgHKtzuwRj3P9BWqVib3K88iwfNlZJic4XBVfqaw7u8O98yFnz83pU+sXjKBEGJxz2wPy71yd9dSM/2e3yGY5Z/7o/xqW+xrGJPqF8ZGaK3PPVmPb/69YcjCJ1ZW2SbsHJ4JPQn1q6I5IVAjXYndyMlvqKuS6dayqxMsTsy/vEBzu9CMdCKS0KlojGlidr22m1FZrKVSQJCu5Gwf4WGQfoa2rfyLV3n+VGlJYxquA2erL3UHrtqtc3f9mWbbpyUC4OeTj61w2p6lc6gz5ZobY9VU4J+p/pVowfdnZ3Ws2Mk/ltLAhTA27hx7+wrObxPFslQtMFjYLkLwRz8w9R29a4SSRISQiqcjuO1V5bt5TzOPoDzWsYmLqPY7iPxapO6S2uFHsQa17PxJaXeE81lY9FkUjNeaRzHIDEVcjlUkZb5geMUPQpSZ6xFJHcAMQknr36Uk1nBPuIO18FQc9B3A9PrXO+G7lL6IpIxE6ADKnBPvWpNNNbTbT+8XHU8GlY0TjMrPoqWSySQL5jycNhRgL25PNczNZ3f2gyBFU5/vbVTHr/QV2UV8HcAllYDo3BqHUYhcQnbhmHADjPPqPepY3Fx1Rl6HewQSESMTJu+Z2bGfpXSnVhK+FdgAMlyScfT1PtXA6nZzWyeYX8sZwI0547kn+lb3h2W1jtlkeUJJjnuR7Vk42GpXOsmlaaEsdwG3oTz+lMgdXVeg4wcetZUl2ZZfLjLBMZJbgkfTtU1hIZSSflxyPpSLPQPgs+/4rICckaLd8/9t7WvoavnL4GnPxY4O7/iTXXOP+m9rX0bXoUP4aPIxX8V/wBdDyj9oj/kB+Gen/IZ/wDbO6rxq9uDEmGcDjIYHj6V7N+0LzovhjBI/wCJz/7Z3VeI30SgMl1GzJn7yruGO2R2rmxXxo7MF8D9TldYu45ZHQqVlOMgkYPuDVTTtNmkmVmEbqeNu47h7nHB+lWvsW69dbYRywr/AAScBSf51vWMT20W+YQpxgLGuBj6ms4o3ld6ElsgtIMbArAdd2ePekS4kmyY+AB949/oP61QmuWuJiOfLB5x3qeyuUaaSIYL4xzVxd9CnDlRzvib5bxImkLHG5mJySawrtfl27s8dq2/EkDJeLK4J/hY44BrOCh89MetKTaOfdu5gTbow7AZIFZ7OzjJJya3rmDMhwoI7+9VRpwc/KjAeg6VvCasYVKcnsQWbNIoLY64zjrW/bAugVsDiqdtaBevAHatO2t3uJUghBZ29KynLmlobQXLHU7vwdGs2ivFNv2K5Kg8YPrV9TJbzhdrSRsdoZR8x+oq3oNj9h0xIRjOPmJ9alvIo/LABGR3Bwf/ANdZ1ZWN8OroZFOyRhYW2JgqgijDEA9c5PP1plvpCzM03zKBxGp5LHvk/wCRWeSkE/CSMZZMs2cgDHXH161r2aqGJREfAxjccfh2qU7nRytbFOC0UMQjZTJyB0BoRXhcsvOD8ygdPpXQkW8yo9sBz8rx4wcfT1qGaxK7pIVLBRnk84pNENlBXWUAxHEh6r6+nFXLKXjY2cZ+Yep9KgeElvMTAb1UYyah87bcIrDDfdb3qtiCzdNtkbHp61g3b8tnHJrTunwzqzD8OlY12QzkZ9cZoZHUmtCR6VfXJKkAADrWba8dcVoowCjmoNCwrY5PU0uVzgjJqsHdjxjn9KcAc4/WgQ6RwuFVeMULOyt8y4U9TTtowcjIHrTmwRkjbnsaBjHBOZCecY/Cqsk5QYOMngVMQQCBzn9KqXSg4LDBHQ0CG5UAKOo6Uxnwn4YqPccgNye1MlY7PwoEWLNwzHPUVuWhyFGePeuesypABOOxPetnT5SpG8DA/WriQ9zqNEBjVpAyZAOCVzn2xS6s628AaRwZX+dj12/0z/Ko9NlZYXCttzy2RnjsPrWRq1wb25baW8mPhdx4HqaHLsOK11MXUbiSUnYOG4HPX6+1Q2dqsbDzQSx5+tdFp2jnbJP5DOM7Y0POT6n145p11BHbqokBMn8QPp6ClbuaqXQzY4VjHmBSWPUEdQO3tVS/SOM+YLeJZm6+WmAp7f59qs3N0IFkboeuG5Ht+NZ9hePqBkMucYIjHoT1Y+p4pX7mnK9zB8Xj/iVwZjTzNwV2Xq3U5NcfOCtvnOAeg9a9Q1/TPtului5LIMp9a8zusKxjIIcdQR0rR7JnI/iszm78yeUwx0OTj0qiWBXiujktC2So5Pf1plvprt91UDGuiFVWOadNt3KMCFgu7lsc1qW0OAPlGOaZ9ieI59OvtVuElAEAzu/X6VhN3ehpFcq1NfwjldUcA/Jt+Y11N6uJc7gRjIz1ql4Y0J1iaR1Ku3LegHpV3VGDSKgQkdsdsVbdkaUk2zOll81FO0ZPQZ60sM8kEiCbPzdD7+lUBLskkj43bs4Jxir9vIt1G0bfK6D5gf51je52tcpbuoEuI2keHzeOQGx+Vcizmzu2EUcioTgc8n6V1unusqtFIMkHBP8AWsjW7WASksX3qepYnb74/rVbo55LlloW9GsJncPO3zN820HOPc+pHb3rYuowgH2clsEAkHr+PrVLSp7ZrddszlgOUY4UH1zWgkxPJkUjHGxcAD2/zzWZR2vwGUr8UlJOc6Ldf+j7WvpCvnD4Eh/+FrlmztOjXe3P/Xe1r6Pr0KH8NHk4n+Kzyf8AaJJGh+GSrKhGsjlhkf8AHpdV4pdX9wCYlt/MkbgGLJFe0/tGhjoHhoIxVv7ZGCO3+iXNeD6pNe24JNwJAw52J29jXPifj+R14P4H6kOl58wyFVQSOeWGCT3wOpqTXblYgEU/TPWs/T7yOPIlRgc9dpy319B7VQ1PUBczuwBxu+T3FZRWh0QdpXYomdQojYh3bAOMke9bWjRRRyngbio57n3rljKcx4Qkoc9cE1p295Pt8xYHOCMt0x/9aqjo7mtSalGyOuvtGGowNgBwRhh6e9cVf6Bd2LMqRlo8nB710NhrepW1wBaQLKXBYRs3FXpL/V7uMu1vbjr0Ugj2rSTizjcZNnBGHa3zIfpjn8aswW7kfu0b8BXQyaJeanG1xI+CpxgcFOf1rS07w1LEMTXczJjk7un1qPdWwOMmclFo8s8oVsRduf8ACuv0HSLLTcM8iiZhzuHNP/4RVUlednk2spABc59j7Go30a2jk/eZ83HDj5iB+PSm5JdClSb6l68vE/eK0yhOxB6/Ss6K6iJILYIHUnn8asXVjHFFDIiM4ABcjjA6EH1qKe2g3oVQKhzkKMVjJcx103y6EFxeoEEbSo0fTAarNndrBAwVv3YHH+yfT6H9OtVntY1YhkUrnngZ+tJHp6bt0LuvPbn8KEjTmvua0Wsx25ikkBQ4wGQ5z9R1rptH1SC5dJjIu8cF8c4+lcLDp7I7GOZixOSHWrttFNFKGMUcsROSgJQnjHBpJ2ZMlFo7K8iEMxIMbKw3AjoR9K53UV8u5j2nPzdTVfbdiVRHJIIAvzByCSe30qvM0iyZmY7lGcGhsxsPupFUP3PvWeWEkoAGe+SOaJZC+QTnmnwqBlu9FyEiSBufoatCQnAqoPlzzgnmp0bGKRoToRjPQfzoikJYk0wnI4IH17UisOi8+/ehCZYeUBjudcdxS7g4yGB9KpS2sU7EuafBbqn3AePWkVZWJZn24JGCP0qCRsrzyO4p8mJVxkqR61UkJQ56+uaZI2TIPBwKQ5ZRmms2RlfyoVvl60ANibZKR2HNatpITtyD+FY8jATDPpVuCQ+WqgjJ7GqT0M2tTrornbZFs/dHFMsBH5abmQE/Mc9zWdauZLTYWIzxxVS60+7kB+yz7E7rj+tQnqXa6Oh1PWLWzZvsj7SoKli2cD/PauWuNXe4y6ug3H5JX5zg88dvxqJtLuzEUkKEkg7gCT9B7VTOiujlmnZj1wo61TdzanyxKV29w9y/nT7y7ZzjhfcVfsoY4lVtxBx3bqPWoJrJyV8yV+OAAOgpv2WNeDkqo53c5pcupq6mlkdHFqUQt/KMqbgPvE81gaxo9pqAaeKVI5SMkg5H40R20Dsu5di4JIU8fjVqbT7d4h5WeexOM1speRxzp3OPl0i6iBYKJUPRkORUttayKrKbfcSMDIOQfUV0dr4WRkLrPNvzyqnhPany6PcWMbzGVxjlPmyfoaem7Ri4Pa5gx6JdztnYUU9d1bekeFvJDTSIW2DJbGcfQVJZLrbqm04LZALqDjHr6U+PUtet5JE/dzMrbMbAAf8ACmnFCUZG9cu1tp2yNfnUAoF5J965LUpBczSshYISOAcc9yRSPfavZsVmjZwWwAinav8Asj/GsibULhbt5JbcqXGcGqm1JG9P3SPVYpFkVklkkdMc9So/rUdteKCCMiQcEgdvWnTX/mfdhdc81SmkcsWChAM5B61jy2OmVVNHR2UzG5VjjDccd6s67beYiyFR7g9R9CK5q2vtirGSAQeCT0rel1aO42gnLgcgciqS0OackyPR45kH3pWjzlQ+1gfp610gXdGpkEgAHRhz+lcxpVyqXRISXnkAACuqivFkiwwfOe9ZME7nY/A9y3xWUFSuNFu/x/f2tfRdfOvwPff8VFOf+YNd8en7+1r6Kr0KH8NHmYn+Kzyr9oRVfRvC6sAQdaHX/rzuq8T1smRxbxsdpwWGPSvZf2kZmt/DnhuVOGXWRj/wEuRXz9cXEkjlRn5j81c+J+O3kdWE+B+pFJD57tgkIOn0qWHTYVjYiJWLHOWHNWrWEFdoztzWisQwAR7cVkjYoW2nx7hleAcgCtCO3RCfLQDPBPar0UQCABFHHGanSIqSxyOMdKbGkRQWiqVYRgNjj6f0FXxE4iKqgU+44xUsUeB9z5cZxU6ruBBOD1wDmi9h8pVjibeSMkhOW4HHpirKKXUrHyc8gHrmphAjYDAKBzx1q0kO4qdoVV7Y4P1o5gehlNbvJgchV4yTnP4npUctjEHwpYEnBUDgn29fxrfmgXeTKdxxgKvQf0NNEUKkA7QWGcYzg0XGmc8LQNFwSQAcgk5H9KrzW3lAhlCnbkj72BW3KwRiwCruH3c/zrNvDvT5d3QdT1I9PalzGiuzJ8lJGIwNpPH1py2yq65YR88EdKlnfAbjDZz15H41UkcsmSQ38Oc8g/4UrsC1DJHvxlRzjce1WBKgYYYH1Oawp96lVByzcAjj8KtpvT/WYQbcDK/zpXQmX7q8WOHcgU54rDuZpJ5S8hznk89KkuGLuTjC9u2agIywXOB3GalsVgiUsxJFTMuB6VJEnA96JF+YUm7ANA4x1qSMHksR+NB2qh65zUBc4+vFHUY52wDyc9s80Qt85PamlSRgY3VIpUJgZJpMRZtxuOSecdKmAznsaqxM65Pf09qtB8kfypoZDKCox1FU5XBUjHINXLlwR1rPZc5yfpT1JsQbuCASTnIp0HMhHr1prnGOOR1p8CkS5xnIpWGSXUQK5x0qFe3OSDmr7D5cjkelVmi5JHFMCzZTOJgN3yHgg/zrcjdUlKrIki9iTjP/ANeubTIOR1q/DMc4LdP0pJaga8kxyAx2nuT0FQ70cYynXG71qm2XX5hliTyTUTwosKv5jCYHBHoKtaAkWbmPDFSAT6jmq8tshJRlYqMZPrUsE5XIPOOmDjn19/pUyMS7FOhI57+5FUiiC3g8oKdqD5urc4HpjvVuC0jmkHmybEVMBAMkk9AD7+pqxGpIAP3eeRV+yRArkcsR8xbnJJ7fhVJiZDZ2kIBi2OsqD+FuWz1PoAKdLYmR1jYeUNwAVjuD+hx6Vr29urDy5kVePlxnqPTFSz2saj9ySw4xvbkH2qua5i3qYyKFXryePmGc1D9ljRhgZ7suP1Na0ltl8YG7GC2evfn3qtLA2DgMvGODmlzCsY89qoB4IRTyByB71RmsbeSPc6BsjBIrddCFOV465A7VQljZdxVvlzmncdjAn0232uDGG9CR0qiloNqpcRj5TkHA5+tdI0ZII4P1HSqdxbtnPbPUdqV0By99YxAMgjAB5HHT2rDuYBGwGCM9xxzXZ3cOc9CKwNQt8MVHBP50NpgR2a74EmUkunU+v1rp9Nl86Fcsp4/GuStXeFjjoDgj1rTtpDGwkhP7s/wnqKhlRPWfgiFHxVUr30W7/wDR9rX0TXzb8A5/P+KSnuNFu+3/AE3ta+kq7qHwI83E/wARnjn7UGf+ES8PY6/20v8A6S3NeE2lvuYHt717z+0yM+F/Dgxn/idL/wCktzXilnGwZyTnJGPauXFfGvQ6cJfkfqWYY9n3VqaMASheCepFOChRkDHoCalt49rFgRljya57nUkX4EUgdvarcaqqkjlh2qtEQCACB7Yq5HhlGSATxihyKSsPjLMu3aOfWrKxgEZ4x6VX4BPepI5SSAP1pXBluNVAzg5B6npVkN8gG/jPLAZxWesoTcWO9zxtPP8A+qn/AGgp2O3rtHr60Jhylx3hR1WQkL/dXn8+1VZ7jYNhIVOhXqaqy3DZUMcd8Af5xVQu2AY1jaQnIz2+tUCVh8txlhtJ3ejZNULkSSr0fceSc4watSvIGySMtxsU559eKikWXbu/i456U0i0ZrowJO0DsQapXDsrbVBUtxgDvWu8LOG25YAZbjGPaqzW+TvJGRxnHJNEnbRBcq29mQqszMxxyR60+4y3Uk+pNWpGCoACcDtiqUsm48VJLKki85By3b2ohgJcbuSTk1YEJzucdO1TJFu2svHtSe4CouMqvU0kyDA9fWplTAz07GopmGM557UbgVZCCQAarl/n6cDtSzSgZ9ar78nJPuaYrk6O0g46nirEYVVwDj2zVQOAoCDOeetTLub+ED1osCLaOAD0yfSlZiBkcA9cVGg244GaSRsZG0Y96BkMj7WwWPPbNQSuR0P4HvUkmCx75qtMpVeORnoaYMiZsnJNWbZ8Y9aznfHTkZ5FWLWUFhg5osTc3IgGXB+6RTXiAXA4xTIXBVR37VK24vgD2NIZUeIrLuXp6etSKwBz0B9atBF6MAGqKaNiucBiPSlqhk8EmBxirDQhkbnPf61nWuCSDkMOh7itKAEHJbIPWncCFoV5AXPuOlPhDbtgGTj9at7Aykqu4d+ah8o78spxjAJqkx3LEbFQcqcng+hrRtpdxKqRzyQcZrOXKsiLG+T/AHe/4VKg+VW3YY8HIxVCOjgKumCRH02nB2t+HX8am2EcRgqDkHJBB+lYqTTIoBweOp9KtRzlwGYEL1LBeh+tJ3M+Ut+WeDgDgdu9MZSHJxz2Hb/PtTEm+TG4bieOeD/gaUvlArAHFF0KzK06jJC59cVSdASWH3vSr8zBsED8qrE8E8cnn60XL6FOVAGzj3rNuY1LMVHf9K1JxlWOTkGs25BZAAex/GlcVrmZMgIPI44rIvYDkEdfUVsyEBTkGq7BZVwBzSuTY5ueHBBUfUUyFihwRhTxWtNBtJJHFU3hwwOOD2qguek/s8f8lSPJJ/sW66/9d7WvpqvmX9njb/wtJtpP/IGuv/R9rX01XfR+BHm4j+IzyD9pcE+GPDgHU60v/pJc143brtbHrXtP7R//ACL/AIa/7DI/9JLmvHYABzxXLivjXodOFfuP1LCrgZNTQr8ufXj6VEjru2gEnvipN21VwDk9AOa5bo7I7FuNDhSOlTqdigEc1Ba/KfnJzjpU4ZAM8k9aT1KHI+5eeCensKlV9sZJBB6VHuzj0J71HdSYQkAZHenYCZJJFzkhfoOaRpWChE7+9QwEEAA5JPOO9WYY85CEDn06/SnHUZDyOcJk8kHPT60m0MA5jDswyOOKuvbcBZX8tm6ADLfkKkWPCDZGY1JKl2Tv39qq4ilFGWGJMRxsfThfwFPFuiHO1z1Acjr+FXyHGAB8pIBZTgHA4yapzuF37nPmLxlTnI9f/rUOXQCsUI5ODj+H1qhI7NcMQqgdx6VauJtw3ZYg8ZJ5qm/CgYyScikFiNgGJzUT7A2F5IHNWiDtPTp1qmGLTNtA2jv70N2CwbdwHr/SpIMkkDgdie9PbByq9O5p0SYBwfxpPcCC4HO0HOarXfACDtyTVxlCE7sDArOvZAAaaQpbGdMwz+tRbsDJ79BTWBJA61JFHl9vVqZK1JYAXPAAHrV2GGQn2p0cRQAhRg8cVftYmH3gPwpdS7MreWRnOOKGTI+ZTir5iJYgDj3FLJB0xt9qTZXKZDQJuJQcVUn4BxggdcVs+WxBDqF+ncVTuLcAbl+nTFMmxhT7SDtGSevvUED+XNjtVy7t9jAqOCeapuoBBJ+tXuRI3rVhIoOK0YiGGSvOOtYmlydFOa3FG9ce3WoBPoKVDHP0oZAq8ZBzT4vlG1ucHnNDLvYFGJwfyoNCu37vBwOT1FW7d+mR845poi3Y34B+vFIm5X2kblPAPp7UDSNFE3LuUfN/OpJAXKLhgy+vb2qlFIY+pO0H1rSHzRfuyGPUHuKBONiJI1Jx5pz2Df49qfHD8xXzVAPqc/hSqdyjI5wcEL1p4tyJS3lhsHOM5AH1qoy6EtFfy5FbJyU9u9OWUx7toQAnOM44q6AsLtiOVVfpyGXPofSkurIsR8gV8ZK7uv09apgQCcYB3YDDvxUiSMRwePXpVdkYRMB8rAfdYZpjMyhMYH+NTJDsXgdvQnZ6GopH+bt7E9qhFxwVkBDd+P1od8LnGQe9RYAYk5JOMVUkCsj8qpUHGT1qUuecHj0phTcOefWmhXM5ogyHPAIqi8XlEbck961JMhtpGR2NV5QN3QDjimnclmbKuQc/jWfdoUweo9BWzJCQCCRnPBrOmiJXJwcGncg7j9nn/kqZ9f7Fuj/5Hta+mq+a/gAAPingD/mC3X/o+1r6Ur0KH8NHnV/4jPJP2jyF8PeGien9sj/0kua8gjHyDH5V7B+0dj/hH/DW7p/bQ/8ASS5rx4nK8nFcuK0l8jpwq935kkUi5x2Jq0O5PPoKr23GDVncuABkk9zXKdg/eGGP5Gp0VSQQWYkY9hVaOIchxhT155NTowSQIiHH8qTQ0x7yYIyQCB1PGKXY87gbsRrzg96TyhJMrk4x0yOtXIRhguFOPXkU15jvYdaxc7mACg8A96vZSMMGL+YQdiRgBT9SeaijnlLqI23TZyRjhf8AHipnkaNSWdPm9xnHsPWm2kTqwnDwqJYpF+09FJOAg9RTGvJQVjdxcSZ/dqnP4j296jiIkDStA5y2Mt+mAe9V7mcAL5MflEDax3fM319PwqdWXa2hLd3z4SN2GFXGzGQvtVCQrsJzuOc4PFDdRtA9ST0FR+Xktg/jTS1KSsVyR0wX9Mio5ScDgbh2qy/7v/VjJHeq8oAYEqSzdqbVxMaxyFUc+ppkydCABjoPepWb5CSRntUSBmyMn8ewpCCPnGeBUwiHDc8c023hLOWHIPr2qwRgHGcDp70xFO4xg8cnisK/cb9vbvWzqEoiU1zsm+WX7pBPP0FURJ30IgAW45rV020JIbGCfWmW1uCRx8oNblogD44AFDZcV0FWBQoL9uM1NHGqA4HJ71ZESsATwO1SxQbzgrx61LZqkiJE3PkjAHpUkyIEG/gDuRirS2xRT1zSLG7l1kUcdKQGTLFwMYJ9hVOdOCWzgdq3TCd3YEDkZqnJETv38DtTJauc1eQ748qTjtWLOuxiGBAYdq6+6t1AK9+uKw7+1Vhlfwqk+5EkVNNkG4A8NXS2rKUUk965BC0MwPr1NdLp0nmInHXFDM1uaUqKwbGMnrUMBCnDZ54JxU0sUhO5DzUJA8zbn5h2pXNSYLgbCAy54oaIFgQwwf502OQFin8XTkdKtCPKgADP9aY07EYiCqBKcrirKERY5IDVB5jMxjZD/vVPH8qhSNy+vpSLepcSUYIck56gcVYgcRsT5aeUeyngj6VnIQvEjgDP3h2q5G+RgbeOoYcGjczasWRHE8j7ZwmOiOh6e/rTcIpkCL5qZ5VTgN7g9R9KrPdP537xST0zjtT7eQAsFAyOc+o/rS5nsLl6kN0o8kBFZZOytnmqpVQB5sbDr07VqszlSG2yRHPbkfTNVbm3IjBByh6FfmA+tFxooxgu2Ad3bBqF3MYIUg84KmrigJGyoVGT1IqtJAQpLZY54OetFxMqEssgZWJUjkelSCboc8Gq9wSoOAxGOg61FFJ+53LyucDNF1sheZOZ1MgVuDnNNkBY4AB781RmcvJsBwV6Z71YDAffbBqkS7rYRkY8nmq9ygERwuQOauqRIM5PAqoxMhZSMMKWxJ2XwIAHxSXH/QFu/wD0fa19H183/AcEfFTB/wCgNd/+j7WvpCvRofw0ebX/AIjPJf2jufD/AIa/7DQ/9JLmvGsBnCnOM17L+0d/yL/hr/sND/0kua8cygiIU7jnnHr71x42Vpr0OvBq8H6k6yIrKByB6c1MH35AB49KrQRl3GevcYq26gRkKeSOi1yc528oiTpkknLdMmrgkygCqF7AHvVO3tBGpdlyx6AetTITvxKMgdMfypc76j5CxFIfNKHIJGAcfoDVu3VxkyjaW/hB6iogShHI2f3j2p6TMU4zjGWbH9aXNcOUsfdm/fMETptjPJ/GpGeNV7cc4jGSPctVVxHhWiRivdn4Gfb1qYsxjwBsUfLk4A/HHWqQWIDJI688DuFbk1XUkvjZxT2Kxggklj1Hc1WIZs7TgGtNbFWJ3cY2oNzD9KifcBgnk84H9aWIGP5Wz1/OluTtYrGQTxkg5ANUirEZJJzgYH86gl3quFHPXPpUgAR95dmB/h7A+1PG9gxCAZHA9vakxWK6xblAJLMeafaoCzAElV7e9WYYhuCryzDJxUscKIMqBtH60IljM4BAIC+pqrdTCJGJbHHapLuSJEbBwa525ne6bamcDqaoggu5pJ5MYzz07Cp7O1JOX+mTUltZE7cLgg81rWtqd2WGPagLdRlta7ASB9KsW1s38YwByT61cVdqkY4OKsRAEZA46HNJoqLsTW8e8qAMp61qRae74C/KSevoPWqdswTA5A6Ct7TLyG3KGYOx3ffUZwPpSW+o5NrYqNp7Dywjq4cjDKeDz1pJNJaJpGODj5m6/pW4L6I3m5DFHGqg7EXgEHrirMGqSRy+XGV8ll24mwc9zk+nNaWRlzSRxtzaCNmLEHHG/GMisq+RVAB6jiu88RCB7e2MLAOq7XAHyt75rhL8KoYls89KhqxcJcxkysCcd+lZVzGSDkYwf0rVchjnHvVeWMSYz09qVrgznLuDLFh0qTSbnypdjcDt7VqyW+9W4wR0rJntSvPcHr6VS8yGjs7F0niGOh7+9UtQhXehX7wPBrM0K8Mb7JTwT6966K6hE6DauenSpepSKFvl+DwwHPFTwrvO4vx1x/UUhgYNlc5HQCnCIrsPXnqOOtK9ikrk8gHGV/EVBJ8jPsbBI5z296kO8ABvmQd8dPY1HNllyo+UcjimaJDFSUJudsA9sZxV62dlxHIozjp2/CqkKO3zKf3ZGNtWEAVVU5A9c9KYNE7B2kURyBh2BOPwOavW1vDK580tHgZxsyQfpWY3mDJJG3sfT61ct1baJGZhg9evPakkTJFg2wBJR9yg8gdR9V601luIwfJZlx0ZO/1FWY7iKVsS7VbqNnT8D6+1V7tZQCbK5ikU8kdNp+h6VElZELfUpgh1I27sdfaqcqMD8meT90npVxgZYzvUo/qO9VixclCivtHfioTZViu0Yzkj+oqlOqIdv+rPXHrWi4wrbGOfQ1m3hxIOc96pz5UDjcpSgoVPXI4NV7ibBUnJUdx1FaJ+6FI59cVnygNmNkYdRkGmpktD4Z87SSBjimK6ySls4NQBGjU8Egc4pI3UrgjP4c1d7kNHofwMUr8VFPY6Ld4/7/2tfRlfN/wHkL/FMD+7o13g/wDbe1r6Qr0qH8NHlYj+Izyf9opd2heGR66yP/SS6ryCGJckbeD+dfQ3xN8HT+M9L062tdSj06ayvReLLJbGdW/dSR7SodO0uc57dK4NfgxratuHizTsn/qDP/8AJNc+Jw86sk4m+GrwpxtI4KCIKu44B/nTkb58bcfWu+/4U5rvH/FW6bx/1BX/APkmlHwd1wHP/CV6Zn/sCyf/ACTXP9TqHSsZSOGZSR976npUkUSL93hf613S/CPXhj/iqtL4/wCoLJ/8lUo+EuvYwfFWlH66LJ/8lUPB1B/XaZw7Kr7QRuVf4T0z61KpViFDblH8I6D8K7KT4Sa867f+Eq0sD20WT/5Jpi/CDXgf+Rs0w/8AcFf/AOSaawdRCeLpHK8k7jlx0AJ4qCbeAS3GeAcYyfYV25+FHiA/8zVpQHoNFk/+Sqjf4R68xJPivTP/AASyf/JNV9VmCxlPqcG8e1wwx5h657VC7EZweD0Oetd8fg7rhXafFmm4/wCwK/8A8k01Pg3rag/8VXppz1J0WT/5Jp/Vqhf12kcGA7NjbgueFHT8KtGCMJtiwrcbiRwPXHvXap8H9dQgjxZpmR0J0V+P/Jmph8J9fU7l8VaUGxjP9iSf/JVP6tMPrtI4GWNQxWMMR/COuKsRw7dpbBJGSAfu12kfwj16MYXxVpf/AIJZP/kqnH4T6+QAfFWlcf8AUFk/+SqPq1QTxtI4kJJ54YMMKefxou5FSJSR8q8H3xXcxfCnX433f8JRpLezaJJj/wBKqqXHwc124AD+LdOAHpo0n/yTQsLNEvGU2eUajdNcylUGADzjtUtjajGSOtekRfA3VoySPFmnsScndoz/APyTVpPg3rSdPFWmEe+iyf8AyTT+rzEsXTOHgtlCepq0V2gbegrth8JtfAwPFWlAf9gST/5KpD8JdfP/ADNel/8Aglk/+SqPq8weLpnENnaSSfaljZsgdjXaH4Ra8f8Ama9M/wDBLJ/8k0qfCPX1GB4r0s/XRZP/AJJo+rzBYumjl4zjKgfjVy3dkZRnKng4rfX4T+IFxjxXpf8A4JZP/kqpR8LvEQ/5mrSTjp/xJJP/AJKpfVqhX12mYUrpnfuZXx/F93PbFOMzu3GDhuQf8K3n+GXiNwQ3inSOf+oJJ/8AJVN/4Vh4j/6GvSv/AASyfl/x9U/q8xLF0upz93dLna0jHH8I4A965u8mLO20gjPavQJfhV4hlOW8VaV/4JZP/kqqr/B3XHJJ8V6YM+miyf8AyTQ8PMFi6SPOGLdDg59PShMA+3pXoR+C+tkf8jbp3/gmf/5JpR8F9bHTxbp3/glf/wCSaFhpk/W6ZwSICDnFU57cEsB35PFemL8HNcUADxZpvHror/8AyTQfg3rZ6+K9M/8ABLJ/8k0fV5h9bpnjc8DxS70zxzj1rpNCvRNFtLbTjA56mu8k+Cusv97xXpv/AIJX/wDkmorf4IaxBIXj8XWAyc4/sZ8f+lNH1aYfW6ZgC38rBUZjJ60lwigZAZi3IOMCu0j+FXiFFCjxXpRA9dFk/wDkqg/CrxAQVPinSdp/h/sSTH/pVR9WmNYymjhGiZowyc5GCv8AjUKEtlWG11ONp7j2rv0+FHiBQAvirSx15/sWT/5KqN/hFrrtuPirS8+2iyf/ACVR9XmafXaRxKFgv7tcYODnv9KE3ZO4Agnr6V3B+Emvf9DVpfp/yBZP/kqmt8I9fOP+Ks0zI7jRZOf/ACZo+rzF9dpHGszFSE9eQwzkVHMzKRglQDyBXa/8Kh1//obdN/8ABK//AMk0q/CPX1JI8WaZk9c6K/8A8k0fV5h9dpHJQ3G3Y+wMoHOOpqZWQgtDwTwM/wAjXSr8INeU/L4s00e39jSf/JNTH4UeIMg/8JVpWR3/ALFk5/8AJqk8NMTxlI415HTg42/3W5GfT1FQFlccYVgMnJ7128nwl8QSABvFmmcdD/YsmR/5NUh+EevEYPirSv8AwSSf/JVT9VqB9cpnn7F++4KeMiiSJWVTtznqDxXdt8HdcYDPizTeDkH+xZP/AJJp/wDwqHXuf+Ks0zn/AKgsn/yTS+qVB/XaR528YLErwV7elVJolLEtjcf1r0t/g5rrAj/hLdNH00V//kmoh8FdZ2bT4s04jOedFfj/AMmaPqlQl4ukzytk2nBHHaopYflJUAH2r1Y/BHWDjPi3T+On/Emfj/yZpT8EtYIx/wAJZp/r/wAgZ/8A5JpxwtTqS8XTOd+ARB+KfHX+xrrP/f8Ata+k68u+G/wtu/CPit9avNdg1AmzltFhisDb43vE5YsZXzjysYwOvWvUa76MXGCTOCtJTm5IKKKK0MgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Nodular skin infiltration.",
"    <br/>",
"    (B) Periorbital and conjunctival edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright &copy; 2012 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42982=[""].join("\n");
var outline_f41_62_42982=null;
var title_f41_62_42983="Female pelvic anatomy sagittal";
var content_f41_62_42983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Female pelvic anatomy sagittal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 606px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Uterus and vagina. Median section of vagina.",
"    <br/>",
"    (B) Magnetic resonance images (MRIs) of the female pelvis. Median (above) and coronal (below) MRIs showing the uriary bladder, body of the uterus, vagina, and intestine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     (A) Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"     <br>",
"      (B) Photo courtesy of Dr. Shirley McCarthy. Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th edition, Lippincott Williams &amp; Williams, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42983=[""].join("\n");
var outline_f41_62_42983=null;
var title_f41_62_42984="Reentry and the development of cardiac arrhythmias";
var content_f41_62_42984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reentry and the development of cardiac arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/62/42984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/62/42984/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/62/42984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/62/42984/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/62/42984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/62/42984/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/62/42984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias are generally produced by one of three mechanisms: enhanced automaticity, triggered activity, or reentry. Reentry, which occurs when a propagating impulse fails to die out after normal activation of the heart and persists to re-excite the heart after the refractory period has ended, is the electrophysiologic mechanism responsible for the majority of clinically important arrhythmias. Included among these arrhythmias are atrial fibrillation, atrial flutter, atrioventricular (AV) nodal reentry, AV reentry involving a bypass tract, ventricular tachycardia after myocardial infarction (MI) with the presence of left ventricular scar, and ventricular fibrillation.",
"   </p>",
"   <p>",
"    The first demonstration of reentry in its simplest form (ie, the ring model) probably occurred in 1906 following the application of a stimulus to tissue from a jellyfish which initiated rhythmic contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/1\">",
"     1",
"    </a>",
"    ]. However, reentry was first conceived as a mechanism for arrhythmias in 1913 when it was recognized that reentrant tachycardias arise from circular electrical pathways, often initiated by a blocked impulse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/2\">",
"     2",
"    </a>",
"    ]. It was subsequently realized that reentry tachycardias may also be due to other mechanisms, including functional or leading circle circuits and abnormal electrical circuits caused by diseased myocardium.",
"   </p>",
"   <p>",
"    The definition and characteristics of the different reentry circuits responsible for the most clinically significant arrhythmias are presented here, along with the electrophysiologic properties of these arrhythmias. The clinical presentation and management of the individual arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentrant tachycardia (variously named reentrant excitation, reciprocating tachycardia, circus movement, and reciprocal or echo beats) is defined as a continuous repetitive propagation of an excitatory wave traveling in a circular path, returning to its site of origin to reactivate that site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/1\">",
"     1",
"    </a>",
"    ]. The one event crucial to the development of a reentrant tachycardia is the failure of a group of fibers to activate during a depolarization wave. The initiation of a reentrant arrhythmia also requires the presence of myocardial tissue with the following electrophysiologic properties (",
"    <a class=\"graphic graphic_figure graphicRef52134 \" href=\"mobipreview.htm?9/50/10017\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjacent tissue or pathways must have different electrophysiologic properties (conduction and refractoriness) and be joined proximally and distally, forming a circuit. These circuits may be fixed or stationary or may move within the myocardial substrate (as occurs with spiral waves).",
"     </li>",
"     <li>",
"      Each involved pathway of the circuit must be capable of conducting an impulse in an",
"      <strong>",
"       antegrade and retrograde direction",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      Transient or permanent",
"      <strong>",
"       unidirectional block",
"      </strong>",
"      must exist as a result of heterogeneity of electrophysiologic properties of the myocardium. This event usually results when one electrical pathway has either a prolonged refractory period or a prolonged repolarization time, producing a wave which only travels down the remaining pathway.",
"     </li>",
"     <li>",
"      Conduction velocity in the normal unblocked pathway must be",
"      <strong>",
"       slow",
"      </strong>",
"      enough relative to the refractoriness of the blocked pathway to allow recovery of the previously blocked pathway. The impulse can then be conducted through the previously blocked but recovered pathway in a retrograde direction.",
"     </li>",
"     <li>",
"      Retrograde conduction in this previously blocked pathway must be slow enough to allow the normal pathway to recover, and again be capable of being excited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sustained reentrant arrhythmia will occur if these conditions are present and maintained.",
"   </p>",
"   <p>",
"    Patients who develop reentrant arrhythmias usually have an anatomic or electrical (functional) abnormality, which could be caused by an accessory pathway, by an abnormal separation of adjacent fibers that may form two limbs of a reentrant circuit, or by juxtaposed fibers that possess different electrophysiologic characteristics, often resulting from abnormalities of the myocardium and Purkinje fibers as the result of a disease process. Susceptible patients with appropriate underlying abnormalities usually do not suffer from incessant tachycardia because the different electrophysiologic mechanisms required for the initiation and maintenance of a reentrant tachycardia are infrequently present at exactly the same time.",
"   </p>",
"   <p>",
"    However, changes in heart rate or autonomic tone, ischemia, electrolyte or pH abnormalities, or the occurrence of a premature beat (which results in transient changes in the electrophysiologic properties of the myocardium) may be sufficient to initiate a reentrant tachycardia. In fact, premature depolarizations frequently initiate these tachyarrhythmias when there are appropriate electrophysiologic conditions (ie, slow conduction and unidirectional block). They are associated with more rapid depolarization (as they are early or premature) that may block in one pathway (ie, unidirectional block), conduct through the second pathway, retrogradely enter the first pathway, and then reenter the second pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CRITERIA FOR DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial criteria for the diagnosis of reentry proposed in the early 20th century are still valid, but are often difficult to prove [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, the following twelve conditions in the electrophysiology laboratory were proposed to either prove or to identify the existence of a reentrant tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activation of the myocardium mapped in one direction around a continuous loop.",
"     </li>",
"     <li>",
"      Correlation of continuous electrical activity occurring when the tachycardia develops.",
"     </li>",
"     <li>",
"      Correlation of unidirectional block with initiation of reentry.",
"     </li>",
"     <li>",
"      Initiation and termination by premature stimulation.",
"     </li>",
"     <li>",
"      Dependence of initiation of the arrhythmia on the site of pacing.",
"     </li>",
"     <li>",
"      Inverse relationship between the coupling interval of the initiating premature beat and the interval to the first tachycardia beat.",
"     </li>",
"     <li>",
"      Resetting of the tachycardia by a premature beat with an inverse relationship between the coupling interval of the premature beat and the cycle length of the first or return beat of the tachycardia.",
"     </li>",
"     <li>",
"      Fusion between a premature beat and the tachycardia beat followed by resetting.",
"     </li>",
"     <li>",
"      Transient entrainment (with external overdrive pacing, the ability to enter the reentrant circuit and \"capture\" the circuit, resulting in a tachycardia at the pacing rate and having fused complexes).",
"     </li>",
"     <li>",
"      Abrupt termination by premature stimulation.",
"     </li>",
"     <li>",
"      Dependence of initiation on a critical slowing of conduction in the circuit.",
"     </li>",
"     <li>",
"      Similarity with experimental models in which reentry is proven and is the only mechanism of tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The segment of the reentrant circuit that is, at any given time, no longer refractory and is capable of being excited is called the excitable gap&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Slowing of impulse conduction or shortening of refractoriness will increase the excitable gap. The longer the excitable gap, the more likely it is for an extrastimulus to enter the reentrant circuit and initiate or terminate a reentrant arrhythmia. In addition, entrainment is more likely to occur when the excitable gap is longer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF REENTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentry tachycardias have been divided into two different forms based upon the type of anatomic substrate used for the development of the arrhythmia: anatomic or functional. The original ring model requires the presence of an anatomic obstruction (due to a structural abnormality). There are also several models of functional reentry (due to electrophysiologic abnormalities) including the leading circle, anisotropic conduction, figure of eight, and spiral wave (",
"    <a class=\"graphic graphic_figure graphicRef52134 \" href=\"mobipreview.htm?9/50/10017\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54711 \" href=\"mobipreview.htm?4/0/4101\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anatomic reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic reentrant tachycardia most closely resembles the original description of reentry arrhythmia because it requires an anatomic obstacle, such as an area of fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/1\">",
"     1",
"    </a>",
"    ]. This discrete anatomic block creates a surrounding circular pathway, resulting in a fixed length and location of the reentrant circuit. A tachycardia is initiated when a depolarization wave splits into two limbs after going around this obstacle, creating a circus movement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Tachycardia rates are determined both by the wavelength (defined as conduction velocity and refractory period) and the length of the circuit or the pathlength.",
"   </p>",
"   <p>",
"    Examples of anatomic reentry are supraventricular tachycardia associated with an accessory pathway (preexcitation syndromes), AV nodal reentrant tachycardia, atrial flutter, ventricular tachycardia originating within the His-Purkinje system (bundle branch tachycardia), and ventricular tachycardia originating at the terminal portion of the His-Purkinje system or around an area of infarcted tissue. There is often a long excitable gap associated with anatomic reentry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Functional reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional reentry depends upon the intrinsic heterogeneity of the electrophysiologic properties of cardiac muscle (ie, dispersion of excitability or refractoriness) as well as anisotropic differences in intercellular resistances. There is no anatomic obstacle present.",
"   </p>",
"   <p>",
"    Functional circuits have the following properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They tend to be small, rapidly conducting, and unstable in that the waves they generate may fragment, establishing other areas of reentry.",
"     </li>",
"     <li>",
"      Circuit times and hence tachycardia rates are significantly dependent upon the refractory period of the involved tissue.",
"     </li>",
"     <li>",
"      The location and size of these tachycardias vary due to the absence of an anatomic block.",
"     </li>",
"     <li>",
"      There is usually a short excitable gap associated with functional reentry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One animal study reported the following additional properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thin layer of activation near the core or central region of the circuit is responsible for the maintenance of reentry; the remaining portion of the tissue is activated passively by the outward propagation of wave fronts away from the core.",
"     </li>",
"     <li>",
"      Access to the tissue near the core is essential for termination of reentry by a point stimulation.",
"     </li>",
"     <li>",
"      To terminate reentry with a stimulus applied away from the core, the stimulus must occur at certain critical coupling intervals and the line connecting the stimulus and the core must be roughly parallel to the fiber orientation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leading circle concept",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this model, functional reentry involves the propagation of an impulse around a functionally determined region of unexcitable tissue or a refractory core and among neighboring fibers with different electrophysiologic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The excitation wave then travels in the smallest possible circuit with the head of the impulse having just enough strength to excite relatively refractory tissue ahead of it. Thus, the \"head of the circulating wave front is continuously biting its tail of refractoriness\" (",
"    <a class=\"graphic graphic_figure graphicRef52134 \" href=\"mobipreview.htm?9/50/10017\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a small excitable gap in this setting. The circulating wave activates peripheral tissue but also gives rise to wavelets that collide at the center, rendering it refractory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anisotropic reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anisotropic reentry is determined by the orientation of myocardial fibers and the manner in which these fibers and muscle bundles are connected to each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In general, the electrical resistances between cells is dependent upon fiber orientation, ie, cell-to-cell communication is more rapid between cell that are parallel to each other, while communication is slower when cells are transverse to each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anisotropic reentry occurs in myocardium composed of tissue with structural features different from those of adjacent tissue, resulting in variations in conduction velocities and repolarization properties (referred to as anisotropic myocardium) (",
"    <a class=\"graphic graphic_figure graphicRef54711 \" href=\"mobipreview.htm?4/0/4101\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/16\">",
"     16",
"    </a>",
"    ]. As an example, an impulse propagating parallel to the long axis of the myocardial tissue will typically travel three to five times faster than the same impulse traveling in the transverse direction. Therefore, anatomic anisotropy can cause heterogeneity of electrophysiologic properties which can result in blocked impulses and slowed conduction, thereby setting the stage for reentry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Figure of eight reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;This model of reentry involves two counter rotating circuits around a center that is anatomically damaged, but is common to both circuits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/18\">",
"     18",
"    </a>",
"    ]. The reentrant beat produces a wavefront that circulates in both directions around a long line of functional conduction block and rejoins on the distal side of the block. This results in two concomitant circuits, forming a \"figure of eight\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Spiral wave (rotor) activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this model of reentry, there are concentric circular waves that result in reverberators or rotating vortices of electrical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Spiral waves, which typically describe reentry in two dimensions, can be initiated in an inhomogeneous, excitable medium whenever there is disruption of the wave front. Spiral waves rotate around an organizing center or core, which includes cells with a transmembrane potential that has a reduced amplitude, duration and rate of depolarization (ie, slow upstroke velocity of phase 0); these cells are potentially excitable, but remain unexcited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/22\">",
"     22",
"    </a>",
"    ]. Anisotropy and anatomic obstacles can modify the characteristics and spatiotemporal behavior of the spiral. In addition, the spiral waves may give rise to daughter spirals which can result in disorganized electrical activity; this may be the mechanism for ventricular fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirals may be stationary (the possible mechanism for monomorphic VT), or may continuously drift or migrate away from their origin (possibly the mechanism for polymorphic ventricular tachycardia or atrial fibrillation), or may be anchored, initially drifting and then becoming stationary by anchoring to a small obstacle (",
"    <a class=\"graphic graphic_waveform graphicRef56857 \" href=\"mobipreview.htm?35/32/36356\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Phase two reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase 2 reentry is a phenomenon largely related to Brugada syndrome and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link&amp;anchor=H17#H17\">",
"     \"Brugada syndrome\", section on 'Ventricular arrhythmias and phase two reentry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL ARRHYTHMIAS DUE TO REENTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentry can cause many clinically significant arrhythmias including sinus node reentry, atrial flutter, atrial fibrillation, AV nodal reentry, AV reentry using an accessory bypass tract, and ventricular tachyarrhythmias (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"mobipreview.htm?38/33/39441\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sinus node reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;SA nodal reentrant tachycardia is due to a reentrant circuit that is in the area of the sinus node and involves this structure and the sinoatrial junction. Thus, electrophysiologic studies reveal atrial activation and conduction that is identical to sinus rhythm, with the earliest recorded atrial activation in the reentrant tachycardia being located near the sinus node [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with any reentrant arrhythmia, SA nodal reentrant tachycardia is usually initiated by a premature atrial stimulus, but also rarely by a ventricular premature stimulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It is clinically and electrocardiographically difficult to distinguish this arrhythmia from sinus tachycardia. Both have identical P waves at a rate that is usually less than 150",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    The abrupt onset and termination of the reentrant arrhythmia is the only clinical distinction from sinus tachycardia which has an onset and termination that is gradual and not abrupt (",
"    <a class=\"graphic graphic_waveform graphicRef76364 \" href=\"mobipreview.htm?17/28/17862\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34166?source=see_link\">",
"     \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reentrant circuit resulting in typical atrial flutter has been localized to the right atrium and is usually due to an anatomic abnormality (area of fibrosis) localized at the bottom of the right atrium, in the area between the inferior vena cava and the tricuspid annulus. This is known as the \"isthmus\" (and hence the term \"isthmus dependent\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. Atrial flutter is divided into two types based upon the atrial rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. Atrial flutter is divided into two types based upon the atrial rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I (classic, typical, or common atrial flutter) has an atrial rate of 240 to 320",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      (",
"      <a class=\"graphic graphic_waveform graphicRef74395 \" href=\"mobipreview.htm?37/54/38757\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type II has rates of 320 to 440",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      (",
"      <a class=\"graphic graphic_waveform graphicRef68846 \" href=\"mobipreview.htm?23/35/24119\">",
"       waveform 4",
"      </a>",
"      ). This form of atrial flutter is due to a functional abnormality. Thus, the circuit is smaller and the rate of conduction faster. It is not isthmus dependent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both forms of flutter have constant beat to beat intervals, polarity, morphology, and amplitude of atrial electrograms; however, only type I can be terminated by rapid overdrive pacing. Type I flutter can also be occasionally entrained or terminated by a single premature beat. This is due to the fact that there is a longer excitable gap with type I flutter. In contrast, there is a short or even absent excitable gap in type II flutter and for this reason it cannot be entrained or terminated by overdrive pacing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is currently felt to be caused by multiple leading circle reentrant impulses, ie, the multiple wavelet theory (",
"    <a class=\"graphic graphic_figure graphicRef73931 \" href=\"mobipreview.htm?30/8/30853\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Coarse atrial fibrillation is thought to be caused by a relatively small number of large sized waves, while fine fibrillation is caused by many small, fragmented waves (",
"    <a class=\"graphic graphic_waveform graphicRef73958 graphicRef53988 \" href=\"mobipreview.htm?8/18/8490\">",
"     waveform 5A-B",
"    </a>",
"    ). It has been estimated that a minimum of six circuits is needed to sustain atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     AV nodal reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV nodal reentrant tachycardia, one of the most frequent paroxysmal supraventricular tachycardias, is caused by a reentrant circuit located within the AV node. It is the result of dual AV nodal pathways, both of which conduct in an antegrade and retrograde direction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. The slow or alpha pathway typically has a slower conduction velocity and shorter refractory period than the faster conducting beta pathway.",
"   </p>",
"   <p>",
"    AV nodal reentrant tachycardias (AVNRT) have been divided into two types based upon their mechanism of conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The common type, comprising about 90 percent of all AVNRTs, is usually initiated by an atrial premature complex that travels down the slow pathway and then back along the fast pathway (slow-fast) (",
"      <a class=\"graphic graphic_figure graphicRef54290 \" href=\"mobipreview.htm?32/3/32830\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79760 \" href=\"mobipreview.htm?1/35/1598\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The uncommon type of AVNRT uses the fast pathway in an antegrade manner and the slow pathway in the retrograde manner (fast-slow) (",
"      <a class=\"graphic graphic_figure graphicRef66828 \" href=\"mobipreview.htm?31/31/32240\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56806 \" href=\"mobipreview.htm?22/16/22799\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Atrioventricular reentry using an accessory bypass tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an accessory bypass tract, which has electrophysiologic properties that are different from those of the normal AV node-His Purkinje system, favors the development of reentrant tachycardia by providing two limbs of a possible reentrant circuit: one limb is the AV node; and the other is the bypass tract which directly connects an atrium and a ventricle, bypassing the AV node [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The circuit, known as a macroreentrant circuit, is formed by a proximal connection via the atria and a distal connection within the ventricular myocardium. Accessory bypass tracts can be found along the perimeter of both the mitral and tricuspid valves, may connect the atrium directly to the distal AV node or His Purkinje system, and may also connect the AV node to either the right bundle or the ventricle, termed nodofascicular and nodoventricular tracts, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accessory bypass tracts may conduct reentrant impulses either in a retrograde or antegrade direction. Orthodromic atrioventricular reentrant tachycardia (AVRT) is defined by conduction of the depolarization impulse down the AV node in an antegrade manner and its return via the accessory tract in a retrograde manner (",
"    <a class=\"graphic graphic_waveform graphicRef68804 \" href=\"mobipreview.htm?6/4/6217\">",
"     waveform 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71302 \" href=\"mobipreview.htm?15/35/15926\">",
"     figure 9",
"    </a>",
"    ). Antidromic AV reentrant tachycardia is characterized by the reverse sequence in which the depolarization wave travels down the bypass tract in an antegrade direction and returns via the AV node (",
"    <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"mobipreview.htm?24/55/25464\">",
"     waveform 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50433 \" href=\"mobipreview.htm?34/52/35655\">",
"     figure 10",
"    </a>",
"    ). Orthodromic AVRT is most common, occurring in about 90 percent of symptomatic patients with accessory bypass tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/45\">",
"     45",
"    </a>",
"    ]; antidromic AVRT accounts for the remaining 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The conduction characteristics of bypass tracts can vary significantly not only among patients, but also between retrograde and antegrade directions within the same tract in a given patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/47\">",
"     47",
"    </a>",
"    ]. As an example, a single bypass tract may be involved in both orthodromic and antidromic AVRTs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia and fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (monomorphic) and fibrillation, the two most lethal arrhythmias, are both caused by reentry (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"mobipreview.htm?28/0/28680\">",
"     waveform 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef80454 \" href=\"mobipreview.htm?29/47/30455\">",
"     waveform 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/48\">",
"     48",
"    </a>",
"    ]. Ischemia, infarction, and the resulting fibrosis most often produce the cardiac substrate necessary for reentrant ventricular arrhythmias: areas of unidirectional block; and sufficiently slow conduction. The reentrant circuits are small, involving the distal Purkinje fibers, and this has been termed \"microreentry\". Monomorphic ventricular tachycardia can be initiated and terminated by appropriately timed premature ventricular impulses, by burst pacing, or by cardioversion. Ventricular fibrillation can be initiated by appropriately time premature ventricular impulses but can be terminated only with defibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although sustained ventricular tachycardias with different QRS morphologies (polymorphic ventricular tachycardia) occur spontaneously or during electrophysiologic study after a myocardial infarction, they most commonly arise from reentrant circuits located in the region of the infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/49\">",
"     49",
"    </a>",
"    ]. Factors responsible for different exit routes from circuits in the same region, leading to multiple morphologies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Different direction of rotation around the same circuit",
"     </li>",
"     <li>",
"      Small differences in the reentrant circuit",
"     </li>",
"     <li>",
"      Reentrant circuits with different sizes and shapes",
"     </li>",
"     <li>",
"      Differences in the refractoriness of the ventricular myocardium and hence its ability to conduct the impulse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While sustained ventricular tachycardia generally involves one reentrant circuit, or perhaps a single spiral, ventricular fibrillation results from multiple circuits simultaneously activating the ventricular myocardium. In an animal model, the most likely underlying mechanism was rotating spiral waves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/50\">",
"     50",
"    </a>",
"    ]. With the development of global ischemia during VF, the rate of VF decreases due to an increase in the rotation period of the spiral waves that results from an increase in the core area.",
"   </p>",
"   <p>",
"    It has frequently been observed that VF is often preceded by a variable period of VT. The transition from a sustained organized VT to disorganized VF probably involves the breakup of a single propagating wave or spiral into multiple daughter wavelets or spirals, a result of heterogeneity of myocardial electrophysiologic properties (functional block) or anatomic obstacles. This is identical to the process seen with atrial fibrillation. These wavelets rarely reenter themselves but can re-excite portions of the myocardium recently activated by another wavefront, a process called random reentry. As a result, there are multiple wavefronts of activation that may collide with each other, extinguishing themselves or creating new wavelets or spiral and wavefronts, thereby perpetuating the arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Spontaneous wave breaks without apparent collision may also occur during ventricular fibrillation; in an experimental model,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    can reduce the incidence of these events, decreasing the number of wavelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneously occurring reentrant arrhythmias are infrequent in a healthy ventricle, because the substrate for reentry is lacking. However, these tachyarrhythmias can occur in a normal heart in the right clinical setting. As an example, bundle branch reentry can be initiated by an early coupled premature impulse; ventricular tachycardia may then develop based upon the difference in the refractory periods either between the two bundles or between one of the bundles and ventricular muscle (",
"    <a class=\"graphic graphic_figure graphicRef75164 \" href=\"mobipreview.htm?4/55/4976\">",
"     figure 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventricular fibrillation can also be induced in a healthy heart if a properly timed, strong stimulus is applied to the ventricle. The critical moment occurs immediately after the refractory period, generally at upstroke of the T wave just prior to its peak, a period of time termed the vulnerable period, when a heterogeneous state of excitability and refractoriness exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/62/42984/abstract/54\">",
"     54",
"    </a>",
"    ]. A strong stimulus applied during the vulnerable period is postulated to set up a number of functional reentrant circuits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6660791\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac arrhythmias are generally produced by one of three mechanisms: enhanced automaticity, triggered activity, or reentry. Reentry, which occurs when a propagating impulse fails to die out after normal activation of the heart and persists to re-excite the heart after the refractory period has ended, is the electrophysiologic mechanism responsible for the majority of clinically important arrhythmias. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the one event which is crucial to the development of a reentrant tachycardia is the failure of a group of fibers to activate during a depolarization wave, the initiation of a reentrant arrhythmia also requires various electrophysiologic properties (eg, ability to conduct antegrade and retrograde, presence of unidirectional block, etc) to be present concurrently within the myocardial tissue making up the circuit. Changes in heart rate or autonomic tone, ischemia, electrolyte or pH abnormalities, or the occurrence of a premature beat (which results in transient changes in the electrophysiologic properties of the myocardium) may be sufficient to initiate a reentrant tachycardia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twelve conditions which may be seen during invasive electrophysiology study in the electrophysiology laboratory have been proposed to either prove or to identify the existence of a reentrant tachycardia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Criteria for diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reentry tachycardias have been divided into two different forms based upon the type of anatomic substrate used for the development of the arrhythmia: anatomic or functional.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anatomic reentrant tachycardia requires a discrete anatomic obstacle, such as an area of fibrosis, resulting in a fixed length and location of the reentrant circuit. Examples of anatomic reentry are supraventricular tachycardia associated with an accessory pathway (preexcitation syndromes), AV nodal reentrant tachycardia, atrial flutter, ventricular tachycardia originating within the His-Purkinje system (bundle branch tachycardia), and ventricular tachycardia originating at the terminal portion of the His-Purkinje system or around an area of infarcted tissue. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Anatomic reentry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional reentry depends upon the intrinsic heterogeneity of the electrophysiologic properties of cardiac muscle (ie, dispersion of excitability or refractoriness) as well as anisotropic differences in intercellular resistances. There is no anatomic obstacle present. Examples of functional reentry include type II (atypical) atrial flutter and atrial tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mayer AG. Rhythmical pulsation in scyphomedusae. Carnegie Institution of Washington Publication No. 47, 1906.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/2\">",
"      Mines GR. On dynamic equilibrium in the heart. J Physiol 1913; 46:349.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis T. The Mechanism and Graphic Registration of the Heart Beat, &amp; Sons, London 1925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/4\">",
"      Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of trachycardia. Circ Res 1973; 33:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/5\">",
"      Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. II. The role of nonuniform recovery of excitability in the occurrence of unidirectional block, as studied with multiple microelectrodes. Circ Res 1976; 39:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/6\">",
"      Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The \"leading circle\" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977; 41:9.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman BF. Circus movement in the AV ring. In: Cardiac Electrophysiology: A Textbook, Rosen MR, Janse MJ, Wi AL (Eds), Futura, Mt Kisco, NY 1990. p.573.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/8\">",
"      Waldo AL, MacLean WA, Karp RB, et al. Entrainment and interruption of atrial flutter with atrial pacing: studies in man following open heart surgery. Circulation 1977; 56:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/9\">",
"      Frame LH, Page RL, Hoffman BF. Atrial reentry around an anatomic barrier with a partially refractory excitable gap. A canine model of atrial flutter. Circ Res 1986; 58:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/10\">",
"      Gough WB, Mehra R, Restivo M, et al. Reentrant ventricular arrhythmias in the late myocardial infarction period in the dog. 13. Correlation of activation and refractory maps. Circ Res 1985; 57:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/11\">",
"      Kamjoo K, Uchida T, Ikeda T, et al. Importance of location and timing of electrical stimuli in terminating sustained functional reentry in isolated swine ventricular tissues: evidence in support of a small reentrant circuit. Circulation 1997; 96:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/12\">",
"      Spach MS, Miller WT 3rd, Geselowitz DB, et al. The discontinuous nature of propagation in normal canine cardiac muscle. Evidence for recurrent discontinuities of intracellular resistance that affect the membrane currents. Circ Res 1981; 48:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/13\">",
"      Spach MS, Dolber PC, Heidlage JF. Influence of the passive anisotropic properties on directional differences in propagation following modification of the sodium conductance in human atrial muscle. A model of reentry based on anisotropic discontinuous propagation. Circ Res 1988; 62:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/14\">",
"      Brugada J, Boersma L, Kirchhof CJ, et al. Reentrant excitation around a fixed obstacle in uniform anisotropic ventricular myocardium. Circulation 1991; 84:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/15\">",
"      Spach MS, Dolber PC, Heidlage JF. Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria. A mechanism for both preventing and initiating reentry. Circ Res 1989; 65:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/16\">",
"      Allessie MA, Schalij MJ, Kirchhof CJ, et al. Experimental electrophysiology and arrhythmogenicity. Anisotropy and ventricular tachycardia. Eur Heart J 1989; 10 Suppl E:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/17\">",
"      Allessie MA, Schalij MJ, Kirchhof CJ, et al. Electrophysiology of spiral waves in two dimensions: the role of anisotropy. Ann N Y Acad Sci 1990; 591:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/18\">",
"      El-Sherif N, Smith RA, Evans K. Canine ventricular arrhythmias in the late myocardial infarction period. 8. Epicardial mapping of reentrant circuits. Circ Res 1981; 49:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/19\">",
"      Davidenko JM, Kent PF, Chialvo DR, et al. Sustained vortex-like waves in normal isolated ventricular muscle. Proc Natl Acad Sci U S A 1990; 87:8785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/20\">",
"      Pertsov AM, Davidenko JM, Salomonsz R, et al. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res 1993; 72:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/21\">",
"      Davidenko JM, Pertsov AV, Salomonsz R, et al. Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature 1992; 355:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/22\">",
"      Athill CA, Ikeda T, Kim YH, et al. Transmembrane potential properties at the core of functional reentrant wave fronts in isolated canine right atria. Circulation 1998; 98:1556.",
"     </a>",
"    </li>",
"    <li>",
"     Garfinkle A, Qu Z. Nonlinear dynamics of excitation and propagation in cardiac muscle. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes DP, Jalife J (Eds), WB Saunders, Philadelphia 1999. p.515.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/24\">",
"      Davidenko JM. Spiral wave activity: a possible common mechanism for polymorphic and monomorphic ventricular tachycardias. J Cardiovasc Electrophysiol 1993; 4:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/25\">",
"      Wathen MS, Klein GJ, Yee R, Natale A. Classification and terminology of supraventricular tachycardia. Diagnosis and management of the atrial tachycardias. Cardiol Clin 1993; 11:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/26\">",
"      Narula OS. Sinus node re-entry: a mechanism for supraventricular tachycardia. Circulation 1974; 50:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/27\">",
"      Wu D, Amat-y-leon F, Denes P, et al. Demonstration of sustained sinus and atrial re-entry as a mechanism of paroxysmal supraventricular tachycardia. Circulation 1975; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/28\">",
"      Wells JL Jr, MacLean WA, James TN, Waldo AL. Characterization of atrial flutter. Studies in man after open heart surgery using fixed atrial electrodes. Circulation 1979; 60:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/29\">",
"      Cosio FG, L&oacute;pez-Gil M, Goicolea A, Arribas F. Electrophysiologic studies in atrial flutter. Clin Cardiol 1992; 15:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/30\">",
"      Cosio FG, Paylos J, Requena M, Fern&aacute;ndez-Y&aacute;&ntilde;ez J. Influence of basic atrial rhythm on intraatrial conduction of extrastimuli. Am J Cardiol 1984; 53:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/31\">",
"      Cosio FG, Arribas F, Palacios J, et al. Fragmented electrograms and continuous electrical activity in atrial flutter. Am J Cardiol 1986; 57:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/32\">",
"      Disertori M, Inama G, Vergara G, et al. Evidence of a reentry circuit in the common type of atrial flutter in man. Circulation 1983; 67:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/33\">",
"      Olshansky B, Okumura K, Hess PG, Waldo AL. Demonstration of an area of slow conduction in human atrial flutter. J Am Coll Cardiol 1990; 16:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/34\">",
"      Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacol Dyn Ther 1962; 140:183.",
"     </a>",
"    </li>",
"    <li>",
"     Allessie MA, Lammers WJEP, Bonke FIM, et al. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In: Cardiac Arrhythmias, Zipes DP, Jalife J (Eds), Grune &amp; Stratton, New York 1985. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/36\">",
"      Denes P, Wu D, Amat-y-Leon F, et al. The determinants of atrioventricular nodal re-entrance with premature atrial stimulation in patients with dual A-V nodal pathways. Circulation 1977; 56:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/37\">",
"      Denes P, Wu D, Dhingra R, et al. Dual atrioventricular nodal pathways. A common electrophysiological response. Br Heart J 1975; 37:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/38\">",
"      Denes P, Wu D, Dhingra RC, et al. Demonstration of dual A-V nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation 1973; 48:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/39\">",
"      Rosen KM, Mehta A, Miller RA. Demonstration of dual atrioventricular nodal pathways in man. Am J Cardiol 1974; 33:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/40\">",
"      Sung RJ, Waxman HL, Saksena S, Juma Z. Sequence of retrograde atrial activation in patients with dual atrioventricular nodal pathways. Circulation 1981; 64:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/41\">",
"      Wu D, Denes P, Dhingra R, et al. New manifestations of dual A-V nodal pathways. Eur J Cardiol 1975; 2:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/42\">",
"      Sung RJ, Styperek JL, Myerburg RJ, Castellanos A. Initiation of two distinct forms of atrioventricular nodal reentrant tachycardia during programmed ventricular stimulation in man. Am J Cardiol 1978; 42:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/43\">",
"      Gallagher JJ, Sealy WC, Kasell J, Wallace AG. Multiple accessory pathways in patients with the pre-excitation syndrome. Circulation 1976; 54:571.",
"     </a>",
"    </li>",
"    <li>",
"     Wellens HJJ, Brugada P. Value of programmed stimulation of the heart in patients with the Wolff-Parkinson-White syndrome. In: Tachycardias: Mechanisms, Diagnosis, Treatment, Josephson ME, Wellens HJJ (Eds), Lea &amp; Febiger, Philadelphia 1984. p.1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/45\">",
"      Newman BJ, Donoso E, Friedberg CK. Arrhythmias in the Wolff-Parkinson-White syndrome. Prog Cardiovasc Dis 1966; 9:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/46\">",
"      Bardy GH, Packer DL, German LD, Gallagher JJ. Preexcited reciprocating tachycardia in patients with Wolff-Parkinson-White syndrome: incidence and mechanisms. Circulation 1984; 70:377.",
"     </a>",
"    </li>",
"    <li>",
"     Wellens HJJ. Electrophysiologic properties of the accessory pathway in Wolff-Parkinson-White syndrome. In: Conduction System of the Heart: Structure, Function, and Clinical Implication, Wellens HJJ, Lie KI, Janse MJ (Eds), Stenfert Krose BV, Leiden 1976. p.567.",
"    </li>",
"    <li>",
"     Josephson ME, Marchlinski FE, Buxton AE, et al. Electrophysiologic basis for sustained ventricular tachycardia: The role of reentry. In: Tachycardias: Mechanisms, Diagnosis, Treatment, Josephson ME, Wellens HJJ (Eds), &amp; Febiger, Philadelphia 1984. p.305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/49\">",
"      Costeas C, Peters NS, Waldecker B, et al. Mechanisms causing sustained ventricular tachycardia with multiple QRS morphologies: results of mapping studies in the infarcted canine heart. Circulation 1997; 96:3721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/50\">",
"      Mandapati R, Asano Y, Baxter WT, et al. Quantification of effects of global ischemia on dynamics of ventricular fibrillation in isolated rabbit heart. Circulation 1998; 98:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/51\">",
"      Lee JJ, Kamjoo K, Hough D, et al. Reentrant wave fronts in Wiggers' stage II ventricular fibrillation. Characteristics and mechanisms of termination and spontaneous regeneration. Circ Res 1996; 78:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/52\">",
"      Kwan YY, Fan W, Hough D, et al. Effects of procainamide on wave-front dynamics during ventricular fibrillation in open-chest dogs. Circulation 1998; 97:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/53\">",
"      Akhtar M, Gilbert C, Wolf FG, Schmidt DH. Reentry within the His-Purkinje system. Elucidation of reentrant circuit using right bundle branch and His bundle recordings. Circulation 1978; 58:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/62/42984/abstract/54\">",
"      Wiggers CJ, Wegria R. Ventricular fibrillation due to single, localized induction and condenser shocks applied during the vulnerable phase of ventricular systole. Am J Physiol 1940; 128:500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 954 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42984=[""].join("\n");
var outline_f41_62_42984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6660791\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CRITERIA FOR DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF REENTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anatomic reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functional reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leading circle concept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anisotropic reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Figure of eight reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Spiral wave (rotor) activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Phase two reentry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL ARRHYTHMIAS DUE TO REENTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sinus node reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AV nodal reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Atrioventricular reentry using an accessory bypass tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ventricular tachycardia and fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6660791\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/954|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/50/10017\" title=\"figure 1\">",
"      Mechanisms of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/0/4101\" title=\"figure 2\">",
"      Anisotropic reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/33/39441\" title=\"figure 3\">",
"      Sites of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/8/30853\" title=\"figure 4\">",
"      Reentry in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/3/32830\" title=\"figure 5\">",
"      Typical atrioventricular nodal reentrant tahcycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/35/1598\" title=\"figure 6\">",
"      Common slow fast AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/31/32240\" title=\"figure 7\">",
"      Atypical atrioventricular nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/16/22799\" title=\"figure 8\">",
"      Uncommon fast slow AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/35/15926\" title=\"figure 9\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/52/35655\" title=\"figure 10\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/55/4976\" title=\"figure 11\">",
"      Mechanism of bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/954|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/32/36356\" title=\"waveform 1\">",
"      Mechanism of torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?17/28/17862\" title=\"waveform 2\">",
"      ECG SA nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?37/54/38757\" title=\"waveform 3\">",
"      Typical atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?23/35/24119\" title=\"waveform 4\">",
"      Atrial flutter Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?6/32/6663\" title=\"waveform 5A\">",
"      Atrial fibrillation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/14/4325\" title=\"waveform 5B\">",
"      Atrial fibrillation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?6/4/6217\" title=\"waveform 6\">",
"      12 lead ECG orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?24/55/25464\" title=\"waveform 7\">",
"      12 lead ECG antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/0/28680\" title=\"waveform 8\">",
"      ECG Monomorphic VT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/47/30455\" title=\"waveform 9\">",
"      ECG Ventricular fibrillation tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34166?source=related_link\">",
"      Sinoatrial nodal reentrant tachycardia (SANRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42985="Ethinyl estradiol and drospirenone: Drug information";
var content_f41_62_42985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and drospirenone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/37/22102?source=see_link\">",
"    see \"Ethinyl estradiol and drospirenone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gianvi&trade;;",
"     </li>",
"     <li>",
"      Loryna&trade;;",
"     </li>",
"     <li>",
"      Ocella&trade;;",
"     </li>",
"     <li>",
"      Syeda&trade;;",
"     </li>",
"     <li>",
"      Vestura&trade;;",
"     </li>",
"     <li>",
"      Yasmin&reg;;",
"     </li>",
"     <li>",
"      Yaz&reg;;",
"     </li>",
"     <li>",
"      Zarah&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Yasmin&reg;;",
"     </li>",
"     <li>",
"      Yaz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acne (Yaz&reg;):",
"     </b>",
"     Females: Oral: Refer to dosing for contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Contraception (Yasmin&reg;, Yaz&reg;), PMDD (Yaz&reg;):",
"     </b>",
"     Female: Oral: Dosage is 1 tablet daily for 28 consecutive days. Dosing may be started on the first day of menstrual period (Day 1 starter) or on the first Sunday after the onset of the menstrual period (Sunday starter).",
"     <b>",
"      With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Day 1 starter:",
"     </i>",
"     Dose starts on first day of menstrual cycle taking 1 tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sunday starter:",
"     </i>",
"     Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Switching from a different contraceptive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral contraceptive: Start on the same day that a new pack of the previous oral contraceptive would have been taken",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Transdermal patch, vaginal ring, injection: Start on the day the next dose would have been due",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     IUD or implant: Start on the day of removal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Use after childbirth (in women who are not breast-feeding) or after second trimester abortion:",
"     </i>",
"     Therapy may be started &ge;4 weeks postpartum. Pregnancy should be ruled out prior to treatment if menstrual periods have not restarted and an additional method of contraception (nonhormonal) should be used until after the first 7 days of consecutive administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Missed doses:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If doses have been missed during the first 3 weeks and the menstrual period is missed, pregnancy should be ruled out prior to continuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Missed doses (monophasic formulations)",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered or 2 tablets next 2 days.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 or three consecutive doses missed at any time:",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Day 1 starter: Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Sunday starter: Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Any number of doses missed in week 4: Continue taking one pill each day until pack is empty; no back-up method of contraception is needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F163815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not to be used prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acne (Yaz&reg;):",
"     </b>",
"     Females: Children &ge;14 years: Oral:  Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Contraception (Yasmin&reg;, Yaz&reg;), PMDD (Yaz&reg;):",
"     </b>",
"     Females: Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F163808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Ethinyl estradiol 0.03 mg and drospirenone 3 mg [21 active tablets and 7 inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gianvi&trade;: Ethinyl estradiol 0.02 mg and drospirenone 3 mg [24 light pink active tablets and 4 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loryna&trade;: Ethinyl estradiol 0.02 mg and drospirenone 3 mg [24 peach active tablets and 4 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocella&trade;: Ethinyl estradiol 0.03 mg and drospirenone 3 mg [21 yellow active tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Syeda&trade;: Ethinyl estradiol 0.03 mg and drospirenone 3 mg [21 yellow active tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vestura&trade;: Ethinyl estradiol 0.02 mg and drospirenone 3 mg [24 pink active tablets and 4 peach inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Yasmin&reg;: Ethinyl estradiol 0.03 mg and drospirenone 3 mg [21 yellow active tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Yaz&reg;: Ethinyl estradiol 0.02 mg and drospirenone 3 mg [24 light pink active tablets and 4 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zarah&reg;: Ethinyl estradiol 0.03 mg and drospirenone 3 mg [21 blue active tablets and 7 peach inactive tablets] (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be taken at the same time each day, either after the evening meal or at bedtime. If severe vomiting or diarrhea occurs, additional contraception (nonhormonal) should be used. If vomiting occurs within 3-4 hours of dosing, consider the dose to be missed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy; treatment of premenstrual dysphoric disorder (PMDD); treatment of acne",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F163819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Yaz&reg; may be confused with Beyaz&trade;, Yasmin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following reactions have been associated with oral contraceptive use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Increased risk or evidence of association with use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gallbladder disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions considered drug related:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, varicose vein aggravation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Melasma, rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), carbohydrate tolerance decreased, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical ectropion, cervical secretion/erosion, vaginal candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adverse reactions in which association is not confirmed or denied:",
"     </i>",
"     Acne, appetite changes, Budd-Chiari syndrome, cataracts, colitis, cystitis-like syndrome, dizziness, dysmenorrhea, erythema multiforme, erythema nodosum, headache, hemolytic uremic syndrome, hemorrhagic eruption, hirsutism, libido changes, nervousness, optic neuritis (with or without partial or complete loss of vision), pancreatitis, premenstrual syndrome, porphyria, renal function impaired, scalp hair loss, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adrenal insufficiency, breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, renal impairment, undiagnosed abnormal uterine bleeding. Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), hypercoagulopathies (inherited or acquired), headaches with focal neurological symptoms, hypertension (uncontrolled), migraine headaches if &gt;35 years of age, thrombogenic valvular or rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation), women &gt;35 years of age who smoke.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Estrogens may induce or exacerbate symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chloasma: Use caution with a history of chloasma gravidarum; women with a tendency to chloasma should avoid sun and ultraviolet radiation exposure during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Drospirenone has antimineralocorticoid activity that may lead to hyperkalemia in patients with renal insufficiency, hepatic dysfunction, or adrenal insufficiency; use caution with medications that may increase serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased (may increase risk of pancreatitis). Use with caution in patients with familial defects of lipoprotein metabolism; consider an alternate form of contraception in women with uncontrolled dyslipidemias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Contraceptives may increase the risk of thromboembolism. Discontinue if an arterial or venous thrombotic event occurs. Risk may be greater with contraceptives containing drospirenone. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with hypercoagulopathies (inherited or acquired).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Unscheduled bleeding/spotting may occur especially within the first 3 months of use. Development of irregular, unresolving vaginal bleeding following previously regular cycles warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for cardiovascular disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of stroke or myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use another form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe, or persistent headaches.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Use is contraindicated in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acne use: For use only in females &ge;14 years of age who have reached menarche, who also desire combination hormonal contraceptive therapy, are unresponsive to topical acne treatments, and have no contraindications to combination hormonal contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Oral contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). Drospirenone can also cause an increase in plasma renin activity and plasma aldosterone. The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PMDD use: For use only in females who desire combination hormonal contraceptive therapy; use for more than 3 menstrual cycles has not been evaluated. Has not been evaluated for the treatment of premenstrual syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Drospirenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Drospirenone may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if oral contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol plasma concentrations; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, the use of oral contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Esophageal atresia was reported in one infant with a single-cycle exposure to ethinyl estradiol and drospirenone",
"     <i>",
"      in utero",
"     </i>",
"     (association not known). Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC,  2011). The manufacturer states that combination hormonal contraceptives should not be started until &ge;4 weeks after delivery in women who choose not to breast-feed, or &ge;4 weeks after a second trimester abortion or miscarriage.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F163790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of drospirenone excreted in breast milk is ~0.02%, resulting in a maximum of ~3 mcg/day drospirenone to the infant. Jaundice and breast enlargement in the nursing infant have been reported following the use of other oral contraceptives. In addition, may decrease the quality and quantity of breast milk. Other forms of contraception are recommended while breast-feeding (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7742056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at the same time each day; may be taken with or without a meal",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Drospirenone-Ethinyl Estradiol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.03 mg (28): $76.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gianvi Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.02 mg (28): $70.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loryna Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.02 mg (28): $70.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ocella Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.03 mg (28): $76.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Syeda Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.03 mg (28): $76.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Yasmin 28 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.03 mg (28): $93.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (YAZ Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.02 mg (28): $93.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zarah Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.03 mg (28): $76.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F163780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; serum potassium in high-risk patients and those on medications with potassium-retaining properties. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F855145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angeliq (AU, BB, BM, BS, BZ, CL, CO, CR, DO, EC, EE, FR, GB, GT, GY, HK, HN, ID, IE, IL, JM, KP, NI, NL, PA, PR, SR, SV, TH, TT);",
"     </li>",
"     <li>",
"      Jasmine (FR);",
"     </li>",
"     <li>",
"      Jasminelle (FR);",
"     </li>",
"     <li>",
"      Melodia (TH);",
"     </li>",
"     <li>",
"      Yarina (RU);",
"     </li>",
"     <li>",
"      Yasmin (AR, AT, AU, BB, BM, BR, BS, BZ, CH, CL, CN, CO, CR, DE, DK, DO, EC, ES, FI, GB, GT, GY, HK, HN, ID, IE, IL, IN, IT, JM, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, SE, SG, SR, SV, TH, TR, TT, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Yasmin IQ (PE);",
"     </li>",
"     <li>",
"      Yasminelle (BE, CH, CZ, DE, EE, NO, PL, PT);",
"     </li>",
"     <li>",
"      Yax Femicare (GT);",
"     </li>",
"     <li>",
"      YAZ (AU, BB, BG, BM, BS, BZ, CR, DO, EC, GT, GY, HK, HN, ID, IL, JM, KP, MY, NI, NL, NZ, PA, PH, PR, SG, SR, SV, TH, TT, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination oral contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, oral contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Oral contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Drospirenone: ~4 L/kg; Ethinyl estradiol: ~4-5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Drospirenone: Serum proteins (excluding sex hormone-binding globulin and corticosteroid-binding globulin): ~97%; Ethinyl estradiol: ~98% to serum albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Drospirenone: To inactive metabolites, minor metabolism hepatically via CYP3A4; Ethinyl estradiol: Hepatic via CYP3A4; forms metabolites; undergoes first-pass metabolism and enterohepatic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Drospirenone: ~76%; Ethinyl estradiol: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Drospirenone: ~30 hours; Ethinyl estradiol: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Drospirenone, ethinyl estradiol: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/15105794/pubmed\" id=\"15105794\" target=\"_blank\">",
"        15105794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jick SS and Hernandez RK, \"Risk of Non-Fatal Venous Thromboembolism in Women Using Oral Contraceptives Containing Drospirenone Compared With Women Using Oral Contraceptives Containing Levonorgestrel: Case-Control Study Using United States Claims Data,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2011, 349:d2151.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/21511805/pubmed\" id=\"21511805\" target=\"_blank\">",
"        21511805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearlstein TB, Bachmann GA, Zacur HA, et al, &ldquo;Treatment of Premenstrual Dysphoric Disorder With a New Drospirenone-Containing Oral Contraceptive Formulation,&rdquo;",
"      <i>",
"       Contraception",
"      </i>",
"      , 2005, 72(6):414-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/16307962/pubmed\" id=\"16307962\" target=\"_blank\">",
"        16307962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/62/42985/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9310 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-2E1E3D353B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42985=[""].join("\n");
var outline_f41_62_42985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708771\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163803\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855144\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163822\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163806\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163815\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163807\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163808\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163782\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163768\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163784\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163783\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163819\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913750\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163820\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163787\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163772\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163816\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163776\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163799\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163778\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163789\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163811\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163790\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7742056\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524564\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163780\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855145\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163771\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163786\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9310|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/37/22102?source=related_link\">",
"      Ethinyl estradiol and drospirenone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_62_42986="Gifted writing sample 1";
var content_f41_62_42986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83647%7EPEDS%2F83648%7EPEDS%2F83649%7EPEDS%2F83650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83647%7EPEDS%2F83648%7EPEDS%2F83649%7EPEDS%2F83650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child at age 5 years, 0 months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    I like to play with Dermot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child at age 5 years, 1 month",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    What did you do over the weekend? I celebrated Diwali on Friday with my teacher from Balivhar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child during kindergarten",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractions mean a part of something. An example is half a pizza or a quarter of a pie.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child at age 5 years, 10 months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When we learned about space we learned about Neptune. A fact is that Neptune has a storm cloud scooter and it chases all the other storms. I also enjoyed being with Nicholas and Nadia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42986=[""].join("\n");
var outline_f41_62_42986=null;
var title_f41_62_42987="Clinical and lab features of primary myelofibrosis";
var content_f41_62_42987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and laboratory features of 1000 consecutive patients with primary myelofibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Result (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median age, years (range)",
"       </td>",
"       <td>",
"        65 (14 to 92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Males",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional symptoms",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spleen &gt;10 cm below left costal margin",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red cell transfusions required",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin &lt;10 g/dL",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell count &gt;25,000/microL",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell count &lt;4000/microL",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet count &lt;100,000/microL",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Circulating blasts &ge;1 percent",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JAK2 V617F mutation present",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MPL mutation present",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IDH mutation present",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012; 87:25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42987=[""].join("\n");
var outline_f41_62_42987=null;
var title_f41_62_42988="Clinical features fibrillary glomerulonephritis";
var content_f41_62_42988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Demographics and presenting clinical features of 186 patients with fibrillary glomerulonephritis or immunotactoid glomerulonephropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Fibrillary variant",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Immunotactoid variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Fibril diameter*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Fibril arrangement*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Fibril diameter*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Fibril arrangement*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients&bull;",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male:female",
"       </td>",
"       <td>",
"        1.0:1.3",
"       </td>",
"       <td>",
"        1.0:1.3",
"       </td>",
"       <td>",
"        1.4:1.0",
"       </td>",
"       <td>",
"        2.6:1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age range",
"       </td>",
"       <td>",
"        10 to 81",
"       </td>",
"       <td>",
"        10 to 81",
"       </td>",
"       <td>",
"        12 to 68",
"       </td>",
"       <td>",
"        10 to 68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Race (white:black)",
"       </td>",
"       <td>",
"        9:1 (n=70)",
"       </td>",
"       <td>",
"        9:1 (n=70)",
"       </td>",
"       <td>",
"        -&Delta;",
"       </td>",
"       <td>",
"        -&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        85/126 (67%)",
"       </td>",
"       <td colspan=\"1\">",
"        81/118 (69%)",
"       </td>",
"       <td>",
"        5/11 (45%)",
"       </td>",
"       <td colspan=\"1\">",
"        11/13 (85%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria",
"       </td>",
"       <td>",
"        109/153 (71%)",
"       </td>",
"       <td colspan=\"1\">",
"        103/146 (70%)",
"       </td>",
"       <td>",
"        7/11 (64%)",
"       </td>",
"       <td colspan=\"1\">",
"        15/20 (75%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria",
"       </td>",
"       <td>",
"        172/172 (100%)",
"       </td>",
"       <td>",
"        164/164 (100%)",
"       </td>",
"       <td>",
"        12/12 (100%)",
"       </td>",
"       <td colspan=\"1\">",
"        22/22 (100%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotic syndrome",
"       </td>",
"       <td>",
"        94/133 (71%)",
"       </td>",
"       <td colspan=\"1\">",
"        87/125 (70%)",
"       </td>",
"       <td>",
"        9/11 (82%)",
"       </td>",
"       <td colspan=\"1\">",
"        18/21 (86%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency",
"       </td>",
"       <td>",
"        78/144 (54%)",
"       </td>",
"       <td colspan=\"1\">",
"        73/136 (54%)",
"       </td>",
"       <td>",
"        5/12 (42%)",
"       </td>",
"       <td colspan=\"1\">",
"        10/22 (45%)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      * To determine whether the fibrillary (F) and immunotactoid (IT) variants have different clinical features, patients were subdivided according to the diameter (F &le;30 nm) or arrangement (F, random; IT, focally organized) of microfibrils and microtubules. In general, these different criteria identified the same subpopulations of patients (&gt;90 percent concordance).",
"      <br>",
"       &bull; Fibril size was not reported in two patients. Study population consists of 25 patients presenting to the Brigham &amp; Women's Hospital and 161 patients reported previously in the literature.",
"       <br>",
"        &Delta; Insufficient data for interpretation.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Brady, HR. Kidney Int 1998; 53:1421.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42988=[""].join("\n");
var outline_f41_62_42988=null;
var title_f41_62_42989="Corrected intrinsic PEEP";
var content_f41_62_42989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spuriously elevated intrinsic PEEP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Individual values of intrinsic PEEP (auto-PEEP) measured on esophageal tracings (PEEPi dyn) compared with values obtained after subtracting for the rise in gastric pressure resulting from expiratory muscle activity (PEEPi corrected). The difference shown represents the contribution of expiratory muscle activity to the measured auto-PEEP. The corrected auto-PEEPi would be that component of auto-PEEP expected to be responsive to the application of PEEP. Thus, the presence of expiratory muscle activity can lead to the erroneous impression of a higher level of auto-PEEP and to the application of PEEP in an amount which might result in worsened dynamic pulmonary hyperinflation.",
"    <div class=\"footnotes\">",
"     PEEP: positive end-expiratory pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Lessard MR, Lofaso F, Brochard L. Am J Respir Crit Care Med 1995; 151:562.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42989=[""].join("\n");
var outline_f41_62_42989=null;
var title_f41_62_42990="Immobile arm in children with fever inflammation systemic signs";
var content_f41_62_42990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F88519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F88519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Immobile arm in children with fever, localized inflammation, or systemic illness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 420px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    * More than one attempt or manuever may be needed for successful reduction.",
"    <br/>",
"    <span class=\"bullet\">",
"     &bull;",
"    </span>",
"    For example, leukocytosis in blood or joint fluid, elevated C-reactive protein or erythrocyte sedimentation rate, or, in young infants, positive serology for syphillis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42990=[""].join("\n");
var outline_f41_62_42990=null;
var title_f41_62_42991="Isometric test forearm strength";
var content_f41_62_42991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Isometric testing of the forearm muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forearm strength can be objectively measured in extension (depicted here) or in flexion (the opposite direction). A progressive number of standard 10-10 resistance bands are placed over the patient's knuckles (extension) or the palm (flexion), and the patient is asked to pull them apart, keeping the wrists perfectly straight. Strength on the right is compared with the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_62_42991=[""].join("\n");
var outline_f41_62_42991=null;
